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Schizophrenia is a chronic psychotic illness affecting ~21 million people globally. Currently
available antipsychotic agents act through a dopamine D2 receptor mechanism, and produce
extrapyramidal or metabolic side effects. Hence, there is a need for novel targets and agents.
The mGlu2/5-HT2A receptor heteromer has been implicated in the action of antipsychotic
agents, and represents a novel and attractive therapeutic target for the treatment of

schizophrenia. A long-term goal of this project is to synthesize bivalent ligands where a 5HT2A receptor antagonist is tethered to an mGlu2 PAM via a linker.

The goals of the investigation were to study the SAR of risperidone (an atypical
antipsychotic agent) at 5-HT2A receptors using a “deconstruction-reconstructionelaboration” approach to determine the minimal structural features of risperidone that
contribute to its 5-HT2A receptor affinity and antagonism, and to determine where on the
“minimized risperidone” structure an mGlu2 PAM can be introduced. Additional goals
included studying the binding modes of various mGlu2 PAMs and identifying where on an
mGlu2 PAM a risperidone “partial” structure could be introduced.

Biological studies of deconstructed/elaborated analogs of risperidone suggest that the entire
structure of risperidone is not necessary for 5-HT2A receptor affinity and antagonism, and
that a fluoro group contributes to 5-HT2A binding. 6-Fluoro-3-(4-piperidinyl)-1,2benz[d]isoxazole that has only half the structural features of risperidone retains 5-HT2A
receptor affinity and antagonist activity, and represents the “minimized risperidone”
structure with the piperidine nitrogen atom representing a potential linker site for eventual
construction of bivalent ligands. Molecular modeling studies at 5-HT2A receptors suggest
that risperidone and its analogs have more than one binding mode.

Modeling studies to evaluate binding modes of various PAMs at mGlu2 receptors, coupled
with known SAR information, were used to identify a PAM (JNJ-40411813), and the

pyridone nitrogen atom of JNJ-40411813 as a potential linker site. Additionally, potential
synthetic routes for JNJ-40411813 were explored that might be of value in the synthesis of
bivalent ligands.

Based on the structural features of 6-fluoro-3-(4-piperidinyl)-1,2-benz[d]isoxazole, a new
pharmacophore for 5-HT2A receptor antagonists, consisting of one aromatic region, a basic
protonated amine and hydrogen bond acceptors, has been proposed.

I. INTRODUCTION

Schizophrenia is a chronic, recurring psychotic illness with an enigmatic etiology that remains a
significant health problem and affects ~1% of the global population.1,2 There is emerging evidence
to show that schizophrenia might be a part of a larger group of disorders called “schizophrenia
spectrum disorder” that is prevalent in ~6% of the general population.1,2 The clinical symptoms of
schizophrenia can be classified into positive symptoms such as hallucinations and delusions,
negative symptoms that include anhedonia and apathy, and cognitive deficits that are related to
working memory, and attention.1,3,4

Several hypotheses have been proposed to link altered brain function and schizophrenia and there
could be abnormalities in dopamine (DA), serotonin (5-HT), glutamate (GLU), γ-aminobutyric
acid (GABA), and acetylcholine (ACh) receptor pathways.4–6 However, most clinically available
antipsychotic agents act through a dopamine D2 receptor mechanism.7

The introduction of chlorpromazine (a “typical” antipsychotic agent) in 1952 marked a new era of
drug treatment in psychiatry.8,9 Chlorpromazine is a dopamine D2 receptor antagonist that is
effective against the positive symptoms of schizophrenia;10 however, extrapyramidal symptoms
(EPS) are a common side effect of chlorpromazine therapy.11
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The introduction of clozapine in 1990 was a hallmark in antipsychotic therapy.12 Clozapine can
ameliorate both the positive and negative attributes of schizophrenia with a lower propensity to
cause EPS.12 The introduction of clozapine led to the development of the concept of “atypical”
antipsychotics, and its clinical success prompted the development of other atypical antipsychotic
agents such as risperidone.13

Risperidone is effective in treating the positive and negative symptoms of schizophrenia and has
a lower propensity to cause EPS.14 It is a dopamine D2 receptor (Ki = 3.1 nM) and 5-HT2A receptor
(Ki = 0.16 nM) antagonist.15 Moderate D2 receptor occupancy, and predominantly 5-HT2A receptor
occupancy, might be the mechanism for its effectiveness against the positive, and negative
symptoms of schizophrenia, with reduced side effects.14 Even though risperidone has a much lower
tendency to cause EPS than typical antipsychotic agents, therapy with risperidone is associated
with other side effects such as hyperprolactinemia, and weight gain.13,16,17

Nearly all currently available antipsychotic agents act through a dopamine D2 receptor mechanism,
and cause either extrapyramidal or metabolic side effects.7 Hence, there is a pressing need for
novel therapeutic targets and agents.

Literature precedent exists for the formation of a functional 5-HT2A/mGlu2 receptor
heterocomplex18–21 that has been implicated in the mechanism of action of antipsychotic agents.22
Roles for the 5-HT2A receptor and the mGlu2 receptor in the pathophysiology of schizophrenia
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have been well established.14,23 5-HT2A receptor antagonists/inverse agonists, and mGlu2 receptor
orthosteric agonists and PAMs, possess antipsychotic character.14,23 The atypical antipsychotic
agent risperidone has been shown to mediate its effects by binding to the 5-HT2A/mGlu2 receptor
heteromer which then balances Gi/o and Gq/11 signaling.22 Gonzalez-Maeso et al.18 have shown that
the 5-HT2A receptor is upregulated and the mGlu2 receptor is downregulated in postmortem brain
samples of untreated schizophrenic patients. These changes suggest that the 5-HT2A/mGlu2
receptor heteromer may be involved in the altered cortical processes in schizophrenia, and
represents an attractive novel therapeutic target for the treatment of schizophrenia.18 A long-term
goal of the project is to synthesize bivalent ligands having a 5-HT2A receptor antagonist portion
based on a risperidone scaffold connected to an mGlu2 receptor PAM via a linker.

Goals of the current investigation are to study structure activity relationships of risperidone at 5HT2A receptors to determine the minimal structural features required for risperidone to retain 5HT2A receptor affinity and antagonist activity, and to identify where on the risperidone “partial
structure” an mGlu2 receptor PAM might be attached. Additional goals include studying the
binding modes of various PAMs at the mGlu2 receptor and identifying a PAM as well as a potential
site to install the “minimized” risperidone structure that will contribute towards the long-term goal
of synthesizing a bivalent molecule that can target the mGlu2/5-HT2A receptor heteromeric
complex.
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II. BACKGROUND

1. Schizophrenia
Schizophrenia is a chronic, recurring psychotic illness that remains a significant health problem
affecting more than 21 million people worldwide are affected by schizophrenia,1,2,24 and the Global
Burden of Disease study has ranked schizophrenia as the ninth leading cause of disability-adjusted
life-years for those aged 15-44.8 There is emerging evidence to show that schizophrenia might be
a part of a larger group of disorders called “schizophrenia spectrum disorder” that is prevalent in
~6% of the general population.1 These disorders are related to each other in terms of
pathophysiology, cognitive characteristics, symptom expression, and genetics, with schizophrenia
being the most severe of the class.1

The concept of schizophrenia as a disease is of recent origin and has been grouped with conditions
such as mania, melancholia and generic “insanity” since ancient times.8,25 During the 19th century
Kraeplin, as reviewed by Jablensky,25 first used the term “dementia praecox’ to describe the illness.
Bleuler, as reviewed by Kuhn and Cahn,26 subsequently changed the name from dementia to
schizophrenia and provided the disease with a distinct diagnostic profile. The word schizophrenia
has Greek origins and translates as “splitting of the mind” (shizein = splitting; phren = soul, spirit,
mind).26
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The diagnosis of schizophrenia is solely based on the presentation of clinical symptoms that can
be classified into positive and negative symptoms, and cognitive deficits.1,3,4 The positive
symptoms include delusions (persecutory, referential, somatic, nihilistic, and grandiose delusions),
hallucinations, reality distortion, paranoia, disorganized speech and grossly disorganized or
catatonic behavior.1,3,4 The negative attributes include anhedonia, asociality, alogia, avolition,
inappropriate social skills, and affective flattening.1,3,4 Cognitive deficits that are sometimes
classified as a part of the negative symptoms are related to working memory, executive functions,
and attention.1,3,4 There can also be neurophysiological disturbances such as abnormal smooth
pursuit and saccadic eye movements and abnormal evoked potentials (P300, P50) in patients with
schizophrenia.1 Various modifications have been made to the diagnosis of schizophrenia over the
years and the current diagnosis of schizophrenia is based on the criteria of the Diagnostic and
Statistical Manual for Mental Disorders, fifth edition (DSM-5)27 or of the older International
Classification of Diseases, tenth addition (ICD-10),28 published by the American Psychiatric
Association and the World Health Organization, respectively.

Schizophrenia is a neurodevelopmental rather than a neurodegenerative disorder and an interplay
between several environmental factors such as substance abuse, trauma, and pre- or perinatal
stressors, developmental factors, and genetic factors (where a risk for schizophrenia is inherited)
contribute to the development of schizophrenia.1,29 There is altered brain function and structure in
schizophrenia, and patients with schizophrenia show enlarged cerebral ventricles, a 5% reduction
in the size of the medial temporal cortex, decreased volume of the superior temporal gyrus, and
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hippocampal shape irregularities.1 Cerebral cortical atrophy is a hallmark feature of
schizophrenia.1,5 Proper functionality of connections between the different spatially-distributed
brain regions is important for higher- order brain function and changes throughout the connected
neural networks rather than damage to a single brain area that might result in schizophrenia.8 At
the neurotransmitter level, there could be abnormalities in dopamine (DA), serotonin (5-HT),
glutamate (GLU), γ-aminobutyric acid (GABA), and acetylcholine (ACh) receptor pathways.4–6
Several hypotheses have been proposed to link altered brain function and schizophrenia.

2. Theories of schizophrenia
a. The dopamine (DA) hypothesis of schizophrenia
DA (1) (Figure 1) functions as a neurotransmitter in the brain and plays an important role in
maintaining normal physiological function.30 DA’s effects are mediated via G-protein coupled DA
receptors (D1-D5).30 The physiological functions of DA include, but are not limited to, sleep
regulation, affect, cognitive function, attention, voluntary movement, reward, feeding, and
hormonal regulation.30 The DA hypothesis is central to the pathophysiology of schizophrenia and
has undergone refinement and modification over the years.31 The initial DA hypothesis was
formulated on the basis of the observed antipsychotic effects of drugs such as chlorpromazine
(CPZ) (2) (Figure 1) that act as DA receptor blockers (i.e.; antagonists).31 The ability of
psychostimulants such as amphetamine (3) (Figure 1) to induce psychosis by increasing the
synaptic concentrations of monoamine neurotransmitters,32 and the effectiveness of the indole
alkaloid reserpine (4) (Figure 1) in treating psychosis by blocking the reuptake of DA and other
monoamine neurotransmitters by irreversibly blocking the vesicular monoamine transporters,33
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provided further evidence for the DA hypothesis of schizophrenia. In the 1970s it was realized that
the effectiveness of clinical antipsychotics such as CPZ (2) and haloperidol (5) (Figure 1) was
related to their affinity for the D2 dopamine receptor.10,31,34 The “first” version of the DA hypothesis
assumed a general dopaminergic hyperfunction.31 A major drawback of the initial DA hypothesis
was that it focused on blockade of DA receptors to treat psychosis, but there was no relation
between abnormal dopaminergic activity and expression of positive and negative symptoms, and
little was known about where the abnormality occurred in the brain.31 The hypothesis was also
unable to explain the inability of antipsychotics to treat the negative symptoms and cognitive
deficits of schizophrenia.31

Figure 1. Structures of the neurotransmitter dopamine (DA) (1), the typical antipsychotic agents
chlorpromazine (CPZ) (2), and haloperidol (5), the psychostimulant amphetamine (3), and the
indole alkaloid reserpine (4).
7

In 1991, a “modified hypothesis of schizophrenia” was proposed by Davis et al.35 They
hypothesized that there is hyperdopaminergia in the subcortical DA pathway that is responsible
for the positive attributes of schizophrenia, and hypodopaminergia in the prefrontal cortex that
accounts for the negative attributes of schizophrenia. They also proposed that the excessive
dopaminergic activity in the mesolimbic region might be a result of low dopaminergic activity in
the prefrontal cortex.35

Based on the availability of newer evidence, Howes et al.31 further modified the DA hypothesis.
They postulated that the DA hypothesis has four distinct components that are as follows: 1.
Psychosis in schizophrenia is the result of DA dysregulation due to the interaction of “multiple
hits” such as stress, genes, drugs and fronto-temporal dysfunction. 2. DA dysfunction is at the
presynaptic control level rather than at the D2 receptor level. 3. The DA hypothesis does not explain
all facets of schizophrenia; rather, it explains the “psychosis” associated with schizophrenia.31 4.
Dysregulation of the dopaminergic system may lead to an altered appraisal of stimuli by a process
of aberrant salience.31,36

The DA model of schizophrenia has been a leading hypothesis, and the role of dopamine in the
pathophysiology of schizophrenia is well established.37,38 However, D2 receptor antagonism alone
did not seem to be addressing the core pathophysiology of schizophrenia, since typical
antipsychotic agents were unable to alleviate the negative and cognitive symptoms of
schizophrenia.37,38 A dysfunction of multiple neural networks and transmitter systems might be
responsible for the negative symptoms and cognitive deficits in patients with schizophrenia.37,38
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The DA hypothesis addressed a more downstream effect and did not account for the
neurocognitive deficits and, the wide range of symptoms, thus eliciting a need for newer
hypotheses.37,38

b. The serotonin (5-HT) hypothesis of schizophrenia
Serotonin or 5-hydroxytryptamine (5-HT; 6) (Figure 2) is a monoamine neurotransmitter that is
essential for maintaining normal brain function.39 5-HT receptors are classified into seven main
classes that are further divided into subtypes.39 The 5-HT1, 5-HT2, and 5-HT4-7 receptors are Gprotein coupled receptors (GPCRs) whereas the 5-HT3 receptor is a ligand-gated ion channel
receptor.39 Lysergic acid diethylamide (LSD; 7) (Figure 2), a hallucinogenic agent, is structurally
similar to 5-HT (6), was found to produce symptoms that resembled the psychotic symptoms of
schizophrenia.40 The hallucinogenic effects of LSD (7) were thought to be a result of its ability to
antagonize 5-HT in the CNS and the initial 5-HT hypothesis of schizophrenia attributed the
symptoms of schizophrenia to a 5-HT deficit in the CNS.40 It was soon realized that LSD (7) could
not only antagonize but also mimic the effects of 5-HT41 and the hypothesis was revised such that
a surplus or deficit of 5-HT could be responsible for the psychosis associated with
schizophrenia.42,43
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Figure 2. Structures of the monoamine neurotransmitter serotonin (5-HT; 6), the hallucinogenic
agent lysergic acid diethylamide (LSD; 7), and the atypical antipsychotic agent clozapine (8).

The focus of schizophrenia research shifted to the DA hypothesis of schizophrenia with the
discovery that neuroleptics (i.e., antipsychotic agents) such as CPZ (2), with DA blocking
properties, were effective antipsychotic agents. The 5-HT hypothesis of schizophrenia took a back
seat and it was only with the discovery of the ability of atypical antipsychotic agents such as
clozapine (8) (Figure 2) to block certain subtypes of the 5-HT receptors, that attention was
refocused on the role of 5-HT in schizophrenia and resulted in a mixed 5-HT/DA hypothesis of
schizophrenia.44

Per the current 5-HT hypothesis of schizophrenia there is a stress-induced serotonergic overdrive
coming from the dorsal raphe nucleus that can disrupt cortical neuronal function in schizophrenia.
This, along with the hyperactivity of 5-HT in the cerebral cortex (mainly in the anterior cingulate
cortex and the dorsolateral frontal lobe), is the upstream cause of schizophrenia.5
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Among the 5-HT receptors, the 5-HT2 (5-HT2A) receptor has been suggested to be most important
for the efficacy of antipsychotic agents.45 The 5-HT2A receptor is widely distributed in many
regions of the brain such as the cerebral cortex and the nucleus accumbens, with high density in
the frontal cortex.10,43 Activation of 5-HT2A receptors in the prefrontal cortex can lead to an
increase in the release of glutamate that is indicated by the enhanced spontaneous excitatory
postsynaptic potentials/currents in layer V pyramidal cells, an effect that can be blocked by αamino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate glutamate receptor
agonists and by group II/III metabotropic glutamate receptor agonists.10,43,46,47 Hence, the 5-HT
hypothesis by itself cannot explain the symptoms of schizophrenia and a number of other
hypotheses have been postulated, one of which was the glutamate hypothesis of schizophrenia

c. The glutamate (GLU) hypothesis of schizophrenia
GLU (9) (Figure 3) is an amino acid that is the most abundant and primary excitatory
neurotransmitter in the brain and accounts for ~40% of neurons and ~60% of synapses in the
brain.48,49 Almost all cortical pyramidal neurons use GLU as the primary excitatory
neurotransmitter.48 Glutamatergic neurotransmission is modulated via two main types of receptors:
the ligand-gated ion channel receptors that include N-methyl-D-aspartate (NMDA), α-amino-3hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate receptors, and the G-protein
coupled metabotropic glutamate receptors that are divided into 3 groups (I-III) and eight
subtypes.50 The similarity between the psychosis induced by dissociative anesthetics such as
phencyclidine (10) and ketamine (11) (Figure 3) and the psychotic syndrome associated with
schizophrenia has been appreciated since the introduction of these agents in the early 1960s. 51,52
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Based on the knowledge that dissociative anesthetics are non-competitive NMDA receptor
antagonists, and the emerging pharmacology of the NMDA receptor, it was proposed that
schizophrenia might result from a hypofunction of NMDA receptors.38,51,53

Figure 3. Structures of glutamate (GLU) (9) and the dissociative anesthetics: phencyclidine (10)
and ketamine (11).

The glutamate hypofunction hypothesis suggested that the positive or psychotic symptoms of
schizophrenia might be linked to excessive release of DA from neurons in the mesolimbic pathway
due to an abnormal functioning of the GLU-GABA-GLU-DA circuit. (Figure 4) The defective and
hypofunctioning NMDA receptors do not receive adequate stimuli form the primary GLU neuron
resulting in a loss of GABA output to the secondary GLU neuron leading to excessive firing of the
neuron and an ultimate excess of DA in the mesolimbic pathway.54
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Figure 4. NMDA receptor hypofunction hypothesis for the positive symptoms of schizophrenia
(adapted from Schwartz et al.54).

The negative and cognitive symptoms of schizophrenia can be attributed to the malfunctioning of
another GLU neurocircuit (GLU-GABA-GLU-GABA-DA neuronal circuit) leading to insufficient
release of DA in the mesocortical region (Figure 5).37,54 Hypofunction of the NMDA receptor on
the GABA interneuron may lead to an increased tone of the secondary GLU neuron and an
increased firing of the GABAergic interneuron in the ventral tegmental area resulting in an
inadequate release of DA by the dopaminergic neurons in the mesocortical DA pathway.37,55
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Figure 5. NMDA receptor hypofunction hypothesis for the negative and cognitive symptoms of
schizophrenia (adapted from Schwartz et al.54).

Direct NMDA receptor agonists or metabotropic glutamate receptor type 2/3 (mGlu2/3) agonists or
PAMs of mGlu2 could be therapeutically useful in patients with schizophrenia, and some of these
agents have advanced into clinical trials.54 mGlu2/3 receptors are autoreceptors located on the
secondary GLU neuron.54 Activation of these receptors with mGlu2/3 receptor agonists or mGlu2
receptor PAMs would lead to a decrease in firing of the overactivated GLU neuron resulting in
modulation of DA release and an amelioration of the positive, negative and cognitive symptoms
of schizophrenia.54
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5-HT (5-HT1A and 5-HT2A) receptors are widely distributed in the prefrontal cortex and can
regulate NMDA receptor activity, and a change in 5-HT signaling in the prefrontal cortex could
alter NMDA receptor activity and also contribute to the cognitive and negative symptoms of
schizophrenia.37,56

The GLU hypofunction hypothesis of schizophrenia looks at more upstream effects that ultimately
leads to a final common pathway culminating in the release of DA. GLU- manipulating agents
may prove to be therapeutically useful in treating both the positive, negative and cognitive
symptoms of schizophrenia.54

d. The GABA hypothesis of schizophrenia
GABA (12) (Figure 6) is an inhibitory neurotransmitter in the central nervous system and plays
an important role in reducing neuronal excitability.

Figure 6. Structure of the inhibitory neurotransmitter GABA (12).

GABAergic neurons play a crucial role in maturation of neural circuitry during the postnatal
period, and impaired maturation of the GABAergic neurons could result in psychiatric disorders
15

such as schizophrenia.29 Additionally, the GABAergic interneurons are important for maintaining
proper cortical functioning29 as well as supporting cortical functions that include maintaining a
balance between excitation and inhibition,57 and proper synaptic inhibition at dendrites and
somata.58 The imbalance between excitation and inhibition in the cerebral cortex due to
GABAergic dysfunction might lead to increased sub-cortical DA and underlie a part of the
pathophysiology of schizophrenia.29,59

e. The cholinergic hypothesis of schizophrenia
The nicotinic and muscarinic cholinergic systems interact with one other as well as other
neurotransmitter systems such as GABA, GLU and DA in a complex and bi-directional manner.6
The cholinergic system is important for maintaining normal dopaminergic tone in the cortex and
striatum.60 The glutamatergic neurons in the mesolimbic and mesocortical dopaminergic pathways
have alpha 7 nicotinic receptors located on them.60 Activation of the alpha 7 nicotinic receptors
(by alpha 7 receptor agonists and PAMs61) on hypofunctional glutamatergic neurons can alleviate
the positive, negative symptoms, and the cognitive deficits of schizophrenia by normalizing
dopaminergic tone in the cortex and striatum.60 The muscarinic agents can have antipsychotic
effects via both direct muscarinic effects (pro-cognitive effects) and by modulating the
dopaminergic system (effects on the positive symptoms of schizophrenia).6 M1 and M4 muscarinic
cholinergic agonists might be therapeutically useful in schizophrenia.6,62
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f. The adenosine hypothesis of schizophrenia
Adenosine (13) (Figure 7) is a homeostatic bioenergetic network modulator and affects brain DA
and GLU activities.63,64

Figure 7. Structure of the bioenergetic network modulator adenosine (13).

Adenosine (13) is relevant to the etiology of schizophrenia because it is not only important for
regulation of immune responses but also for early brain development. The adenosine hypothesis
suggests that a dysfunction of the purinergic system, resulting in reduced adenosinergic activity,
might be responsible for the dysfunctioning of multiple neurotransmitter systems that are
associated with schizophrenia. Adenosine (13) can be controlled and rebalanced in multiple ways
to modulate brain function and restore the homeostatic bioenergetic network balance. Some of the
targets include enzymes such as adenosine kinase and transporters that control the tone of
adenosine levels.64

g. The α-adrenoceptor hypothesis of schizophrenia
α1-, α2-Adrenoceptor blockade might contribute to the antipsychotic efficacy of atypical agents
such as clozapine (8) (Figure 2).65 α1-Adrenoceptor blockade leads to a reduction of striatal DA
and a reduction in the positive symptoms of schizophrenia. α2-Adrenoceptor blockade can
17

ameliorate the negative and cognitive symptoms of schizophrenia by improving prefrontal
dopaminergic functioning.66

The ability of the atypical antipsychotics such as clozapine (8) and risperidone (14) (Figure 8) to
antagonize α2- adrenoceptors might be important for their superior clinical profiles.66,67

Figure 8. Structure of the atypical antipsychotic agent risperidone (14).

g. The cannabinoid hypothesis of schizophrenia
The relationship between the use of cannabinoids and schizophrenia is complex and not completely
understood. It has been proposed that hyperactivity of the central cannabinoid system might be
involved in the pathogenesis of schizophrenia and that the endogenous cannabinoid system could
represent a novel therapeutic target for the treatment of schizophrenia.68,69 The CB1 receptor
system and the dopaminergic system interact in a complex manner and studies have suggested that
cannabidiol (15) (Figure 9) ( a CB1 and CB2 receptor antagonist) and SR141716 (16) (Figure 9)
(a selective CB1 receptor antagonist), have a pharmacological profile similar to that of atypical
antipsychotic agents.68,70 The antipsychotic agent-like profile of cannabidiol might also be due to
its actions at other targets.
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Figure 9. Structures of cannabidiol (15) and SR141716 (16).

2. Antipsychotic agents
a. History
Psychiatric states have been associated with specific areas of the cerebral cortex since the late 19th
century, and the process of lobotomy was common practice for the treatment of neuropsychiatric
disorders in the early 1900s.8 Lobotomies involve localized lesions or surgical destruction of
certain cerebral sites, and were based on the hypothesis that their anatomical location correlated
with functional effects, and severance of certain sections of the brain, especially the frontal lobes,
would modify the affective expression of psychosis or neurosis.71,72

The introduction of CPZ (2) (Figure 1) by Rhône-Poulenc in 1952 marked a new era of drug
treatment in psychiatry and resulted in the demise of psychosurgery.8,9 CPZ (2) was initially
developed as an antihistaminic agent that was used to potentiate the effect of other anesthetic
agents; its antipsychotic effects were discovered serendipitously by Delay and Deniker, as
reviewed by Shen13 and Tamminga.73 Patients that were administered CPZ (2) behaved in a manner
that was similar to lobotomized patients, and CPZ (2) was regarded as a non-permanent
pharmacological lobotomy.9
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In 1952, extrapyramidal symptoms (EPS) were observed as a side effect associated with CPZ (2)
therapy, and led clinicians and pharmacologists to believe that antipsychotic efficacy and EPS
were linked.11 EPS include dystonia, akathisia, parkinsonism, tardive dystonia, and tardive
dyskinesia.11 The introduction of haloperidol (5) (Figure 1) in 1958 further bolstered this belief.74
The widespread use of CPZ (2) resulted in large decreases in psychiatric inpatient populations
worldwide, and fueled a search for other antipsychotic drugs.13 By the 1970s, at least 40 new
antipsychotic agents were introduced worldwide.13 These agents were “typical” antipsychotic
agents (Figure 10) that exerted their antipsychotic effects by blocking DA (particularly D2)
receptors and included drugs such as CPZ (2), haloperidol (5) (Figure 1), thioridazine (17),
trifluoperazine (18), thiothixene (19), and loxapine (20) (Figure 10) among others.13,73,75
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Figure 10. Examples of typical antipsychotic agents.

There was a lull in antipsychotic drug development from 1975 to 1990. The introduction of
clozapine (8) (Figure 2) in 1990 was a hallmark in antipsychotic therapy. Clozapine (8) was
initially introduced as an antipsychotic in the mid-1960s.76 However, it was withdrawn from the
market for two reasons: it produced life-threatening agranulocytosis as a side effect, and it did not
produce EPS, a side-effect that was thought to be correlated with antipsychotic efficacy.13
Clozapine (8) was reintroduced to the market in the 1990s following a successful double-blind
study in treatment-resistant patients whose blood levels were carefully monitored. Clozapine (8)
was different from the previously marketed antipsychotics in being able to ameliorate both the
positive and negative attributes of schizophrenia, as well as in having a lower propensity to cause
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EPS.12 The introduction of clozapine (8) led to the development of the concept of “atypical”
antipsychotics, and its clinical success prompted the development of other atypical antipsychotic
agents (Figure 11) such as risperidone (14) (Figure 8) (1994), olanzapine (21) (1996), and
quetiapine (22) (Figure 11) (1997).13 Risperidone (14) was developed using the chemical structure
of haloperidol (5) (Figure 1) as a starting point,74 while the chemical structures of olanzapine (21)
and quetiapine (22) were derived from clozapine (8).13

Figure 11. Examples of atypical antipsychotic agents.

Antipsychotic therapy has come a long way from the serendipitous discovery of the antipsychotic
effects of CPZ (2) to a more precise receptor-targeted approach for the synthesis of newer
antipsychotics.13 There has been a paradigm shift in the design of antipsychotic agents from drugs
that solely target the dopaminergic system to a more multi-target approach with newer drugs
targeting multiple neurotransmitter systems that include, but are not limited to, 5-HT, GLU, and
cholinergic systems.13
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b. Classification
Antipsychotics can be classified into two main groups: first-generation or “typical”
antipsychotics/“neuroleptics” and second-generation or “atypical” antipsychotics. There is an
emerging class of atypical antipsychotic agents that are also commonly referred to as thirdgeneration antipsychotic agents.77 The terminology, and classification of antipsychotics have been
a subject of considerable debate until the early 1970s, and terms such as “neuroleptic”,
“tranquilizer” and “ataraxic” have been used to refer to “typical” antipsychotic agents. The terms
tranquilizer, and ataractics were popular until the 1960s, while the term neuroleptic was a more
lasting term. These terms have been replaced by the term antipsychotic, and it now is the most
popular term used to describe both typical and atypical agents.78

Typical antipsychotic agents include drugs such as CPZ (2), haloperidol (5) (Figure 1), thioridazine
(17), trifluoperazine (18), thiothixene (19), and loxapine (20) (Figure 10) among others, and are
mainly D2 receptor antagonists.73,75

Atypical antipsychotic agents are classified based on their pharmacological action and reflect their
affinities for specific receptors.79 They can be classified into serotonin-dopamine antagonists
(SDAs), multi-acting receptor-targeted antipsychotics (MARTAs), and combined D2/D3 receptor
antagonists.79 The third-generation atypical antipsychotic agents include partial DA receptor
agonists such as aripiprazole (23) (Figure 12).79 SDAs are atypical antipsychotic agents that
possess a high affinity for 5-HT2A and D2 receptors and include agents such as risperidone (14)
(Figure 8), iloperidone (24) (Figure 12), and ziprasidone (25) (Figure 12).79 MARTAs include
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agents that have high affinities for 5-HT2A receptors, D2 receptors, and receptors of other
neurotransmitter systems such as cholinergic, histaminergic, and other serotonin receptors such as
5-HT1A and 5-HT2C, some representative examples include agents such as clozapine (8) (Figure
2), quetiapine (22), and olanzapine (21) (Figure 11).67 Agents such as amisulpride (26) and
remoxipride (27) (Figure 12) are combined D2/D3 receptor antagonists.79

Figure 12. Structures of the partial DA receptor agonist aripiprazole (23), the SDAs: iloperidone
(24), and ziprasidone (25), and the combined D2/D3 receptor antagonists: amisulpride (26) and
remoxipride (27).
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c. Typical versus atypical antipsychotic agents
Typical antipsychotic agents, effective against only the positive symptoms of schizophrenia, are
known to cause multiple side effects.7 The side effect profiles for different chemical classes vary,
however, the most prominent side effects that are common to conventional (i.e., typical)
antipsychotics are EPS and hyperprolactinemia.7 Neuroleptic malignant syndrome can occur at
higher doses.7

Atypical antipsychotic agents have a broader spectrum of clinical efficacy and ameliorate the
positive symptoms, negative symptoms, and cognitive deficits of schizophrenia.79 They are more
sparing in their side effects and have a reduced propensity to cause EPS and hyperprolactinemia,
the side effects that are commonly associated with the use of typical antipsychotic agents.79 Even
though atypical antipsychotic agents have their own adverse effects such as metabolic side effects,
they have an overall better safety profile and are associated with a lower risk of suicide, higher
rate of responders and an improved quality of life.79

Studies have suggested that atypical antipsychotic agents are equally effective in the control of
positive attributes, and are superior in controlling the negative symptoms, and cognitive deficits
of schizophrenia as compared to typical antipsychotic agents.79,80 However, evidence of their
superior efficacy is inconsistent, and several double-blind, randomized, controlled trials have been
conducted to compare the clinical efficacy of atypical antipsychotic agents over conventional
antipsychotic agents as well as a placebo.79,80 Meta-analyses of published clinical trials by two
groups; Geddes et al.81 and Leucht et al.82 have suggested that atypical antipsychotic agents offer
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modest clinical efficacy over typical antipsychotic agents. Geddes et al.81 concluded that the
atypical antipsychotic agents were moderately better than conventional antipsychotics. At lower
doses of the conventional antipsychotic agent; haloperidol (5) (Figure 1), there was no difference
in terms of efficacy and overall tolerability over atypical agents; however, the first-generation
antipsychotic agents demonstrated a liability for EPS even at low doses. A meta-analysis study of
published clinical trials using low-potency conventional antipsychotics by Leucht et al.82 was in
agreement with the study by Geddes et al.81 and suggested that the benefits of atypical agents over
typical agents with the exception of clozapine (8) (Figure 2) were only moderate. These studies
were limited by the lack of available data to evaluate other dimensions such as suicide risk, and
quality of life. Contrary to the studies by Geddes et al.81 and Leucht et al.82 the meta-analysis of
124 trials by Davis et al.83 has suggested that some atypical antipsychotic agents such as clozapine
(8), risperidone (14) (Figure 8), olanzapine (21) (Figure 11), and amisulpride (26) (Figure 12) were
significantly more efficacious than conventional antipsychotics.

The US clinical antipsychotic trials of intervention effectiveness (CATIE) study, in 2005, and the
UK cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1), in 2006,
showed no differences in effectiveness and overall quality of life between the first- and secondgeneration (i.e., typical and atypical) agents.84

Atypical antipsychotic agents are a heterogeneous group of agents, and differ in terms of
effectiveness and side-effects.79 It has been suggested that rather than using a dichotomous typical-
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atypical antipsychotic agent classification, viewing these agents in a dimensional fashion might be
best,80 and the choice of use of drug should be based on the drug as well as patient profile.84

3. Newer concepts
i. Serotonin-dopamine antagonists (SDA)
Clozapine (8), the first atypical antipsychotic agent, lacked EPS, a side effect associated with
conventional antipsychotic therapy, and is a potent antagonist at multiple receptors with the 5HT2A receptor being one among the many.85 Activity at serotonergic pathways that impinge on
striatal dopaminergic pathways can reduce DA-mediated activity in these pathways, leading to the
hypothesis that EPS could be reduced by the addition of 5-HT2A receptor blockade to D2 receptor
antagonism.85,86 The addition of ritanserin (28) (Figure 13), a selective 5-HT2A receptor antagonist
as an adjunctive treatment to conventional antipsychotics in patients with schizophrenia resulted
in a significant reduction of EPS, and further bolstered the hypothesis.87

Figure 13. Structure of the 5-HT2A receptor antagonist ritanserin (28).

Medicinal chemistry efforts to synthesize agents that combined D2 receptor and 5-HT2A receptor
antagonism in one molecule have resulted in several drugs, with risperidone (14) (Figure 8) being
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the first marketed SDA. As opposed to conventional antipsychotic agents that are more potent D2
rather than 5-HT2 receptor antagonists, SDAs have a higher affinity for 5-HT2A receptors as
compared to D2 receptors.85 The 5-HT2A/ D2 receptor binding affinity ratio has been defined by
Meltzer et al.45 and most atypical antipsychotic agents have a 5-HT2A/D2 receptor binding affinity
ratio ≥ 1.12. Disinhibition of dopaminergic neurotransmission in the nigrostriatal pathway by 5HT2A receptor blockade resulting in the release of DA in the striatum by offsetting the D2 receptor
blockade may be a potential mechanism by which SDAs can reduce the expression of EPS. SDAs
shift the EPS dose-response curve to the right while the antipsychotic dose response curve remains
unchanged, resulting in a reduced propensity to cause EPS.85 These agents not only produce lower
incidence of EPS, but might also be effective against the negative symptoms of schizophrenia and
have pro-cognitive effects. The antiserotonergic component of SDAs may increase dopaminergic
activity in the frontal cortex leading to an amelioration of negative symptoms of schizophrenia.45

Rather than using the term SDAs, a better term to describe these agents is 5-HT spectrum dopamine
modulators (SSDMs), since most of these agents have a wide spectrum of activity at 5-HT
receptors that includes 5-HT2A receptor antagonism, direct or indirect 5-HT1A receptor agonism,
and/or 5-HT2C, 5-HT6, and 5-HT7 receptor antagonism, and could be either antagonists or partial
agonists at D2/D3 receptors. The spectrum of action at 5-HT receptors differs among various
members of this class of agents resulting in differences in efficacy and tolerability among the
different SSDMs.88
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ii. Role of inverse agonists in antipsychotic activity
The ability of active conformations of receptors to produce a response in the absence of an agonist
is known as constitutive activity, and ligands that decrease constitutive activity are known as
inverse agonists. Most ligands (>80% of classical GPCR ligands) that were initially classified as
antagonists are inverse agonists.89,90 5-HT2A and 5-HT2C receptors modulate the release of DA in
the brain.90 5-HT2A receptor inverse agonists such as M100907 (29) (Figure 14) increase the
release of DA in the mesocortical and mesolimbic brain regions,90,91 whereas 5-HT2C receptor
inverse agonists such as SB206553 (30) (Figure 14) increase the release of DA in the nucleus
accumbens.90,92 The activity of atypical antipsychotic agents at 5-HT2A, 5-HT2C, and 5-HT1A
receptors increases the release of DA in the prefrontal cortex.90 Most atypical antipsychotic agents
such as clozapine (8) (Figure 2), risperidone (14) (Figure 8), and olanzapine (21) (Figure 11) are
5-HT2A and 5-HT2C receptor inverse agonists, and it has been hypothesized that inverse agonist
action at these receptors might be responsible for the ability of atypical antipsychotic agents to
ameliorate the negative attributes and cognitive deficits of schizophrenia.90,93 An effective
therapeutic strategy to treat the positive symptoms of schizophrenia might be the use of 5-HT2A/2C
receptor inverse agonists to indirectly modulate DA levels. Pimavanserin (31) (Figure 14), a
selective 5-HT2A receptor inverse agonist was found to have antipsychotic activity as well as a
better side effect profile than the other atypical and conventional agents in animal models
predictive of antipsychotic activity.94 Although clinical trials with pimavanserin (31) monotherapy
were disappointing, it is currently available for treating secondary psychosis associated with
Parkinsonism.90,95 The therapeutic potential of 5-HT2 receptor inverse agonists in treating
psychosis associated with Alzheimer’s disease is also being evaluated.96

29

Even though targeting a single receptor subtype may not be effective in treating disorders with
multiple etiologies such as schizophrenia, understanding the role of 5-HT receptor inverse agonism
might pave the way for development of novel agents.90

Figure 14. 5-HT2A receptor inverse agonists: M100907 (29) and pimavanserin (31), and the 5HT2C receptor inverse agonist: SB206553 (30).

iii. Dopamine stabilizing agents
DA stabilizing drugs are a novel therapeutic approach to reduce the side effects associated with
conventional antipsychotic agents.97 D2 receptor partial agonists represent one class of “DA
stabilizers”, and can reduce hyperdopaminergia in the mesolimbic area without producing a state
of hypodopaminergia in the nigrostriatal DA pathway, thus avoiding EPS, a troublesome side
effect that is associated with the first-generation antipsychotic agents that are D2 receptor
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antagonists.98 Aripiprazole (23) (Figure 12), a prototypical DA stabilizing agent that was approved
by the US FDA in the early 2000s for the treatment of schizophrenia, is a D2 receptor partial
agonist.77,99 It can reduce the hyperactivity of the dopaminergic system in a manner that is
dependent not only on its intrinsic efficacy but also on systems downstream of DA receptors, and
can also enhance dopaminergic activity in the mesocortical circuit, and improve the negative and
cognitive symptoms of schizophrenia.97,98 Besides D2 receptor partial agonist action, another
feature that makes aripiprazole (23) (Figure 12) unique, is its functional selectivity at the D2
receptor: it inhibits accumulation of cAMP and affects the release of arachidonic acid to a much
greater extent as compared to its ability to activate mitogen-activated protein kinases (MAPK).98–
101

Aripiprazole (23) regulates dopaminergic function based on the hypoactivity or hyperactivity

of the system, and based on the cellular environment of the receptor.98,99 An advantage of using
D2 receptor partial agonists is that they do not up-regulate the D2 receptors, a phenomenon that is
observed with long-term treatment with DA receptor antagonists99 Aripiprazole (23) also binds to
5-HT receptors (5-HT1A receptor partial agonist, 5-HT2A receptor antagonist), and this combined
with D2 receptor partial agonist action may be responsible for its therapeutic efficacy in
schizophrenia.99 Brexpiprazole (32) (Figure 15) is another D2, and 5-HT1A receptor partial agonist,
and a potent antagonist at 5-HT2A, α2A, and α2c receptors that was approved by the US FDA in
2015 for the treatment of schizophrenia.102
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Figure 15. Structure of the DA stabilizing agent brexpiprazole (32).

D2 receptor partial agonists such as aripiprazole (23) (Figure 12) are as efficacious as first-and
second-generation antipsychotic agents in terms of antipsychotic action, with the added advantages
of lower incidence of EPS, and reduced side effects such as hyperprolactinemia and weight gain.98

4. Serotonin receptors
Gaddum and Picarelli103 had initially classified the 5-HT receptors into two groups, the ‘D’- type
that was responsible for the contraction of smooth muscles, and the ‘M’- type that mediated
cholinergic nerve depolarization. The effects of 5-HT at the 5-HT-D receptor subtype could be
blocked by an irreversible antagonist phenoxybenzamine (33) (Figure 16) whereas the effects of
5-HT at the 5-HT-M receptor subtype could be blocked by morphine (34) or cocaine (35) (Figure
16).

Figure 16. Structures of phenoxybenzamine (33), morphine (34), and cocaine (35).
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In 1979, Peroutka and Snyder104 identified two distinct brain 5-HT binding sites and named them
5-HT1 and 5-HT2 receptors. 5-HT-D, and 5-HT-M receptors were renamed as 5-HT2 and 5-HT3
receptors, respectively. By the early 1990s, several 5-HT receptor sub-populations had been
identified, and cloned, and currently 5-HT receptors are classified into seven different families, 5HT1 through 5-HT7; except for the 5-HT3 receptor, which is a ligand-gated ion channel receptor,
all the others are type A or rhodopsin-like GPCRs. These receptors are further divided into subpopulations, and a total of 14 different 5-HT receptor sub-types have been described (Table 1).39

Table 1. Classification of 5-HT receptors (adapted from Glennon and Dukat39).

Populations and
subpopulations
(Currently
accepted name)

Second
messenger
system*

Comments

5-HT1
5-HT1A (5-HT1A)

AC(-)

Cloned and pharmacological
5-HT1A receptors.

5-HT1B (5-HT1B)

AC(-)

Rodent homolog of h5-HT1B receptors

5-HT1Bβ

A mouse homolog of 5-HT1B receptors

5-HT1D
5-HT1Dα

AC(-)

A cloned human 5-HT1D subpopulation
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(h5-HT1D)
5-HT1Dβ
(h5-HT1B)

AC(-)

5-HT1E

AC(-)

5-HT1Eα
5-HT1Eβ
(5-HT1F)
5-HT1F

AC(-)

A second cloned human 5-HT1D subpopulation;
human counterpart of rat 5-HT1B

An alternate name that has been used for cloned
human 5-HT1E receptors
A cloned mouse homolog of 5-HT1F receptors
A cloned human 5-HT1 receptor population

5-HT2
5-HT2 (5-HT2A)

PI

5-HT2F (5-HT2B)

PI

Original “5-HT2” (sometimes called 5-HT2α)
receptors
5-HT2-like receptors originally found in rat fundus

5-HT1C (5-HT2C)

PI

Originally described as 5-HT1C (5-HT2β) receptors

5-HT3

Ion channel

An ion channel receptor

5-HT4

AC (+)

5-HT4s

Short form of cloned 5-HT4 receptors

5-HT4L

Long form of cloned 5-HT4 receptors

5-HT4(b)-4(d)

Recently identified human 5-HT4 receptor isoforms

5-HT5

AC (-)105

5-HT5A

Cloned mouse, rat, and human 5-HT5 receptors

5-HT5B (5-HT5A)

Cloned mouse, and rat 5-HT5A-like receptor

5-HT6

AC (+)

Cloned rat and human 5-HT receptor

5-HT7

AC (+)

Cloned rat, mouse, guinea pig, and human 5-HT
receptors

*AC: adenylate cyclase; (-): negatively coupled; (+) positively coupled; PI: phospholipase
coupled.
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a. 5-HT2A Receptors
Branchek et al106 cloned the human 5-HT2A receptor in 1990. The 5-HT2A receptor plays a role in
maintaining normal physiological function, and is widely distributed in the CNS. The 5-HT2A
receptor has been mapped by receptor binding, autoradiography using radioligands such as
[3H]ketanserin (36), [3H]spiperone (37), [125I]1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane
(DOI) (38) (Figure 17), and [3H]M100907 (29) (Figure 14), in situ hybridization, and
immunocytochemistry. High densities of 5-HT2A receptors have been identified in forebrain
regions that include cortical areas such as the neocortex, claustrum, entorhinal and pyriform cortex,
and the olfactory tubercle, nucleus accumbens, caudate nucleus and hippocampus.107 The 5-HT2A
receptor is also expressed in C-fibers and dorsal root ganglia of the spinal cord, activation of these
receptors produces analgesia. Peripherally, 5-HT2A receptors have been identified on
cardiovascular-related tissues, where they modulate functions such as arterial vasoconstriction and
proliferation of arterial fibroblasts.105

Figure 17. Examples of radioligands used to label the 5-HT2A receptor.
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The 5-HT2A receptor is a class A GPCR that has seven transmembrane-spanning helices, an
intracellular C-terminus, and an extracellular N-terminus. The transmembrane (TM) domains are
connected via extracellular and intracellular loops. The intracellular loop between TM5 and TM6
is associated with coupling to second messenger systems (Figure 18). The orthosteric binding site
is located in the TM domain, and involves an aspartate moiety in TM3.39

Figure 18. Schematic representation of the 5-HT2A receptor. Transmembrane (TM) spanning
helices are numbered as TM1 to TM7 (adapted from Glennon and Dukat39).

5-HT2A receptors are coupled to Gαq, and activation of the receptor leads to hydrolysis of
membrane phosphoinositides by the activation of phospholipase C (PLC) resulting in diacyl
glycerol (DAG) and inositol phosphates; DAG activates other downstream effectors such as
protein kinase C, whereas inositol phosphates can result in an increase in intracellular Ca2+ levels,
which then activates inwardly rectifying chloride channels.39,105,107,108 Activation of the rho
signaling pathway regulates structural changes in cells.105
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Agonist action at 5-HT2 receptors might be involved in the action of classical hallucinogens such
as LSD (7) (Figure 2), and DOI (38) (Figure 17).109 There is a close correlation between the human
hallucinogenic potency of these agents and 5-HT2A receptor affinity, and 5-HT2A receptors might
play an important role in the behavioral effects of hallucinogenic agents.39,110 The 5-HT2A receptor
is an important target for antipsychotics, antidepressants, and anxiolytics.108 The role of 5-HT2A
receptors in antipsychotic drug action has evoked considerable interest based on the relationship
between 5-HT2A receptors, and hallucinogens, and the high affinity of atypical antipsychotic agents
such as clozapine (8) (Figure 2), olanzapine (21) (Figure 11), and risperidone (14) (Figure 8) for
5-HT2A receptors.107,108

5. Metabotropic glutamate receptors (mGluRs)
mGlu Receptors are class C GPCRs.111 There are eight different mGluR subtypes that are divided
into three groups, group I through group III, based on sequence homology, pharmacology, and
coupling mechanism.111 Group I consists of mGlu1 and mGlu5 receptors, group II includes mGlu2
and mGlu3 receptors, and Group III consists of mGlu4, mGlu6, mGlu7 and mGlu8 receptor
subtypes.111 Group I receptors couple to Gq/11 and activate phosphoinositide hydrolysis, while
group II and III couple to Gi/o and inhibit adenylyl cyclase.112 The sequence identity between
groups is ~45%, while the sequence identity among members of a group is ~70%. 113

Class C GPCRs differ from class A GPCRs in having a large extracellular N-terminal domain,
termed the venus flytrap domain that houses the orthosteric binding site.111,113 The venus flytrap
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domain is a clam-shaped structure composed of two lobes with the orthosteric binding site located
in between the two lobes.111,113 The extracellular domain is connected to the heptahelical
transmembrane domain via a cysteine rich domain.111,113 The cysteine-rich domain transmits
signals from the venus flytrap domain to the heptahelical transmembrane domain111,113 (Figure 19).
mGlu2/5 receptor PAMs, Group II orthosteric agonists have demonstrated antipsychotic activity in
preclinical models, and some have advanced into clinical trials.54,112

Figure 19. Schematic representation of an mGlu receptor. Transmembrane (TM) spanning helices
are numbered as TM1 to TM7 (adapted from Conn et al.113).

a. Group II mGlu receptors: mGlu2 and mGlu3 receptors
Group II mGlu receptors are widely expressed in the CNS with higher expression levels in brain
regions such as the prefrontal cortex, the thalamus, the hippocampus, the amygdala, and dorsal
and ventral striatum.23 These regions of the brain have been shown to be involved in cognition and
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emotional states, and the distribution of the mGlu3 receptor is more dispersed than that of the
mGlu2 receptor.23 mGlu2 receptors are found both presynaptically and postsynaptically while
mGlu3 receptors are mainly presynaptic.23 The mGlu2 receptors can function as autoreceptors that
serve as a negative feedback mechanism and suppress the excessive release of GLU, thus
maintaining homeostasis.23 Group II mGluRs can also modulate the release of other
neurotransmitters such as GABA, DA, 5-HT, and norepinephrine.114 They are coupled to Gi/o
proteins and mediate downstream effects via inhibition of adenylyl cyclase and modulation of
voltage-gated ion channels.23 They might also activate phosphoinositide-3 kinase (pI3K) and
MAPK pathways.23

There is a large body of evidence suggesting that activation of group II mGlu receptors, specifically
the mGlu2 receptor, might be a novel and promising approach to treat anxiety and
schizophrenia.23,115 Preclinical data with orthosteric group II mGlu receptor agonists has been
promising, and agents such as LY354740 (39), LY404039 (40), LY379268 (41) (Figure 20) have
been shown to possess antipsychotic action in animal models of schizophrenia.23 LY2140023 (42)
(Figure 20), an oral prodrug of the Group II mGlu2/3 orthosteric agonist LY404039 (40), entered
clinical trials; however, it was found to be no more efficacious than placebo in multiple
studies.23,116,117
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Figure 20. Group II mGlu receptor orthosteric agonists.

Studies with mGlu2- and mGlu3-receptor knock-out mice have suggested that the antipsychotic
effects mediated by group II mGlu orthosteric agonists might be due to its action at the mGlu2
receptors, rather than mGlu3 receptors.118 However, due to similarity and high homology between
the orthosteric binding sites of the mGlu2 receptor and mGlu3 receptor, there are no agents that are
selective for either subtype thus far.115 Orthosteric agonists have the disadvantages of nonselectivity and development of tolerance. mGlu2 receptor PAMS are an alternative strategy.112
Several mGlu receptor PAMs such as BINA (43), LY487379 (44), JNJ-40411813 (45), JNJ40068782 (46), CBiPES (47), and AZD8529 (48) (Figure 21) have demonstrated antipsychotic
activity in preclinical trials, with some of them such as JNJ-40411813 (45)119 and AZD8529 (48)120
having advanced into clinical trials.23
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Figure 21. mGlu2 receptor-selective PAMs.

6. Role of the 5-HT2A-mGlu2 receptor heteromer
Roles for the 5-HT2A receptor and the mGlu2 receptor in the pathophysiology of schizophrenia
have been well established.23,88 Several lines of evidence point towards the formation of a
functional 5-HT2A-mGlu2 receptor heterocomplex,18–21 that has been implicated in the mechanism
of action of both antipsychotic agents22 as well as hallucinogenic agents.20,121 Gonzalez-Maeso et
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al.18 and Moreno et al.20,121 have validated the necessity of a 5-HT2A/mGlu2 receptor
heterocomplex for the behavioral effects of hallucinogenic agents such as LSD (7) (Figure 2) and
DOI (38) (Figure 17). Additionally, Moreno et al.20 have also identified that three amino acid
residues Ala677, Ala681, and Ala685, located at the intracellular end of the TM4 of the mGlu2
receptor are important for formation of the heteromer. Fribourg et al.22 have demonstrated that the
high affinity 5-HT2A receptor atypical antipsychotic agents clozapine (8) (Figure 2) and risperidone
(14) (Figure 8) mediate their effects by binding to the 5-HT2A/mGlu2 receptor heteromer, which
then balances Gi/o and Gq/11 signaling. Gonzalez-Maeso et al.18 have demonstrated that the 5-HT2A
receptor is upregulated and the mGlu2 receptor is downregulated in postmortem brain samples of
untreated schizophrenic patients. These changes suggest that the 5-HT2A/mGlu2 receptor
heteromer may be involved in the altered cortical processes in schizophrenia, and represents an
attractive novel target for the treatment of schizophrenia.18
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III. SPECIFIC AIMS

In pursuit of new antipsychotic agents that cause reduced incidence of EPS than haloperidol (5)
(Figure 1), Dr. Paul Janssen, as reviewed by Awouters and Lewi,74 designed more compounds,
and based on their pharmacological properties and clinical information selected agents that were
better than haloperidol (5) (Figure 1). The goal was to synthesize an antipsychotic agent that had
an additional effect that could complement DA blocking activity.74 Central 5-HT2A receptor
blockade has been found to rectify and complement central D2 receptor antagonism, leading to
development of molecules such as risperidone (14) (Figure 8) that combine 5-HT2A and D2
receptor antagonism in one molecule.15,122 Some of the earlier butyrophenone analogs such as
pipamperone (49) (Figure 22) did possess serotonin activity (strong tryptamine antagonism),74,123
however, this effect was overlooked since the clinical implications of serotonin in schizophrenia
were not clear at that time.74 Pipamperone (49) had efficacy in treating the negative symptoms of
schizophrenia, and had resocializing effects.74,124 However, the relationship between 5-HT
antagonism and amelioration of negative symptoms of schizophrenia had not been established at
that time.74 The pharmacological and clinical profiles of pipamperone (49) were quite distinctly
different from that of haloperidol (5) (Figure 1).74,122,125 Risperidone (14) (Figure 8), a prototypical
SDA, was found to have a pharmacological profile very similar to that of pipamperone (49) (Ki =
1 nM (5-HT2A receptor), Ki = 98 nM (D2 receptor)), with serotonin receptor antagonism preceding
D2 receptor occupancy,14 and with risperidone (14) (Figure 8) (Ki = 0.16 nM (5-HT2A receptor), Ki
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= 3.1 nM (D2 receptor) being more potent.15 Risperidone (14) is effective in treating the positive
and negative symptoms of schizophrenia, and has a lower propensity to cause EPS.14 Moderate D2
receptor occupancy, predominantly 5-HT2A receptor occupancy, and the avoidance of D2 receptor
over blockade, might be the mechanism for its effectiveness against the positive, and negative
symptoms of schizophrenia, with reduced side effects.14 There has been marked progress from
pipamperone (49) to risperidone (14), with a hundred-fold reduction in dosing.74

Figure 22. Structure of the butyrophenone analog pipamperone (49).

The pharmacological differences between haloperidol (5) (Figure 1) and pipamperone (49), and
the chemical structures of benperidol (50) and lenperone (51) (Figure 23), led to the development
of risperidone (14) (Figure 23).15

Benperidol (50) and lenperone (51) are butyrophenone analogs that bind to D2 receptors.15 The
butyrophenone moiety is common to both molecules, and since they both bind to D2 receptors
(Table 2), it was hypothesized that the benzimidazolone fragment of benperidol (50) and the
benzoyl fragment of lenperone (51) had pharmacophoric similarity.15 Lenperone (51) can be
considered to be an almost symmetrical molecule that has two aromatic regions at a distance of
four carbon atoms from the central nitrogen atom, with the only difference being the cyclic form
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of the chain in the 4-benzoylpiperidine fragment.15 Hence the open form of the benzimidiazolone
fragment of benperidol (50) might have potential activity like the open form of the 4benzoylpiperidine fragment (butyrophenone fragment) of lenperone (51).15 Declenperone (52)
and milenperone (53) (Figure 23) were a result of combining fragments of benperidol (50) and
lenperone (51).15 Declenperone (52) and milenperone (53) were both centrally active and potent
DA antagonists, and weak 5-HT antagonists, (Table 2) with milenperone (53) being more potent
than declenperone (52).15 However, milenperone (53) was no more efficacious than haloperidol
(5) (Figure 1) in clinical trials.15

Expansion of the five membered imidazolone ring to a larger ring system that retained the urea
moiety, and four atoms between the aromatic ring and central nitrogen atom, resulted in ketanserin
(36) (Figure 23), a molecule that possessed 100-fold higher affinity for 5-HT2A receptors as
compared to D2 receptors.15 Ketanserin (36) is a potent peripheral 5-HT2A receptor antagonist, and
an α1-adrenoceptor antagonist at higher doses.15 Ketanserin (36) is therapeutically useful as an
antihypertensive agent.15

Chemical modification of the quinazolinedione ring of ketanserin (36) led to pirenperone (54) and
setoperone (55) (Figure 23).15 Both these agents were centrally active D2 receptor, and 5-HT2A
receptor antagonists with a higher affinity for 5-HT2A receptors (Table 2).15 Setoperone (55)
showed antipsychotic potential in preclinical studies,126 however, it had limited bioavailability due
to enzymatic reduction of the keto functionality to an inactive alcohol, and hence was not pursued
further.15 Bioisosteric replacement (to avoid metabolism) of the 4-fluorobenzoyl moiety with 6-
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fluorobenzisoxazole resulted in risperidone (14) (Figure 23).15 Risperidone (14) was a potent and
centrally active D2 and 5-HT2A receptor antagonist, with higher affinity for 5-HT2A receptors
(Table 2), and good bioavailability.15 Risperidone (14) also antagonizes the α1-adrenoceptors (Ki
= 2.4 nM), and histamine H1 receptors.(Ki = 2.1 nM).15,127 Paliperidone (56) (Figure 23), an active
metabolite of risperidone, has a pharmacological profile (Table 2) similar to that of risperidone
(14).15,128–130
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Figure 23. Development of risperidone.15
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Table 2. Activity profile of risperidone and other analogs (adapted from Megens and Kennis15).
Compound

Binding affinity*
Ki (nM)
5-HT2A

Functional activity**
ED50 (mg/kg)

Benperidol (50)

D2
0.35

Apomorphine
0.0093

6.6

Lenperone (51)

4.6

Not tested

0.085

0.39

Declenperone (52)

9.3

2.4

0.44

2.4

Milenperone (53)

3.9

9.2

0.025

0.51

> 40

Tryptamine
0.29

Ketanserin (36)

220

2.1

2.4

Pirenperone (54)

16

2.1

0.098

0.11

Setoperone (55)

24

2.3

0.22

0.11

Risperidone (14)

3.1

0.16

0.15

0.13

Paliperidone (56)
4.1
0.22
0.39
0.22
*Radioligand: [3H]spiperone (37) (Figure 17).
**ED50 for antagonism of apomorphine-, and tryptamine-induced behavioral effects in the
apomorphine- tryptamine- and norepinephrine-interaction test in rats.

The pharmacological profile of risperidone (14) has been compared to that of haloperidol (5), a D2
receptor antagonist, and ritanserin (28) a selective 5-HT2A receptor antagonist.122 Similar to
ritanserin (28), risperidone (14) showed activity in tests related to central and peripheral 5-HT2A
receptor antagonism such as a reduction in central serotonergic over activity induced by agents
such as 5-hydroxytryptophan, mescaline or tryptamine at doses of 0.014-0.049 mg/kg, and is a
more potent 5-HT2A receptor antagonist than ritanserin (28).122 Similar to haloperidol (5),
risperidone (14) inhibits the central and peripheral expression of hyperdopaminergia.122 It inhibits
behavioral reactions linked to normal dopaminergic function such as conditioned responses, and
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ICS; additionally, it inhibits central hyperdopamaninergia produced by dopaminomimetic agents
such as amphetamine, cocaine, and apomorphine at doses of 0.016-0.16 mg/kg.122

Ritanserin (28) when given as an additional therapy with a typical antipsychotic agent can help
decrease EPS, and cause an improvement in the negative and affective symptoms of
schizophrenia.122,131,132 The effects of haloperidol (5) include antimanic, antihallucinatory, and
antidelusional actions, with the possibility of EPS at higher doses.122 Hence, since risperidone is
an SDA, it should be able to produce clinical effects of both ritanserin (28) and haloperidol (5)
(Figure 1).122 However, the haloperidol-like antidopaminergic effects can be modified with greater
5-HT2A receptor blockade.122 Induction of catalepsy and inhibition of locomotor activity by
haloperidol (5) was seen at the doses used to inhibit evoked responses, while much larger doses of
risperidone were required to inhibit locomotor activity and induce catalepsy.122 Risperidone differs
from haloperidol (5) and ritanserin (28) in being able to antagonize LSD in drug discrimination
studies, an effect that is common to SDAs, and thought to be a result of simultaneous 5-HT2 and
D2 receptor antagonism.122 Ritanserin (28) (Figure 13) is a poor blocker of the LSD cue,133,134
while haloperidol (5) reduces response rates without affecting the discriminative stimulus.122
Hence, in spite of being able to antagonize 5-HT2A and D2 receptors, it has a pharmacological
profile that is different from that of ritanserin (28) and the typical antipsychotic agent haloperidol
(5).
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Studies have suggested that risperidone (14) is an inverse agonist at 5-HT2A receptors.135,136
Risperidone has structural features that make it unique and distinguish it from structurally-related
compounds such as ketanserin (36) (Figure 17).

Risperidone is used as monotherapy for schizophrenia, as well as an adjunct therapy to lithium or
valproate to treat acute manic episodes, and for the maintenance treatment of bipolar disorder I.16
Even though risperidone has a much lower tendency to cause EPS than typical antipsychotic
agents, therapy with risperidone is associated with side effects such as hyperprolactinemia, weight
gain, and metabolic disorders such as glucose dysregulation,13,16,17 and there is a need for newer
antipsychotic agents with fewer side effects.

Goals of this project are to study the structural features of risperidone (14) (Figure 8), and
determine the minimal structural features required for 5-HT2A receptor antagonist activity, and to
identify an mGlu2 receptor PAM from known mGlu2 receptor PAMs, that will contribute towards
the long-term goal of synthesizing a bivalent molecule that can target the mGlu2/5-HT2A receptor
heteromer.

The specific aims of the current project are:
1.

Deconstruction of risperidone to determine the minimal structural features
responsible for its 5-HT2A receptor antagonist activity
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2.

Elaboration of risperidone to investigate the role of the two halves of risperidone in
its 5-HT2A receptor antagonist activity
a. Investigation of the potential role of the two halves of risperidone in its activity by
examination of structural hybrids of risperidone and ketanserin.
b. Investigation of the potential role of the “right half “(i.e., the 6-fluoro-3-(4piperidinyl)-1,2-benz[d]isoxazole portion) of risperidone in its activity by making
the right half of risperidone similar to serotonin.
c. Aromatization of the “left half” (i.e., the 2-methyl-6,7,8,9-tetrahydro-4Hpyrido[1,2-a]pyrimidin-4-one portion) of risperidone.
d. Investigation of the role of the “left half” (i.e., the 2-methyl-6,7,8,9-tetrahydro4H-pyrido[1,2-a]pyrimidin-4-one portion) of risperidone by making the “left
half” of risperidone similar to other antipsychotic agents such as iloperidone.

3. Molecular modeling studies of risperidone and its deconstructed and elaborated
analogs at 5-HT2A receptors to study their binding mode

4. mGlu2 receptor PAMs
a. Molecular modeling studies of the allosteric site of the mGlu2 receptor to determine
whether structurally diverse PAMs of the mGlu2 bind in a similar manner and in the
same binding pocket.
b. Synthesis of the mGlu2 receptor PAM JNJ-40411813.
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5. Redefining a pharmacophore for 5-HT2A receptor antagonists.
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IV. APPROACH, RESULTS AND DISCUSSION

A. Specific Aim 1: Deconstruction of risperidone to determine the minimal structural
features responsible for its 5-HT2A receptor antagonist activity
1. Approach
To study the structure-activity relationships (SAR) of risperidone at 5-HT2A receptors and to
possibly identify a 5-HT2A receptor antagonist pharmacophore a “deconstruction-reconstructionelaboration” approach was used.137 The "deconstruction-reconstruction-elaboration" approach
involves assigning an arbitrary core to a given agent, and removing one structural feature at a
time.137 Biological activity of the deconstructed analogs will enable us to “reconstruct” analogs
incorporating only those structural features contributing to activity.137 The “elaboration” phase
involves further exploration of various substituents and functional groups.137

Risperidone (14) (Figure 24) can be divided into two halves consisting of the 2-methyl-6,7,8,9tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one portion (hereafter referred to as the “left half”) and
the 6-fluoro-3-(4-piperidinyl)-1,2-benz[d]isoxazole portion (hereafter referred to as the “right
half”) connected by an ethyl linker.
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Risperidone (14) (Figure 24) was systematically deconstructed into truncated analogs 57-68
(Figure 24) to study the structural features necessary to retain 5-HT2A receptor affinity and (where
applicable) antagonist activity.

Analogs 57-59 represent deconstructed analogs where the benz[d]isoxazole portion of risperidone
(14) (the “right half”) was removed and the “left half” of risperidone (14) was further
deconstructed. Analogs 60-63 will examine the “right half” of risperidone (14), whereas analogs
64-68 will help examine other whole-molecule features.

A “deconstruction-reconstruction-elaboration” approach was used by our group138 to study the
SAR of ketanserin (36) (Figure 25), a molecule that bears structural resemblance to risperidone
(14) (Figure 25), at 5-HT2A and 5-HT2C receptors. The structural analogs of ketanserin (36) were
tested for binding affinity at 5-HT2A and 5-HT2C receptors in frontal brain cortical regions of
Sprague-Dawley rats using 3[H]ketanserin as the radioligand.138 Figures 25 and 26 illustrate a
comparison of the deconstruction of risperidone (14) with the deconstruction of ketanserin (36)
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Figure 24. Deconstructed analogs of risperidone (14).
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Figure 25. A comparison of the deconstruction of risperidone (14) with the deconstruction of
ketanserin (36). Data for ketanserin analogs are from Herndon et al.138
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Figure 26. A comparison of the deconstruction of risperidone (14) with the deconstruction of
ketanserin (36). Data for ketanserin analogs are from Herndon et al.138

Analog 57 (Figure 24) lacks the 6-fluoro-1,2-benz[d]isoxazole portion (the “right half”) and will
help establish the contribution of the “left half” of risperidone (14) towards 5-HT2A receptor
affinity and antagonist activity of risperidone (14). In analogs 58 and 59 (Figure 24), the piperidine
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ring has been deconstructed into a simpler tertiary amine and then an even simpler primary amine,
and will additionally help ascertain the role of the piperidine ring, as well as the nature of the amine
in binding. A comparison of analog 57 with 58 will additionally help understand the importance
of a constrained ring system. Analog 59 represents the “left half” of risperidone with the linker
and the amine portion of the “right half”. The amine has been retained because the protonated
amine of orthosteric agonists and antagonists of the 5-HT2A receptor is involved in a crucial ionic
interaction with an aspartate moiety (Asp 155) in TM3.139 Herndon et al.138 had deconstructed
ketanserin in an analogous manner (analogs 69-71) and the deconstructed analogs lacked affinity
for 5-HT2A receptors. If analogs 57-59 bind in a manner similar to analogs 69-71, they should also
lack affinity for 5-HT2A receptors. If they bind with higher affinity it will indicate that the “left
half” of risperidone (14) contributes to a greater extent to its binding affinity as compared to the
“left half” of ketanserin (36).

Analog 60 (Figure 24) represents the “right half” of risperidone (14) and retains a part of the linker
in the form of a methyl group, and will help study the importance of the “right half” of risperidone
in its 5-HT2A receptor affinity and antagonist activity. Deconstructed analog 61 (Figure 24)
represents the desmethyl analog of 60, whereas analogs 62 and 63 (Figure 24) represent the
desfluoro analogs of 60 and 61, respectively. Analog 61 has been shown to be a 5-HT2A receptor
antagonist previously by our laboratory.140 In the prior study, the radioligand binding assay was
performed in rat brain homogenates using [3H]ketanserin as the radioligand and analog 61 was
found to bind at 5-HT2A receptors with only 16 fold lower affinity than risperidone (14). It was
shown to be a potent 5-HT2A receptor antagonist in an in vitro assay that measures serotonin
58

induced inositol phosphate production, as well as in an in vivo assay. The in vivo assay was
performed in rats that could discriminate 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (a
5-HT2 receptor agonist) from vehicle. Our laboratory has recently reported that analogs 60 (Ki =
12.27 nM) and 61 (Ki = 71.41 nM) both bind to 5-HT2A receptors and are 5-HT2A receptor
antagonists (discussed in the results section).141 In fact, analog 60 (Ki = 12.27 nM) binds with only
~ 2 fold lower affinity than risperidone (14; Ki = 5.29 nM).141 Herndon et al.138 had tested the “right
halves” of ketanserin (analogs 72 and 73) and they demonstrated a decrease in affinity for the 5HT2A receptors as compared to ketanserin (36).138 Analogs 62 and 63 will help establish the
importance of the fluoro group for 5-HT2A receptor affinity and antagonism.

Deconstructed analog 64 (Figure 24) retains only the 6-methyl-3H-pyrimidin-4-one portion of the
“left half” of risperidone (14), whereas in abbreviated analogs 65-68 (Figure 24) the 6-methyl-3Hpyrimidin-4-one ring system has been deconstructed and will help ascertain the role of the “left
half” of risperidone (14) in its 5-HT2A receptor antagonist activity. Analog 65 retains the amide
portion of the 6-methylpyrimidin-4(3H)-one ring system. In analog 66 the carbonyl group present
in analog 65 has been removed, whereas in analog 67 the amide nitrogen of 65 has been replaced
by a methylene group. Deconstructed analog 68 represents the descarbonyl analog of 67.
Analogous deconstruction of ketanserin (36) resulted in molecules (75-77) that bind to 5-HT2A
receptors with high affinity.138 Our laboratory has recently reported that analogs 65 (Ki = 39.81
nM) and 66 (Ki = 34.83 nM) bind with high affinity to 5-HT2A receptors and are 5-HT2A receptor
antagonists (discussed in the results section).141
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2. Results
A. Chemistry
The synthesis of compound 57 was initially attempted as outlined in Scheme 1 via a nucleophilic
substitution reaction. Piperidine was alkylated with the primary alkyl halide 78 in DMF in the
presence of K2CO3. K2CO3 was added to neutralize the HCl that is formed as a by-product of the
reaction. However, the reaction did not progress, and analog 57 was ultimately synthesized using
a Finkelstein reaction (Scheme 1- ii and iii). The Finkelstein reaction is a nucleophilic substitution
reaction. A small amount of KI is added to the reaction mixture to facilitate halide exchange
between the chloride of the alkyl chloride and the iodide of the KI. Synthesis of compound 57 was
attempted in two solvents- DMF and MeCN. When MeCN was used as a solvent for the reaction,
the yield was comparatively higher (yield: 20%) as compared to when DMF was used as a solvent
(yield: 12%). Reported literature suggests that solvents such as i-PrOH and MeCN work better
than DMF.142 Compound 57 was unknown and was characterized by NMR and elemental analysis
for C, H and N.

Scheme 1. Synthesis of compound 57.a

a

Reagents and conditions: (i) piperidine, K2CO3, DMF, reflux, 17 h; (ii) (a) piperidine, K2CO3,
KI, DMF, reflux, 17 h; (b) EtOH, HCl/EtOH; (iii) (a) piperidine, K2CO3, KI, MeCN, reflux, 17
h; (b) EtOH, HCl/ EtOH.
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Compound 58 was synthesized in a manner analogous to compound 57, and the synthesis is
outlined in Scheme 2. Analog 58 was synthesized by a Finkelstein reaction between 3-(2chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one

(78)

and

dimethylamine in the presence of K2CO3 and KI (catalytic amount) in MeCN. Compound 58 was
unknown and was characterized by NMR and elemental analysis for C, H and N.

Scheme 2. Synthesis of compound 58.a

a

Reagents and conditions: (i) (a) N,N-dimethylamine (2 M solution in MeOH), K2CO3, KI, MeCN,
reflux, 30 h; (b) CHCl3, (COOH)2/Et2O.

Compound 59 was synthesized using a Gabriel synthesis reaction (Scheme 3). The Gabriel
synthesis is a nucleophilic substitution reaction that utilizes potassium phthalimide as an
-NH2 synthon. The primary alky halide 78 was allowed to react with potassium phthalimide to
yield intermediate 79 that was subsequently converted to compound 59 by hydrazine hydrate.
Compound 59 was unknown and was characterized by NMR and elemental analysis for C, H and
N.
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Scheme 3. Synthesis of compound 59.a

a

Reagents and conditions: (i) Potassium phthalimide, DMF, 22h, reflux; (ii) (a) hydrazine hydrate,
EtOH, reflux, 4h; (b) 1 N HCl, reflux, 5 min; (c) EtOH, HCl/EtOH.

The Gabriel synthesis was used to synthesize analog 59 as opposed to the direct alkylation of
ammonia, since alkylation of ammonia is often unselective with poor yields, and can result in a
mixture of primary, secondary, tertiary, and quarternary amines.

Compounds 60-63 were synthesized by Dr. Supriya A. Gaitonde, who was a graduate student in
the Dukat and Glennon laboratory, and their syntheses are outlined in Schemes 4 (60, 61) and 5
(62, 63).143

62

Scheme 4. Synthesis of compounds 60 and 61.a

a

Reagents and conditions: (i) (a)HCOOH, Ac2O, 65 ºC, 1 h; (b) room temperature, 16 h; (ii) SOCl2,
DMF, room temperature, 6 h; (b) 1,3-difluorobenzene, AlCl3, reflux, 45 h; (iii) NH2OH•HCl,
NaOH/H2O, EtOH, reflux, 96 h; (iv) (a) NaH, DMF, room temperature, 48 h; (v) (a) conc. HCl,
EtOH, reflux 3 h; (b) room temperature, 48 h; (vi) (a) HCOOH, HCHO, reflux, 10 h; (b) HCl/Et2O.
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Scheme 5. Synthesis of compounds 62 and 63.a

a

Reagents and conditions: (i) (a) 4-Chloro-N-methylpiperidine, THF, Mg, bromoethane, reflux,
1h; (b) room temperature, 2-fluorobenzonitrile, reflux, 3 h; (c) room temperature, 36 h; (d) NH4Cl,
50 ºC, 2 h; (e) HCl/Et2O; (ii) (a) KOH (85%), hydroxylamine hydrochloride, ethoxyethanol, reflux,
6 h; (b) HCl/Et2O (iii) (a) NaOH, toluene, phenyl chloroformate, reflux, 24 h; (b) petroleum ether;
(iv) (a) KOH (85%), EtOH, reflux, 48 h; (b) HCl/Et2O.

The synthesis of analog 64 is outlined in Scheme 6.
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Scheme 6. Synthesis of compound 64.a

a

Reagents and conditions. (i) (a) EtONa, EtOH, room temperature, 0.5 h; (b) 2-bromoethyl ether,
reflux, 18 h; (ii) thiourea, EtONa, EtOH, reflux, 4 h. (iii) NiCl2, NaBH4, MeOH, room temperature,
0.5 h; (iv) conc. HCl, 150 ºC, 3 h; (v) (a) 6-fluoro-3-(4-piperidinyl)benz[d]isoxazole, K2CO3, KI,
DMF, 134 °C, 18 h; (b) CHCl3, (COOH)2/Et2O.

Intermediate 89 was synthesized from ethyl acetoacetate (88). Intermediate 89 has been reported
in the literature,144 however, the procedure was modified. The literature procedure generates
sodium ethoxide in situ from sodium metal and EtOH. For the purpose of this reaction,
commercially available sodium ethoxide, available in the laboratory, was used instead. Ethyl
acetoacetate (88) was allowed to stir with sodium ethoxide for 0.5 h to generate a carbanion, and
was followed by the addition of 2-bromoethyl ether to ultimately yield intermediate 89.
Intermediate 89 was cyclized with thiourea to yield intermediate 90. Intermediate 90 is a known
compound;145 however, here, it was synthesized using a literature procedure for a similar
compound146 so as to avoid the in situ generation of sodim ethoxide. Reductive desulfurization of
intermediate 90 yielded the substituted pyrimidone 91. Intermediate 91 has been reported in the
literature,145 however, the procedure necessitates the use of reagents such as lead acetate, hydrogen
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peroxide as well as hydrogen sulfide that are potentially toxic. Hence, a different procedure that
has been reported for the synthesis of quinazolin-4(3H)-ones and 2,3-dihydro-4(1H)quinazolinones,147 that are structurally similar to intermediate 91, was used and resulted in good
yields. The reaction uses relatively milder conditions, has higher selectivity, and is relatively
cleaner.147 The reaction involves the slow addition of sodium borohydride to a solution of
intermediate 90 and nickel chloride that results in the in situ generation of nickel boride.147 Nickel
boride is responsible for the reductive desulfurization reaction.147 It has been hypothesized by
Khurana and Kukreja,147 that the reaction mechanism might involve hydrogenolysis of the CHSH bond that has been obtained from the reduction of the C=S bond, and that there is no formation
of colloidal sulfur. The nickel boride needs to be formed in situ since preformed nickel boride
loses its activity.147 However, the reaction could potentially result in a mixture of intermediate 91
and its reduced form 93 (Figure 27) (a second product was noted on TLC but was not isolated),
and this was circumvented by optimizing the conditions and using a specific molar ratio of
substrate: nickel chloride: sodium borohydride. The use of a 1:3:9 molar ratio of substrate: nickel
chloride: sodium borohydride147 yielded only intermediate 91, and the time was optimized to 0.5
h. However, the work-up presented a problem due to low solubility of product 91, in multiple
solvents such as dichloromethane, chloroform, and ethyl acetate, and a modified work-up
procedure was explored. Intermediate 92 was synthesized according to a literature procedure145 by
heating intermediate 91 in a sealed tube with conc. HCl. The hydrochloride salt of intermediate 92
is known,145 however, it was extremely hygroscopic and, hence, the free base was synthesized.
Analog 64 was synthesized using a Finkelstein reaction. The yields of the reaction were poor (5%)

66

but most of the unreacted starting material was recovered and could be re-used. Compound 64 was
unknown and was characterized by NMR and elemental analysis for C, H and N.

Figure 27. Reduced form of intermediate 91.

Compounds 65 and 66 were synthesized by Dr. Supriya A. Gaitonde, and it might be noted that
we, both, were working on similar projects, to a common goal, and the synthesis is illustrated in
Scheme 7.143
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Scheme 7. Synthesis of compounds 65 and 66.a

a

Reagents and conditions. (i) 4-Chlorobutyryl chloride, Et3N, CH2Cl2, room temperature, 75 h;
(ii) 6-fluoro-3-(4-piperidinyl)benz[d]isoxazole, K2CO3, KI, MeCN, 88 ºC, 16 h; (iii) (a)
BH3.THF, reflux, 2 h; (b) 6N HCl, reflux, 1 h.

The synthesis of analogs 67 and 68 is described in Scheme 8. The synthesis of analog 67 and 68
was initially attempted via common intermediate 98. Intermediate 97 was synthesized using a
Grignard reaction. The Grignard reagent was synthesized in situ by reacting freshly distilled
cyclohexylbromide with magnesium, and was subsequently reacted with cyclobutanone.
Intermediate 97 is known and was synthesized using a literature procedure.148,149 Intermediate 98
is also known and was synthesized by a literature procedure.150 Phenyliodine diacetate might be
playing a role by forming a complex with intermediate 97, leading to C-C bond cleavage and the
generation of a cation, followed by nucleophilic addition of H2O.150 The purpose of the 1,1,1,3,3,3hexafluoro-2-propanol is to stabilize the cationic intermediate.150 Intermediate 99 was synthesized
by tosylating intermediate 98. Synthesis of analog 67 was attempted via a nucleophilic substitution
reaction, however the reaction led to multiple side-products and analog 67 could not be isolated.
The synthesis of analog 67 was abandoned.
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The carbonyl group of intermediate 98 was reduced using a Wolff-Kishner reduction to yield
intermediate 100. Intermediate 100 was also synthesized via the reduction of 4-cyclohexylbutanoic
acid (101) using LiAlH4. Intermediate 100 was known151 and was synthesized via a procedure for
a similar compound.152 Tosylation of 100 resulted in known intermediate 102,151 and,
subsequently, analog 68 was synthesized via a nucleophilic substitution reaction between 102 and
6-fluoro-3-(4-piperidinyl)benz[d]isoxazole (61). Compound 68 was unknown and was
characterized by NMR and elemental analysis for C, H and N.
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Scheme 8. Synthesis of compounds 67 and 68.a

a

Reagents and conditions: (i) (a) Magnesium turnings, iodine, Et2O, 40 °C, 2h; (b) cyclobutanone,
room temperature, 4 h; (ii) phenyliodine diacetate, 1,1,1,3,3,3-hexafluoro-2-propanol, H2O, room
temperature, 15 min; (iii) tosyl chloride, Et3N, CH2Cl2, room temperature, 48 h; (iv) 6-fluoro-3-(4piperidinyl)benz[d]isoxazole, K2CO3, MeCN, 80 ºC, 18 h; (v) (a) Hydrazine hydrate, KOH,
diethylene glycol, 135 °C, 2 h; (b) 200 ºC, 6 h; (vi) LiAlH4, THF, room temperature, 6 h; (vii) tosyl
chloride, Et3N, CH2Cl2, room temperature, 48 h; (viii) (a) 6-fluoro-3-(4piperidinyl)benz[d]isoxazole , K2CO3, MeCN, 80 ºC, 96 h; (b) EtOH, HCl/EtOH.

B. Radioligand binding studies
Radioligand binding studies of the compounds were performed in HEK 293 cells expressing 5HT2A receptors. [3H]Ketanserin ([3H]36) (Figure 17) was used as the radioligand, and non-specific
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binding was determined in the presence of methysergide. Competition curves were generated and
analyzed by nonlinear regression to determine the binding affinities (Ki values) of the compounds.

The binding affinities of risperidone (14) and the compounds 57, 60, 61, 62, 63, 65, and 66 for 5HT2A receptors were found to be 5.29 nM (log Ki = -8.27 ± 0.06), 2732 nM ( n = 1, performed in
duplicate), 12.27 nM (log Ki = -7.91 ± 0.1), 71.41 nM (log Ki = -7.14 ± 0.09), 307.7 nM (n = 1;
performed in duplicate), 198.9 nM (n = 1; performed in duplicate), 39.81 (log Ki = -7.40± 0.11),
34.83 nM (log Ki = -7.45 ± 0.12), respectively. The displacement curves for compounds 57, 62
and 63 are shown in Figure 28.
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Figure 28. Ketanserin competition binding curves of deconstructed analogs 57, 62, and 63 in HEK
293 cell membrane preparations expressing 5-HT2A receptors (n = 1, performed in duplicate).

C. Functional activity studies
Functional activity studies of risperidone (14), and the deconstructed analogs 60, 61, 65, and 66
were conducted in Dr. Diomedes Logothetis’s laboratory and have already been published.141

Risperidone (14), and compounds 60, 61, 65, and 66, were initially tested in a two-electrode
voltage-clamp (TEVC) electrophysiological assay that utilized a Xenopus laevis oocyte
heterologous expression system that expresses 5-HT2A receptors and the G protein-gated inwardly
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rectifying K+ channel (GIRK4*) that serves as a sensitive reporter for GPCR activity.141 However,
the ability of the compounds to directly inhibit the GIRK4* channel at higher concentrations (10
µM) for analogs 60, 61, and 65 limited their full characterization.141 Analog 66 inhibited the
GIRK4* channel at concentrations as low as 5 µM, and its actions could not be characterized.141
The assay indicated that analogs 60, 61 and 65 are 5-HT2A receptor antagonists, however, to fully
characterize them, a complementary epifluorescence assay in HEK 293 cells expressing 5-HT2A
receptors that utilizes the Fura-2 dye to detect changes in intracellular Ca2+ concentrations was
used.141 The IC50 values in order of decreasing potency were as follows: risperidone (14) (IC50 =
5.59 ± 1.41 µM), analog 60 (IC50 = 7.40 ± 1.45 µM), analog 65 (IC50 = 16.65 ± 1.39 µM), analog
61 (IC50 = 20.12 ± 2.24 µM), and analog 66 (IC50 43.88 ± 1.47 µM).141

Additionally, analog 61 was able to crosstalk at the 5-HT2A/mGlu2 heteromer (Figure 29), whereas
analogs 60, 65, and 66 were unable to exert this effect.

Figure 29. The crosstalk exhibited by analog 61 in the 5-HT2A/mGlu2 heteromeric receptor
system (figure provided by Jason Younkin).
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3. Discussion
Deconstruction studies of risperidone (14) suggest that the entire structure of risperidone (14) is
not needed for 5-HT2A receptor affinity or antagonist activity. Analog 60, that bears only half the
structural features of risperidone (14), binds with only ~2-fold lower affinity than risperidone (14)
and is nearly equipotent as a 5-HT2A receptor antagonist as compared to risperidone (14).
Additionally, the other structurally abbreviated analogs (61, 62, 63, 65, and 66) of risperidone (14),
bind with nanomolar affinity and retain 5-HT2A receptor antagonist activity.

Analog 61, the desmethyl analog of 60, binds with ~6-fold lower affinity at 5-HT2A receptors than
analog 60, suggesting that the methyl group makes additional interactions at the receptor.

Analogs 62 and 63 represent desfluoro analogs of 60 and 61, respectively. Preliminary data suggest
that analogs 62 and 63 bind with ~24- and ~3-fold lower affinity than analogs 60 and 61, indicating
additional interactions by the fluoro group at the receptor. Analog 63 binds with similar affinity as
analog 62, suggesting that the methyl group might not be making favorable interactions at the
receptor, and that analogs 60 and 61 might be binding differently as compared to analogs 62 and
63. However, additional replications are required to confirm the present results.

Analog 66 is the descarbonyl analog of 65. Both bind with comparable affinities at 5-HT2A
receptors, suggesting that the carbonyl group may not be an important structural requirement for
binding affinity. However, the descarbonyl analog is ~2.5-fold less potent as a 5-HT2A receptor
antagonist as compared to analog 65, suggesting that the carbonyl group might be contributing.
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Even though this difference is very small it is statistically significant. (Unpaired t test; P- value =
0.0027; α = 0.05).

The “right half” of risperidone (14) seems be important for high binding affinity, since the “right
half” of risperidone (14) i.e. analog 61 binds with ~13-fold lower affinity than risperidone (14),
whereas, the “left half” of risperidone (14) i.e. analog 57 binds with ~500-fold lower affinity than
risperidone (14). These and other studies previously conducted in our laboratory on analog 61,140
suggest that the “right-half” portion of risperidone (14) is more important than the “left-half”
portion of risperidone (14). However, the “left-half” portion of risperidone (14) seems to contribute
to binding.
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B. Specific Aim 2: Elaboration of risperidone to investigate the role of the two halves of
risperidone in its 5-HT2A receptor antagonist activity
1. Approach
Elaboration is a part of the “deconstruction-reconstruction-elaboration” approach that is
commonly used to study SAR.137 It involves modifying certain structural features one at a time. In
this study, elaboration was used to investigate the roles of the “right” (i.e., the 6-fluoro-3-(4piperidinyl)-1,2-benz[d]isoxazole portion) and “left” (i.e., the 2-methyl-6,7,8,9-tetrahydro-4Hpyrido[1,2-a]pyrimidin-4-one portion) halves of risperidone in their contribution to its 5-HT2A
receptor affinity and/or antagonist activity.

a. Investigation of the potential role of the two halves of risperidone in its activity by
examination of structural hybrids of risperidone and ketanserin
Ketanserin (36) (Figure 30) is a prototypical, and the first identified, 5-HT2A receptor antagonist
that has high affinity for 5-HT2A receptors (Ki = 19 nM). The structure of ketanserin (36) (Figure
30) can be divided into two halves in a manner analogous to that of risperidone (14) (Figure 30;
see also, Figure 25), consisting of the 4-(4-fluorobenzoyl)piperidine ring system (right half) and
the 2,4-(1H,3H)-quinazolinedione ring (“left half”) connected by an ethyl linker.

The structures of ketanserin (36) and risperidone (14) possess some structural similarities as well
as some structural differences. In fact, the “right halves” of ketanserin (36), [4-(4fluorobenzoyl)piperidine], and risperidone (14), [6-fluoro-3-(4-piperidinyl)-1,2-benz[d]isoxazole,
are considered as being bioisosteres.153 Previous studies by our laboratory have shown that the
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right halves of ketanserin (36), analogs 72 and 73 (Ki = 125 nM and 430 nM, respectively) bind to
5-HT2A receptors with ~35- and ~123-fold lower affinity than ketanserin (36) (Ki = 3.5 nM)
(Figure 25).138 Deconstructed analogs 60 and 61 (Ki = 12.27 and 71.41 nM) bind with only 2- and
13-fold lower affinity than risperidone (14) (Ki = 5.29 nM) while retaining 5-HT2A receptor
antagonist action,141 suggesting that the right half of risperidone (14) might contribute to binding
affinity to a greater degree as compared to the right half of ketanserin (36).

As a part of this study, two structural hybrids of risperidone (14) and ketanserin (36), Ris/Ket (103)
and Ket/Ris (104) (Figure 30), were synthesized to study the contribution of the “left” and “right”
halves of risperidone (14), and to determine if risperidone (14) and ketanserin (36) bind in a similar
manner. Analog 104 was synthesized by Dr. Supriya A. Gaitonde of our laboratory, but its
synthetic details are provided here.143

Ket/Ris (104)

Ris/Ket (103)

Figure 30. Compounds 103 and 104 represent structural hybrids of risperidone (14) and ketanserin
(36). Compound 103 has been termed Ris/Ket, and 104 has been termed Ket/Ris.
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Hypothesis
If the right half of risperidone (14) is important for binding affinity and functional activity, Ket/Ris
(104) will have a higher binding affinity and/or activity than Ris/Ket (103), and vice versa.

If ketanserin (36) and risperidone (14) bind in a common manner, hybrid ligands bearing features
of both should bind with high affinity.

In hybrid molecule 103, the “right half” of risperidone (14) was replaced with the “right half” of
ketanserin (36), whereas in hybrid molecule 104, the “left half” of risperidone (14) was replaced
by the “left half” of ketanserin (36). If Ris/Ket (103) retains high 5-HT2A receptor affinity, it might
indicate that the “right half” of risperidone (14) is not important or that the “left half” is important
for binding affinity. Conversely, if Ket/Ris (104) retains high affinity for 5-HT2A receptors, it
might indicate that either the “left half” of risperidone (14) is not crucial or that the “right half” of
risperidone (14) is important for 5-HT2A receptor antagonism and binding affinity. If both the
hybrids bind with equally high affinity it might suggest that risperidone (14) and ketanserin (36)
bind in a similar manner.

b. Investigation of the potential role of the “right half” (i.e., the 6-fluoro-3-(4-piperidinyl)1,2-benz[d]isoxazole portion) of risperidone in its binding by making the “right half” of
risperidone similar to serotonin
The “right half” of risperidone (14) was substituted with moieties found in agonists [i.e.; the
tryptamine portion of 5-HT (6)] such as compounds 105-108 (Figure 31) to give compounds 10978

112 (Figure 31), respectively. Compounds 105, and 107 are known to bind to 5-HT2A receptors
and are partial agonists.154 Binding affinities were measured in COS-1 cells expressing 5-HT2A
receptors using [3H]ketanserin as the radioligand.154 Analogs 105, and 107 bind with affinities of
960 nM and 509 nM, respectively.154 Functional activities of analogs 105 (EC50 = 2647 nM, Emax
= 0.43) and 107 (EC50 = 1736 nM, Emax = 0.12) were determined in HEK 293 cells that stably
express 5-HT2A receptors in an assay that measures accumulation of [3H] inositol phosphates.154
Compound 106 is 5-HT2A receptor agonist in an in vitro calcium mobilization assay in HEK 293
cells that over-express 5-HT2A receptors. (EC50 = 4.56; Emax = 101).155

Hypothesis
If the right half of risperidone (14), and the tryptamine portion of 5-HT (6) bind in a similar
manner then analogs bearing the tryptamine portion of 5-HT should bind.

If analogs 109-112 retain high binding affinity, it will indicate that the indole ring binds in a
manner similar to the benz[d]isoxazole ring of risperidone (14). If compounds 109-112 retain
antagonist activity, it will be in accordance with the Ariens hypothesis of conversion of agonists
to antagonists by addition of bulky substituents on amines. Lack of antagonist activity would
indicate that the “left half” of risperidone (14) might not be contributing or that the “right half” of
risperidone (14) is important for 5-HT2A receptor antagonist activity. Additionally, 109 and 110
are secondary amines, whereas 111 and 112 retain the tertiary amine nature of risperidone (14),
and will help ascertain the importance of the nature of the amine. Also, analogs 109 and 111 lack
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the fluoro group and comparing them to analogs 110 and 112 will help investigate the role of the
fluoro group.

Figure 31. Elaboration of risperidone (14) by substituting the “right half” of risperidone with
tryptamines.
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c. Aromatization of the “left half” (i.e., the 2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2a]pyrimidin-4-one portion) of risperidone
Several different, but relatively similar, pharmacophores for 5-HT2A receptor antagonists exist,
and they all imply that multiple binding modes might exist for these antagonists. 156–159 The
pharmacophore consists of a basic amine and two hydrophobic/aromatic portions.156–159 The
distances of the hydrophobic moieties from each other and from the basic amine vary among the
different pharmacophores156–159 (discussed in detail in specific aim 5). These pharmacophores
suggest that aromatization of the left-hand portion of risperidone (14) should result in enhanced
binding affinity. Hence, we prepared analog 113 (Fgure 32), wherein the “left half” of risperidone
(14) (Fgure 32) was aromatized.

Figure 32. Aromatization of the “left half” of risperidone (14).
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d. Investigation of the role of the “left half” (i.e., the 2-methyl-6,7,8,9-tetrahydro-4Hpyrido[1,2-a]pyrimidin-4-one portion) of risperidone by making the “left half” of
risperidone similar to other antipsychotic agents such as iloperidone
Iloperidone (24) (Figure 33) is an atypical antipsychotic agent that has high affinity for 5-HT2A
receptors (Ki = 5.6 nM).160,161 Risperidone (14) and iloperidone (24) both have the same “right
half” consisting of the 6-fluoro-3-(4-piperidinyl)-1,2-benz[d]isoxazole moiety. We synthesized
analogs 114 and 115 (Figure 33), wherein the “left half” of risperidone was made similar to the
left half of iloperidone (24). Also, our laboratory has previously shown that deconstructed analogs
76 and 77 (Figure 33) of ketanserin (36) that have the same “left half” as that of analogs 114 and
115 respectively, retained 5-HT2A receptor antagonist activity and bind with only ~2 fold lower
affinity than ketanserin (36).138 Since the 4-(4-fluorobenzoyl)piperidine moiety present in analogs
76 and 77 and the 6-fluoro-3-(4-piperidinyl)-1,2-benz[d]isoxazole moiety present in analogs 114
and 115 are bioisosteric,153 we might expect analogs 114 and 115 to bind with at least equally high
affinity.

In analogs 116 and 117 (Figure 33) we extended the chain connecting the phenyl ring and the
piperidinyl nitrogen by one carbon atom to investigate the influence of chain length on 5-HT2A
receptor binding affinity and activity.
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If analogs 114-117 retain high affinity for 5-HT2A receptors and 5-HT2A receptor antagonism, it
might indicate that either the entire “left half” of risperidone (14) is not crucial for activity and
affinity or that the “right half” of risperidone (14) is important for 5-HT2A receptor activity and
affinity.

Figure 33. Elaboration of risperidone (14) by making the “left half” of risperidone similar to
iloperidone (25).
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2. Results
A Chemistry
a. Investigation of the potential role of the two halves of risperidone in its activity by
examination of structural hybrids of risperidone and ketanserin
Hybrid molecule 103 was synthesized using a Finkelstein alkylation reaction between the primary
alkyl chloride 78 and 4-(4-fluorobenzoyl)piperidine. The synthesis is outlined in Scheme 9. The
reaction was carried out in the presence of KI as a catalyst and 2 equivalents of K 2CO3 (since the
hydrochloride salt of 4-(4-fluorobenzoyl)piperidine was used) in MeCN as the solvent. Analog
103 was unknown and was characterized by NMR and elemental analysis for C, H, and N atoms.

Scheme 9. Synthesis of compound 103.a

a

Reagents and conditions. (i) (a) 4-(4-fluorobenzoyl)piperidine hydrochloride, K2CO3, KI, MeCN,
reflux 24 h; (b) CHCl3, (COOH)2/Et2O.

Hybrid molecule 104 was synthesized by Dr. Supriya A. Gaitonde and its synthesis is outlined in
Scheme 10.143
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Scheme 10. Synthesis of compound 104.a

118

119

104

a

Reagents and conditions. (i) K2CO3, acetone, reflux, 2 h; (ii) (a) 6-fluoro-3-(4-piperidinyl)-1,2benz[d]isoxazole, toluene, sealed tube, 100 °C, 44 h (b) 12 N HCl.
b. Investigation of the potential role of the “right half “(i.e., the 6-fluoro-3-(4-piperidinyl)1,2-benz[d]isoxazole portion) of risperidone in its activity by making the “right half” of
risperidone similar to serotonin
Compound 106 was successfully synthesized after attempting several synthetic routes. The
synthesis of compound 106 is illustrated in Scheme 11. The first synthetic route attempted to
synthesize 6-fluorotryptamine (106) was the Speeter-Anthony synthesis of tryptamines.162 The
method involves reacting an indole with oxalyl chloride to yield the corresponding 3-indoleglyoxyl
chloride, that is subsequently converted to the corresponding glyoxylamide. Reduction of the
gyloxylamide should yield the corresponding tryptamine.162 Glyoxyl chloride intermediate 121 is
known, and a literature procedure was followed for its synthesis.163 Intermediate 121 was
synthesized from 6-fluoroindole (120) by treating it with with oxalyl chloride, and was
subsequently reacted with ammonium hydroxide to afford the glyoxylamide 122. However, the
product could not be isolated. Hence the synthetic route was changed. Intermediate 122 is
unknown and a literature procedure that has been reported for the synthesis of 3indolylglyoxylamide was used instead.164 The alternative synthetic route utilized a modified Henry
reaction, and involved reacting 6-fluoroindole (120) with 1-dimethylamino-2-nitroethylene in the
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presence of trifluoroacetic acid to yield intermediate 123. The reduction of intermediate 123 should
yield compound 106. Intermediate 123 is known165,166 and was synthesized using a procedure for
the same compound.165 The reduction of intermediate 123 was initially attempted using NaBH4
and boron trifluoride etherate as the reducing agent (using a procedure for a similar compound167),
however, product 106 was difficult to isolate.

Hence, a similar model reaction was tried using indole (124), to synthesize tryptamine (105), and
is outlined in Scheme 12. Indole (124) was treated with 1-dimethylamino-2-nitroethylene in the
presence of trifluoroacetic acid to yield intermediate 125, that was subsequently reduced using two
different reducing agents- one with NaBH4, boron trifluoride etherate complex (yield: 40%) using
a procedure for a similar compound,167 and another method utilizing LiAlH4 (yield: 80%) using a
procedure for the same compound.168

Compound 105168 is known and was characterized by melting point. Both these methods yielded
tryptamine (105), however the yields with LiAlH4 as a reducing agent were much better.

Based on the model reaction for the synthesis of tryptamine (105), LiAlH4 was chosen as the
reagent of the choice for the reduction of intermediate 123 to 6-fluorotryptamine (106). For the
synthesis of tryptamine (105), 20 equivalents of LiAlH4 were used. However, the number of
equivalents of LiAlH4 that could be used for the synthesis of compound 106 was limited by the
fact that it could potentially defluorinate the compound. Several different reaction conditions were
evaluated (Scheme 11 v-viii). A literature procedure for the same compound was used for the
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reduction, wherein 6 equivalents of LiAlH4 were used, and the reaction was carried out in THF at
room temperature for 36 h (Scheme 11 v).166 However, the reaction yielded multiple products and
106 could not be isolated. We next utilized conditions reported in a patent,165 wherein 5 equivalents
of LiAlH4 were used and the reaction was carried out in THF at 60 ºC for 1 h. (Scheme 11 vi). The
reaction was relatively cleaner and purification using Kugelrohr distillation was attempted, a
hydrochloride salt was made. However, the yield was low and the salt was hygroscopic. The
reaction was next carried out using the same conditions (Scheme 11 vii), however the work-up
procedure was modified. A short column using CHCl3, MeOH and NH4OH (90:10:1) as eluents,
was used to separate 106 from the side products and an oxalate salt was made. The yield was low
and hence the reaction conditions were further optimized. We altered the solvent used for the
reaction and used a mixture of THF and Et2O, as opposed to only using THF, keeping all the other
reaction conditions constant (Scheme 11 viii). The reaction was much cleaner, and the oxalate salt
was made. The oxalate salt was purified by reflux in MeCN for 0.5 h to remove impurities, and
was subsequently recrystallized from acetone/H2O to yield compound 106. The oxalate salt of
compound 106 was unknown, and was characterized by NMR and elemental analysis for C, H,
and N atoms.
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Scheme 11. Synthesis of compound 106.a

a

Reagents and conditions. (i) Oxalyl chloride, Et2O, room temperature, 3.5 h; (ii) NH4OH, THF,
room temperature, 48 h; (iii) 1-dimethylamino-2-nitroethylene, trifluoroacetic acid, room
temperature, 1 h; (iv) (a) NaBH4, BF3.Et2O, THF, reflux 2 h; (b) 1N HCl, 85 ºC, 2h; (c) Et2O,
HCl/Et2O; (v) LiAlH4 (6 equivalents), THF, room temperature, 36 h; (vi) (a) LiAlH4 (5
equivalents), THF, 60 ºC, 1 h; (b) Et2O, HCl/Et2O; (vii) (a) LiAlH4 (5 equivalents), THF, 60 ºC ,
1 h; (b) Et2O, (COOH)2/Et2O (viii) (a) LiAlH4 (5 equivalents), THF, Et2O, 60 ºC, 1 h; (b) Et2O,
(COOH)2/Et2O.
Scheme 12. Synthesis of compound 105.a

a

Reagents and conditions. (i) 1-dimethylamino-2-nitroethylene, trifluoroacetic acid, room
temperature, 1 h; (ii) (a) NaBH4, BF3•Et2O, THF, reflux 2 h; (b) 1N HCl, 85 ºC, 2h; (c) Et2O,
HCl/Et2O; (iii) (a) LiAlH4 (20 equivalents), THF, Et2O, reflux; (1) 3 h, reflux; (2) 12 h, room
temperature; (b) Et2O, HCl/Et2O.
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The synthesis of compound 108 is illustrated in Scheme 13. The initial synthetic route attempted
was the Speeter-Anthony synthesis of tryptamines.162 6-Fluoroindole (120) was converted to the
gyloxyl chloride intermediate 121 as previously described,163 and was followed by conversion to
the corresponding glyoxylamide 126. Reduction of intermediate 126 was attempted using LiAlH4.
Intermediate 126 is unknown, and a procedure for a similar compound was followed.163 However,
the reaction for the reduction was not clean and multiple products were formed that were difficult
to isolate.

A model reaction was attempted to synthesize N-methyltryptamine (107), and the synthesis is
outlined in Scheme 14. Indole (124) was allowed to react in a similar manner to yield the
corresponding glyoxylamide 129 via the gyloxyl chloride intermediate 128. Intermediate 128 has
been reported in the literature and was synthesized using the same procedure.169 Intemediate 129
is known170 and was synthesized using a general procedure. The reaction for the reduction of the
glyoxylamide intermediate 129 to the tryptamine was cleaner,163 and we observed that rather than
getting the tryptamine (107) we obtained a side product that was characterized by melting point
and found to be 130,171 and hence utilized a different synthetic route. The reaction of 105 with
ethyl chloroformate yielded intermediate 131 that was subsequently converted to the tryptamine
107 by LiAlH4. Intermediates 131,172 and compound 107,172,173 have been reported in the literature
and were synthesized using the procedures reported by Ignatenko et al.172 Analog 107 is known
and was characterized by melting point and NMR. Tryptamine 108 was synthesized in an
analogous manner from tryptamine 106 (synthesized as previously described), and the synthesis is
illustrated in Scheme 13 (v-viii). Compound 108 was unknown and was synthesized from 106
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using the procedures for the synthesis of 107 that have been reported in the literature by Ignatenko
et al.172 Compound 108 was characterized by NMR and elemental analysis for C, H, and N atoms.

Scheme 13. Synthesis of compound 108.a

a

Reagents and conditions. (i) Oxalyl chloride, Et2O, room temperature, 3.5 h; (ii) methylamine in
water (40%), THF, room temperature, 48 h; (iii) LiAlH4 (5 equivalents), THF, reflux, 8 h; (iv)
LiAlH4 (1.2 equivalents), THF, reflux, 20 h (v) 1-dimethylamino-2-nitroethylene, trifluoroacetic
acid, room temperature, 2 h; (vi) LiAlH4 (5 equivalents), THF, Et2O, 60 ˚C, 1 h; (vii) ethyl
chloroformate, Et3N, CH2Cl2, room temperature, 3 h. (viii) (a) LiAlH4 (3 equivalents), THF, reflux,
1.5 h; (b) Et2O, HCl/Et2O.
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Scheme 14. Synthesis of compound 107.a

a

Reagents and conditions. (i) Oxalyl chloride, Et2O;(a) 0 ºC, 3 h; (b) room temperature, 1 h; (ii)
methylamine in water (40%), THF, room temperature, 24 h; (iii) LiAlH4 (5 equivalents), THF,
reflux, 8 h; (iv) ethyl chloroformate, Et3N, CH2Cl2, room temperature, 3 h; (v) (a) LiAlH4 (3
equivalents), THF, reflux, 1.5 h.

Compound 109 was synthesized after modifying several reaction conditions (Schemes 15 a-d), and
the synthesis is outlined in Scheme 15 c xiii. The synthesis of 109 was initially attempted using a
Finkelstein alkylation reaction, wherein an attempt was made to alkylate 105 with the primary
alkyl chloride 78, in the presence of KI as a catalyst and K2CO3 as the base in DMF as the solvent.
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The reaction mixture was heated at 80 ºC for 48 h. DMF was used as the solvent as opposed to
MeCN, since 105 had limited solubilty in MeCN at room temperature. The reaction was not clean
and it was impossible to isolate the product. We next used MeCN as the solvent. The tryptamine
was solubilized by heating. Keeping the other conditions constant we gradually increased the
temperature from room temperature (5 h- no reaction) to 60 ºC (18 h- no change), to finally 85 ºC
for 48 h. A mixture of products was obtained that could not be characterized. We next carried out
the reaction in a sealed tube at 80 ºC for 5 days using MeCN as the solvent. The reaction was
cleaner with one spot being more prominent than the others on TLC, however, the desired product
could not be separated. Keeping the other conditions constant we varied the solvent (toluene), to
study whether the solvent was playing any role, and subsequently changed the base to Et3N instead
of K2CO3 to evaluate if the base was negatively affecting the reaction. However, both attempts
were fruitless. Further, to reduce the reaction time, the solvent MeCN was reduced to 1/3rd while
keeping all the other reaction conditions constant (KI, K2CO3). The reaction gave multiple spots,
however, there was one prominent spot that could be separated from the others by column
chromatography. Characterization by NMR and mass spectrometry suggested that the product
could be 132 (Figure 34), which indicates that the primary alkyl chloride 78 initially reacts with
105 to yield product 109 that undergoes further N-alkylation to potentially yield 132. This was
quite unexpected because we would not have expected an amine having a bulky substituent to react
a second time. However, it is not unlikely since the secondary amine 109 would be more basic
than the primary amine 105. The formation of 132 could be prevented in multiple ways (i) by
increasing the dilution, so as to keep the reactants apart; (ii) by eliminating KI; (iii) by increasing
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the equivalents of tryptamine (105) (not very feasible since the starting material had to be
synthesized); and/or (iv) protecting the amine of the tryptamine.

We first tried to dilute the reaction mixture (Scheme 15 b) and modified the amount of solvent
keeping all other conditions constant, However, we still observed the formation of the side product
132. We simultaneously also evaluated reaction conditions wherein we increased the equivalents
of tryptamine (105) from 1 equivalent to 2 equivalents, and utilized K2CO3 as the base, KI as the
catalyst, in MeCN (dilution: 1X) (Scheme 15 c). However, we still observed the side product 132.
We next increased the dilution factor to 2X, and utilized 2 equivalents of 105, keeping all other
conditions constant, and at the same time also tried to evaluate a different synthetic route (Scheme
15 d). The alternate synthetic route involved protecting the amine terminal using an N-benzyl
group and was achieved by a reductive amination reaction. The reaction of the protected
tryptamine 133 yielded unknown intermediate 134 that was characterized by NMR, however, it
was extremely hygroscopic and the HCl salt seemed to degrade.

We seemed to have reduced the amount of side product that was being formed when the conditions
as outlined in scheme 15 c were used. Hence, to further optimize the reaction conditions we
eliminated KI. These conditions seemed to yield relatively lower amounts of the side product 132,
and we were able to isolate and purify 109 by column chromatography and recrystallization
techniques. Compound 109 was unknown and was characterized by NMR and elemental analysis
for C, H and N atoms.
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Figure 34. A side product of the Finkelstein alkylation reaction.

Scheme 15 a. Synthesis of compound 109.a

a

Reagents and conditions. (i) Tryptamine (105), K2CO3, KI, DMF, 80 °C, 48 h; (ii) Tryptamine
(105), K2CO3, KI, MeCN; (a) room temperature, 5h; (b) 60 °C, 18 h; (c) 85 °C, 48 h; (iii)
Tryptamine (105), K2CO3, KI, MeCN (dilution- 1X), sealed tube, 80 °C, 5 days; (v) Tryptamine
(105), K2CO3, KI, toluene, sealed tube, 80 °C, 5 days; (vi) Tryptamine (105), Et3N, KI, MeCN
(dilution- 1X), sealed tube, 80 °C, 5 days; (iv) Tryptamine (105), K2CO3, KI, MeCN (dilutionX/3), sealed tube, 80 °C, 5 days.
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Scheme 15 b. Synthesis of compound 109.a

a

Reagents and conditions. (vii) Tryptamine (105), K2CO3, KI, MeCN (dilution - 2X), reflux, 18 h;
(viii) Tryptamine (105), K2CO3, KI, MeCN (dilution - 10X), reflux, 18 h;(ix) Tryptamine (105),
K2CO3, KI, MeCN (dilution - 20X), reflux, 18 h; (x) Tryptamine (105), K2CO3, KI, MeCN
(dilution - 1.8X), reflux, 18 h.
Scheme 15 c. Synthesis of compound 109.a

a

Reagents and conditions. (xi) Tryptamine (105) (2 equivalents), K2CO3, KI, MeCN (dilution 1X), reflux, 18 h; (xii) Tryptamine (105) (2 equivalents), K2CO3, KI, MeCN (dilution - 2X), reflux,
18 h; (xiii) (a) Tryptamine (105) (2 equivalents), K2CO3, MeCN (dilution - 2X), reflux, 17 h; (b)
CHCl3, (COOH)2/Et2O.
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Scheme 15 d. Synthesis of compound 109.a

a

Reagents and conditions. (i) (a) Benzaldehyde, MgSO4, EtOH, 60 °C, 1 h; (b) NaBH4, room
temperature, 1.5 h; (ii) 3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2a]pyrimidin-4-one (78), KI, K2CO3, MeCN, reflux, 48 h. (b) CH2Cl2, HCl/EtOH.

The synthesis of compound 110 is outlined in Scheme 16. The conditions that we had optimized
for the synthesis of 109 were used to synthesize compound 110. The tryptamine 106, was Nalkylated by compound 78 to yield compound 110. We observed a mixture of compound 135
(Figure 35) and compound 110. Column chromatography and recrystallization techniques were
used to separate them. Compound 110 was unknown and was characterized by NMR and elemental
analysis for C, H and N atoms.

Figure 35. A side product of the Finkelstein alkylation reaction.
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Scheme 16. Synthesis of compound 110.a

a

Reagents and conditions. (i) 1-Dimethylamino-2-nitroethylene, trifluoroacetic acid, room
temperature, 2 h; (ii) LiAlH4 (5 equivalents), THF, Et2O, 60 ºC, 1 h; (iii) (a) 3-(2-Chloroethyl)-2methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (78), K2CO3, MeCN, reflux, 17 h; (b)
CHCl3, (COOH)2/Et2O.

The synthesis of compounds 111 and 112 are outlined in Scheme 17 and 18, respectively.
Compounds 107 and 108 were synthesized as previously described in Schemes 14 and 13,
respectively. Finkelstein alkylation reactions between compounds 107, 108 with compound 78 in
MeCN yielded compounds 111 and 112, respectively. Compounds 111 and 112 were unknown
and were characterized by NMR and elemental analysis for C, H and N atoms.
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Scheme 17. Synthesis of compound 111.a

Reagents and conditions. (i) Ethyl chloroformate, Et3N, CH2Cl2, room temperature, 3 h; (ii) (a)
LiAlH4 (3 equivalents), THF, reflux, 1.5 h; (iii) (a) 3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro4H-pyrido[1,2-a]pyrimidin-4-one (78), K2CO3, KI, MeCN. Reflux, 48 h; (b) CH2Cl2,
(COOH)2/Et2O.
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Scheme 18. Synthesis of compound 112.a

a

Reagents and conditions: (i) 1-Dimethylamino-2-nitroethylene, trifluoroacetic acid, room
temperature, 2 h; (ii) LiAlH4 (5 equivalents), THF, Et2O, 60 ˚C, 1 h; (iii) ethyl chloroformate,
Et3N, CH2Cl2, room temperature, 3 h; (iv) (a) LiAlH4 (3 equivalents), THF, reflux, 1.5 h; (b) Et2O,
HCl/Et2O; (v) (a) 3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4one (78), K2CO3, KI, MeCN, reflux, 48 h; (b) CH2Cl2, (COOH)2/Et2O.
c. Aromatization of the “left half” (i.e., the 2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2a]pyrimidin-4-one portion) of risperidone
Scheme 19 outlines the synthesis of compound 113. A Finkelstein alkylation reaction between 6fluoro-3-(4-piperidinyl)benz[d]isoxazole (61) and 136 in MeCN, yielded compound 113. The free
base of compound 113 is known.174 The oxalate salt of compound 113 was unknown and was
characterized by NMR and elemental analysis for C, H and N atoms.
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Scheme 19 Synthesis of compound 113.a

a

Reagents and conditions. (i) (a) 6-Fluoro-3-(4-piperidinyl)benz[d]isoxazole (61), KI, K2CO3,
MeCN, reflux, 20 h; (b) CH2Cl2, COOH2/Et2O.
d. Investigation of the role of the “left half” (i.e., the 2-methyl-6,7,8,9-tetrahydro-4Hpyrido[1,2-a]pyrimidin-4-one portion) of risperidone by making the “left half” of
risperidone similar to other antipsychotic agents such as iloperidone

Scheme 20 illustrates the synthesis of compounds 114 and 115. A Finkelstein alkylation reaction
between 137, 138 with 6-fluoro-3-(4-piperidinyl)benz[d]isoxazole (61) in MeCN, yielded
compounds 114 and 115 respectively. Compounds 114 and 115 were unknown and were
characterized by NMR and elemental analysis for C, H and N atoms.
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Scheme 20. Synthesis of compound 114 and 115.a

a

Reagents and conditions. (i) (a) 6-Fluoro-3-(4-piperidinyl)benz[d]isoxazole (61), KI, K2CO3,
MeCN, reflux, 20 h; (b) 1 M HCl; (ii) (a) 6-fluoro-3-(4-piperidinyl)benz[d]isoxazole (61), KI,
K2CO3, MeCN, reflux, 36 h; (b) EtOAc, HCl/EtOAc.
The synthesis of compound 116 is illustrated in Scheme 21. Compounds 140175 and 141176 are
known and were synthesized by procedures for the same compounds. 5-Chlorovaleroyl chloride
(140) was synthesized by the reaction of 5-chlorovaleric acid (139) with thionyl chloride. A
Friedel-Crafts acylation reaction between 140 and benzene yielded intermediate 141. Several side
products were obtained (potentially the Freidel-Crafts alkylation product), and 141 was separated
from the side-products by recrystallization and column chromatography. A Finkelstein alkylation
reaction between 141 and 6-fluoro-3-(4-piperidinyl)benz[d]isoxazole (61) in MeCN yielded
compound 116. Compound 116 was unknown and was characterized by NMR and elemental
analysis for C, H and N atoms.
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Scheme 21. Synthesis of compound 116.a

a

Reagents and conditions: (i) SOCl2, reflux, 3 h; (ii) AlCl3, benzene; (a) 0 ºC, 1 h; (b) room
temperature, 1 h; (iii) 6-fluoro-3-(4-piperidinyl)benz[d]isoxazole (61), K2CO3, KI, sealed tube, 80
ºC, 48 h; (b) EtOH, HCl/EtOH.

The Finkelstein alkylation of 6-fluoro-3-(4-piperidinyl)benz[d]isoxazole (61) with 142 yielded
compound 117, and the synthesis is outlined in Scheme 22. Compound 117 was unknown and was
characterized by NMR and elemental analysis for C, H and N atoms.

Scheme 22. Synthesis of compound 117.a

Reagents and conditions: (i) (a) 6-Fluoro-3-(4-piperidinyl)benz[d]isoxazole (61), KI, K2CO3,
MeCN, sealed tube, 80 ºC, 96 h; (b) MeOH, HCl/EtOH.
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B. Radioligand binding studies
Radioligand binding studies of the compounds were performed in HEK 293 cells expressing 5HT2A receptors. [3H]Ketanserin (36) was used as the radioligand, and non-specific binding was
determined in the presence of methysergide. Competition curves were generated and analyzed by
nonlinear regression to determine the binding affinities of the compounds (Ki values).

Binding affinities of risperidone (14), ketanserin (36) and their structural hybrids Ris/Ket (103)
and Ket/Ris (104) were determined. The displacement curves for risperidone (14), ketanserin (36),
103 and 104 are shown in Figure 36.

Ketanserin (36) and risperidone (14) bound with affinities of 18.55 nM (log Ki = -7.7 ± 0.1), and
5.29 nM (log Ki = -8.27 ± 0.06). Both the structural hybrids Ris/Ket (103) (Ki = 12.74 nM; log Ki
= -7.8 ± 0.15) and Ket/Ris (104) (Ki = 0.96 nM; log Ki = -9.0 ± 0.12) bound with high affinity to
5-HT2A receptors.
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Figure 36. [3H] Ketanserin competition binding curves for risperidone (14), ketanserin (36), and
their hybrids 103 (Ris/Ket) and 104 (Ket/Ris) in HEK 293 cell membrane preparations expressing
5-HT2A receptors (for analogs 103 and 104: n = 2, performed in duplicate; figures provided by Dr.
Jose Moreno).

Preliminary competition curves for elaborated analogs 111 and 112 are shown in Figure 37.
Analogs 111 and 112 exhibited high affinity for 5-HT2A receptors and bound with affinities of 285
nM (n = 1; performed in duplicate), and 4.82 nM (n = 1, performed in duplicate), respectively.
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Figure 37. [3H] Ketanserin competition binding curves for elaborated analogs 111 and 112 in HEK
293 cell membrane preparations expressing 5-HT2A receptors (n = 1, performed in duplicate).

C. Functional activity studies
Risperidone (14), ketanserin (36) and their structural hybrids were tested in a TEVC
electrophysiological assay that utilizes the Xenopus laevis heterologous expression system as
previously described.

The Gαq mediated activity of 1 µM 5-HT was antagonized by 10 µM of risperidone (14), ketanserin
(36), and the structural hybrid Ris/Ket (103), and reduced the activity to ~20, 15 and 21 %
respectively. (Figure 38) Analog 104 did not reduce the activity of 5-HT. When ketanserin (36) (a
5-HT2A receptor antagonist) and 104 were tested in the absence of 5-HT, both showed activities of
~45 and 20% as compared to 5-HT suggesting potential partial agonist activity (Figure 39). This
positive efficacy might be attributed to its direct effects on the GIRK4* channel or other effects
and needs to be investigated further.
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Figure 38. Functional activity of risperidone (14), paliperidone (pali, 56), ketanserin (36), and
hybrids 103 and 104 in the presence of 5-HT.

Figure 39. Functional activity of ketanserin (36) and hybrid 104 in the absence of 5-HT.
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3. Discussion
The structural hybrids of risperidone (14) and ketanserin (36) i.e. Ris/Ket (103) and Ket/Ris (104)
both retain high affinity for 5-HT2A receptors. Ris/Ket (103) (Ki = 12.7 nM) binds with ~ 2-fold
lower affinity than risperidone (Ki = 5.3 nM), and ~1.5-fold higher affinity than ketanserin (36)
This suggests that the “right half” of risperidone (14) might be contributing more to binding
affinity as compared to the “right half” of ketanserin (36). Ket/Ris (104) (Ki = 0.96 nM) binds with
~5.5- and ~19- fold higher affinity than risperidone (14) (Ki = 5.29 nM), and ketanserin (36) (Ki =
18.6 nM), respectively, suggesting that the “left half” of ketanserin (36) might be contributing to
the binding affinity at 5-HT2A receptor to a greater extent as compared to the “left half” of
risperidone (14). Hence, consistent with our results from deconstruction of risperidone (14)
studies, the “right half” of risperidone (14) seems to be contributing to its binding affinity to a
greater extent as compared to its “left half”.

The hybrid molecules seem to have different functional activities at the 5-HT2A receptor. In the
presence of 5-HT, risperidone (14), ketanserin (36) and Ris/Ket (103) were antagonists, whereas
Ket/Ris (104) appeared to have partial agonist activity. In the absence of 5-HT, both ketanserin (a
known neutral 5-HT2A receptor antagonist) as well as analog 104 exhibited partial agonist activity.
This could be due to their direct effects at the GIRK4* channel or due to other effects. However,
to determine if analog 104 is a partial agonist, further investigation is needed.
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Analogs 111 and 112 both retain high affinity for 5-HT2A receptors. Analog 112 binds with
nanomolar affinity that is comparable to the binding affinity of risperidone. Analog 111 binds with
~57-fold lower affinity than analog 112 and risperidone (14). Analog 111 represents the desfluoro
analog of 112 and indicates that the fluoro group might be making additional interactions with the
5-HT2A receptors that enhances the binding affinity of analog 112 as compared to analog 111.
Since analog 112 and risperidone (14) bind with comparable affinity, it might indicate that the
benz[d]isoxazole ring of risperidone (14), and the indole ring of analog 112 might be interacting
in a similar manner at 5-HT2A receptors.
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C. Specific Aim 3. Molecular modeling studies of risperidone and its deconstructed and
elaborated analogs at the 5-HT2A receptor to study their binding modes
1. Approach
Molecular modeling studies at 5-HT2A receptors were conducted to compare the binding modes of
risperidone (14) (Figure 8) and its deconstructed and elaborated analogs, and to study receptorligand interactions at a molecular level. Studying receptor-ligand interactions will help put into
perspective the importance of different structural features. We also wanted to compare the binding
modes of risperidone (14) to the prototypical 5-HT2A receptor antagonist ketanserin (36) (Figure
17) to gain insight into the similarities and differences in their interactions at the 5-HT2A receptor.

The 5-HT2A receptor has not been crystallized; hence, 3-dimensional homology models of 5-HT2A
receptors were generated for the purpose of the study, and risperidone (14), ketanserin (36) and
deconstructed and elaborated analogs of risperidone (14) were docked in the homology models.
The homology models were already available in our laboratory, and were used for these studies;143
their construction is briefly described below.

a. Template, alignment and generation of homology models of 5-HT2A receptors
The 5-HT2 subfamily of receptors share ~70% homology with each other.39 The crystal structure
of the human (h)5-HT2B receptor (PDB ID: 4IB4; resolution: 2.7 Å) in complex with the agonist
ergotamine that was solved by Wacker et al.177 in 2013 was used as a template to construct
homology models of h5-HT2A receptors.143 The software CLUSTALX 2.1178 was used to generate
the multiple sequence alignment between 5-HT2A and 5-HT2B receptors.143 Homology models
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were constructed using MODELLER 9.1179 and were further processed to add hydrogen atoms and
build disulfide bonds using SYBYL-X 2.1.143

b. Validation of homology models, docking studies, and HINT analysis
The models were validated by docking ketanserin (36) and comparing the results to those that have
been reported in published homology models of 5-HT2A receptors as well as by site-directed
mutagenesis data.143

Homology models reported in the literature, and site-directed mutagenesis studies, have implicated
a number of residues in TM3, TM5, TM6, and TM7 to be important for binding of orthosteric
agents to 5-HT2A receptors, and include Trp151,180 D155,139,180,181 S159 (TM3),182 S239 (TM5),183
S242 (TM5),183 W336,180 F339,184 F340 (TM6),184–186 and Y370 (TM7).184

Ketanserin (36), risperidone (14), and deconstructed, and elaborated analogs of risperidone were
docked using GOLD Suite 5.2, GOLD Suite 5.3, or GOLD Suite 5.4187 depending on the version
available at the time the docking studies were performed. Risperidone (14), an orthosteric 5-HT2A
receptor antagonist/inverse agonist, binds at the same site as 5-HT (6).127 The amino acid residue
Asp155 was used to define the binding site (radius: 10 Å) as this residue has been shown to be
important and necessary for the binding both of orthosteric agonists such as 5-HT, as well as
orthosteric antagonists such as ketanserin (36), by site-directed mutagenesis.139,181 Asp155,
anchors the terminal amine moiety of 5-HT via an ionic interaction.181 The docked solutions were
clustered (using a script provided by Dr. Philip D. Mosier). Solutions in the same cluster have a
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similar docking pose, and the intra-cluster RMSD is less than 2 Å. Models were chosen based on
ChemPLP scores (the higher the score, the better the interactions), cluster size, and the ability of
the protonated amines of the compounds to form an ionic interaction with Asp155. The selected
models were energy minimized in SYBYL-X 2.1 and the interactions were quantified by
Hydropathic INTeraction (HINT) analysis.188 The HINT score is the sum of interactions between
two molecules and accounts both for favorable and unfavorable interactions. A positive HINT
score indicates overall favorable interactions.188 In our study, the HINT score indicates the sum of
the interactions between the 5-HT2A receptor and the docked ligand. The HINT scores for the
receptor-ligand complexes can be converted into free energy values and ~515 HINT score units
correspond to 1 kcal/mol.189,190

2. Results and discussion
Risperidone (14) showed two docking/binding modes at 5-HT2A receptors (Figures 40 and 41). In
one binding mode, the fluorine atom was oriented towards TM5 and is shown in Figure 40
(docking mode 1). In the other mode, the fluorine atom was oriented towards TM7 and is shown
in Figure 41 (docking mode 2). The second docking mode is consistent with what has been
previously reported in the literature for risperidone.191

111

Figure 40. Docking mode 1 of risperidone (14) (cyan) at the 5-HT2A receptor with the fluorine
atom oriented toward TM5. The red dashed lines indicate ionic interactions and the blue dashed
lines indicate hydrogen bonds.

Figure 41. Docking mode 2 of risperidone (14) (cyan) at the 5-HT2A receptor with the fluorine
atom oriented toward TM7. The red dashed lines indicate ionic interactions and the blue dashed
lines indicate hydrogen bonds.

Risperidone (14) formed strong hydrophobic and polar interactions at the receptor. In docking
mode 1, the 6-fluoro-(3-piperidinyl)benz[d]isoxazole moiety (“right half”) of risperidone (14)
predominantly formed polar interactions whereas the 6,7,8,9-tetrahydro-4H-pyrido[1,2112

a]pyrimidin-4-one ring system (“left half”) of risperidone (14) appeared to predominantly form
hydrophobic interactions. On the other hand, in mode 2, while the “right half” formed
predominantly polar interactions, the “left half” seemed to form polar as well as hydrophobic
interactions. In both modes, the indispensable ionic interaction between the protonated amine of
the piperidine ring and Asp155 (TM3) was present. In mode 1, the nitrogen and oxygen atoms of
the benz[d]isoxazale ring formed a bifurcated hydrogen bond with Ser159. In mode 2, the oxygen
atom of the 6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one ring system formed a hydrogen
bond with Ser159, whereas the fluorine atom and the oxygen atom of the benz[d]isoxazole ring
formed hydrogen bonds with Trp367 and Thr134, respectively. Additionally, hydrophobic
interactions with Trp151, Leu228, Leu229, Trp336, Phe339, Phe340, Trp367 and Tyr370 were
observed for both binding modes.

Both binding modes of risperidone at 5-HT2A receptors seem possible; however, mode 1 (HINT
score = 1204) has a higher total HINT score as compared to mode 2 (HINT score = 1001),
indicating more overall favorable interactions at the receptor (Table 3). However, the differences
in the total HINT scores do not appear to be substantial. The binding and functional activity data
available so far suggest that the fluorine atom is important for enhancing binding affinity, and that
the carbonyl group of the 6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one ring system might
be important for functional activity (albeit to a very small extent). In mode 2 the carbonyl oxygen
and fluorine atom both formed hydrogen bonds with Ser159 and Trp367 making this mode more
likely. However, both binding modes might exist, or be in equilibrium.
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Table 3. Summary of HINT scores of the two binding modes of risperidone (14).
Binding mode

Polar

Hydrophobic

Total HINT score*

Mode 1

1523

1225

1204

Mode 2

1475

1280

1001

*Other terms, e.g., hydrophobic-polar, acid-acid and base-base are reflected in this total.
a. Molecular modeling studies of the deconstructed analogs at 5-HT2A receptors
Figure 42 shows docking modes of truncated analogs 57, 58 and 59 relative to risperidone (14).
They docked at the 5-HT2A receptor in a manner similar to docking mode 2 of risperidone (14).
Analogs 57-59 predominantly show only one binding mode.

For analogs 57-59, the 6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one ring system is flipped
by ~180 ° about the horizontal axis. (Figure 42).

Figure 42. Docking modes of deconstructed analogs 57 (light pink), 58 (salmon), and 59 (violet)
at the 5-HT2A receptor relative to risperidone (14) (cyan).

Figure 43 illustrates the interactions that analogs 57-59 make with the 5-HT2A receptor. The
protonated amines of analogs 57, 58 and 59 made the crucial ionic interaction with Asp155. The
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protonated amine of 59 also formed a hydrogen bond with Tyr370. Analogs 57, 58 and 59 showed
hydrophobic interactions with the residues: Leu229, Phe234, Val235, Trp336, Phe339, and
Phe340. Analog 57 made an additional hydrophobic interaction with Val366.

Figure 43. Docking modes of deconstructed analogs 57 (light pink), 58 (salmon), and 59 (violet)
at the 5-HT2A receptor. The red dashed lines indicate ionic interactions and the blue dashed lines
indicate hydrogen bonds.
HINT scores for analogs 57, 58 and 59 are shown in Table 4.
Table 4. Summary of HINT scores for risperidone (14) and analogs 57, 58 and 59.
Binding mode

Polar

Hydrophobic

Total HINT score*

Risperidone (14); Mode 1

1523

1225

1204

Risperidone (14); Mode 2

1475

1280

1001

57

1103

1037

670

58

1194

988

309

59

2793

734

1851
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*Other terms, e.g., hydrophobic-polar, acid-acid and base-base are reflected in this total.

The total HINT scores for analogs 57 and 58 are lower than that for risperidone (14) (Table 4), and
suggest that risperidone (14) makes overall more favorable interactions with 5-HT2A receptors as
compared to analogs 57 and 58. The binding affinity of analog 57 (Ki = ~2732 nM) is ~500-fold
lower than the binding affinity of risperidone (Ki = 5.29 nM), and the “right half” of risperidone
(14) seems to be more important for retaining binding affinity since analogs 60 (Ki = 12.27 nM
and 61 (Ki = 71.41 nM) bind with only ~2 and ~14 fold lower affinity than risperidone (14) (Ki =
5.29 nM) The total HINT score for analog 59 is higher than that for risperidone (14) suggesting
that it makes overall more favorable interactions at the 5-HT2A receptor as compared to risperidone
(14). However, preliminary binding data suggests that analog 59 might have a very low binding
affinity for 5-HT2A receptors [(Ki > 10,000 nM]. The binding affinity might reflect the hydrophobic
interactions (Table 4) since analog 59 has a lower score for total favorable hydrophobic
interactions as compared to risperidone and analog 57.

Molecular modeling studies for analogs 60-63, 65, and 66 have been reported previously.143

Analogs 64 and 68 (Figure 44 and 45) have two binding modes that closely resemble docking
modes 1 and 2 of risperidone (14). Figures 44 and 45 illustrate the interactions that the
deconstructed analogs 64, 68, and risperidone (14) make with the 5-HT2A receptor in docking
modes 1 and 2, respectively.
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In binding mode 1 (Figure 44), analogs 64 and 68 docked in a manner similar to risperidone (14)
and formed the interactions that were previously described for binding mode 1 of risperidone (14).
In addition to those interactions, the pyrimidone oxygen of deconstructed analog 64 formed a
hydrogen bond with Ser131.

Figure 44. Docking modes of risperidone (14) (cyan), and analogs 64 (magenta) and 68 (green) at
the 5-HT2A receptor (docking mode 1). The red dashed lines indicate ionic interactions and the
blue dashed lines indicate hydrogen bonds.
In binding mode 2 (Figure 45), the molecules 64 and 68 docked in a manner similar to binding
mode 2 of risperidone (14), and formed interactions that were consistent with what was previously
described for binding mode 2 of risperidone (14). The pyrimidone oxygen of deconstructed analog
64 formed a hydrogen bond with Ser159 whereas analog 68 lacks the carbonyl group that is present
in risperidone (14), and hence lacks the hydrogen bond with Ser159.
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Figure 45. Docking modes of risperidone (14) (cyan), and analogs 64 (magenta) and 68 (green)
at the 5-HT2A receptor (docking mode 2). The red dashed lines indicate ionic interactions and the
blue dashed lines indicate hydrogen bonds.

As seen previously with risperidone (14), both binding modes seem possible. HINT scores for both
analogs are summarized in Table 5. Total HINT scores for analogs 64 and 68 in binding mode 1
were higher than that for binding mode 2 suggesting that it makes more overall favorable
interactions in binding mode 1 with the receptor. However, the differences in HINT scores do not
appear to be substantial.
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Table 5. Summary of HINT scores for binding modes 1 and 2 of risperidone (14) and analogs 64
and 68.
Binding mode

Polar

Hydrophobic

Total HINT score*

Risperidone (14); Mode 1

1523

1225

1204

Risperidone (14); Mode 2

1475

1280

1001

64; Mode 1

1936

810

847

64; Mode 2

1538

811

616

68; Mode 1

1464

1036

1166

68; Mode 2

1156

1111

1057

*Other terms, e.g., hydrophobic-polar, acid-acid and base-base are reflected in this total.

b. Molecular modeling studies of elaborated analogs of risperidone
Figures 46-49 show risperidone (14), ketanserin (36) and their structural hybrids (103 and 104)
docked in homology models of the 5-HT2A receptor.
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Figure 46. Docking modes of risperidone (14) (cyan), ketanserin (magenta), analogs 103 (green)
and 104 (salmon) at the 5-HT2A receptor (docking mode 1). The red dashed lines indicate ionic
interactions and the blue dashed lines indicate hydrogen bonds.
Figure 46 shows Ris/Ket (103) and Ket/Ris (104), as well as ketanserin (36), docked in a manner
that is consistent with binding mode 1 of risperidone (14). The protonated amines of all analogs
formed the crucial ionic interaction with Asp155. Ketanserin (36) interacts with the 5-HT2A
receptor in a manner similar to that described previously for binding mode 1 of risperidone (14).
The oxygen atom of the carbonyl group of the 4-fluorobenzoyl piperidine ring (“right half” of
ketanserin) is engaged in a hydrogen bond with Ser159. Ris/Ket (103) has the “left half” of
risperidone (14) and the “right half” of ketanserin (36). The “left half” of Ris/Ket (103) aligned
well with the “left half” of risperidone (14) whereas the “right half” of Ris/Ket (103) aligned well
the “right half” of ketanserin (36). The “left half” of Ris/Ket (103) interacts with the receptor in a
manner similar to the binding mode 1 of risperidone (14), whereas the “right half” interacts in a
manner that has been described for the “right half” of ketanserin (36). Ket/Ris (104) has the “left
half” of ketanserin (36) and the “right half” of risperidone (14). Despite having the “left half” of
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ketanserin (36) i.e. the quinazolinedione ring, the molecule docked in a manner such that the
quinazolinedione ring was flipped by ~180 ° about the horizontal axis [when compared to the
docking solution for ketanserin (36)] (Figure 47 A), and seemed to align better with the “left half”
of risperidone (14) (Figure 47 B). The “right half” of Ket/Ris (104) overlapped well with the “right
half” of risperidone (14) and showed the same interactions at the 5-HT2A receptor as were
previously described for docking mode 1 of risperidone (14).

Figure 47. A comparison between (A) binding modes of Ket/Ris (104) (salmon) and ketanserin
(36) (magenta); (B) binding modes of Ket/Ris (104) (salmon) and risperidone (14) (cyan).

Figure 48 shows a comparison of the Ris/Ket (103) and the Ket/Ris (104) hybrid with risperidone
(14) and ketanserin (36) at the 5-HT2A receptor when oriented in docking mode 2. The “left half”
of Ris/Ket (103) docked in a manner similar to risperidone (14) (Figure 48 B), whereas the “right
half” was flipped by ~180 º about the horizontal axis as compared to the “right half” of ketanserin
(36) (Figure 48 A). The “left half” of Ket/Ris (104) was flipped by ~180 º about the horizontal
axis as compared to the “left half” of ketanserin (36) (Figure 48 C), and aligned better with the
“left half” of risperidone (14) as opposed to the “left half” of ketanserin (36) (Figure 48 D) whereas
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the “right half” of Ket/Ris (104) docked in a manner similar to the “right half” of risperidone (14)
(Figure 48 D).

Figure 48. A comparison between (A) binding modes of Ris/Ket (103) (green) and ketanserin (36)
(magenta); (B) binding modes of Ris/Ket (103) (green) and risperidone (14) (cyan); (C) binding
modes of Ket/Ris (104) (salmon) and ketanserin (36) (magenta); (D) binding modes of Ket/Ris
(104) (salmon) and risperidone (14) (cyan).
Figure 49 shows Ris/Ket (103), Ket/Ris (104) and ketanserin (36) docked in a manner that was
consistent with binding mode 2 of risperidone (14). Risperidone (14) interacts with the 5-HT2A
receptor in a manner previously described for binding mode 2 of risperidone (14). The protonated
amines of ketanserin (36) and the two structural hybrids 103 and 104 formed an ionic salt-bridge
interaction with Asp155. The carbonyl oxygen atom of Ris/Ket (103) formed a hydrogen bond
with Ser131. The O2 and O1 oxygen atoms of the quinazolinedione rings of the Ket/Ris hybrid
(104) and ketanserin (36), respectively, and the oxygen atom of the 6,7,8,9-tetrahydro-4Hpyrido[1,2-a]pyrimidin-4-one ring of risperidone (14) formed a hydrogen bond with Ser159. The
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fluorine atoms of risperidone (14), ketanserin (36) and the Ket/Ris hybrid (104) formed a hydrogen
bond with Trp367. The oxygen atoms of the benz[d]isoxazole rings of risperidone (14), and the
Ket/Ris hybrid (104) formed a hydrogen bond with Thr134. Additionally, hydrophobic interactions
with Trp151, Leu228, Leu229, Trp336, Phe339, Phe340, Trp367, and Tyr370 were observed for
hybrid molecules 103 and 104, risperidone (14) and ketanserin (36).

Figure 49. Docking modes of risperidone (14) (cyan), ketanserin (magenta), analogs 103 (green)
and 104 (salmon) at the 5-HT2A receptor (docking mode 2). The red dashed lines indicate ionic
interactions and the blue dashed lines indicate hydrogen bonds.

Total HINT scores for risperidone (14), ketanserin (36), and their structural hybrids are
summarized in Table 6. Both binding modes seem possible for risperidone (14) and the Ris/Ket
(103), and Ket/Ris (104) hybrid. However, our molecular modeling studies suggest that binding
mode 1 appears to be more likely for ketanserin (36) (total HINT score for binding mode 1 is 2fold higher than total HINT score for binding mode 2), and hence, risperidone (14) and ketanserin
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(36) might not be binding in a similar manner at the 5-HT2A receptor. This could potentially explain
the differences in binding affinities of the hybrids. Also the Ket/Ris (104) hybrid binds in a manner
similar to risperidone (14), and this is supported by binding data since Ket/Ris (104) (Ki = 0.96
nM) had a binding affinity similar to that of risperidone (14) (Ki = 5.29 nM).

Ris/Ket (103) (Ki = 12.74 nM) binds with ~ 2-fold lower affinity than risperidone (Ki = 5.29 nM)
and ~1.5-fold higher affinity than ketanserin (36). This suggests that the “right half” of risperidone
(14) makes stronger interactions as compared to the “right half” of ketanserin (36). Ket/Ris (104)
(Ki = 0.96 nM) binds with ~5.5- and ~19-fold higher affinity than risperidone (14) (Ki = 5.29 nM),
and ketanserin (36) (Ki = 18.55 nM), respectively, suggesting that the “left half” of ketanserin (36)
makes stronger interactions at the 5-HT2A receptor as compared to the “left half” of risperidone
(14). The high binding affinity of the Ket/Ris hybrid might be attributed to the quinazolinedione
ring of the Ket/Ris hybrid (104) aligning/superimposing better with the 6,7,8,9-tetrahydro-4Hpyrido[1,2-a]pyrimidin-4-one ring of risperidone (14) as opposed to the quinazolinedione ring of
ketanserin (36).
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Table 6. Summary of HINT scores for binding modes 1 and 2 of risperidone (14), ketanserin
(36), and analogs 103 and 104.
Binding mode
Polar
Hydrophobic
Total HINT score*
Risperidone (14); Mode 1

1523

1225

1204

Risperidone (14); Mode 2

1475

1280

1001

Ketanserin (36); Mode 1

1658

900

1112

Ketanserin (36); Mode 2

1649

872

556

Ris/Ket (103); Mode 1

1387

1054

1044

Ris/Ket (103); Mode 2

1429

1357

992

Ket/Ris (104); Mode 1

1547

870

1121

Ket/Ris (104); Mode 2

1699

872

848

*Other terms, e.g., hydrophobic-polar, acid-acid and base-base are reflected in this total.

Figure 50 shows analogs 109 and 110 docked at the 5-HT2A receptor. It can be compared to
docking mode 1 of risperidone (14), however, the 6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin4-one ring system ring system was displaced, and the fluorine atom of analog 110 is oriented
differently as compared to the fluorine atom of risperidone (14) (Figure 50).
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Figure 50. A comparison of the docking modes of analogs 109 (salmon) and 110 (green) with
risperidone (14) (cyan) (docking mode 1).
Figure 51 shows the receptor-ligand interactions that analogs 109 and 110 make with the 5-HT2A
receptor in docking mode 1. A bidentate ionic interaction between the protonated amines of
analogs 109 and 110 and Asp155 as well as a hydrogen bond between the oxygen atom of the
6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one ring system and Tyr370 was observed.
Hydrophobic interactions with the amino acids Thr134, Ile152, Val156, Leu228, Phe234, Val235,
Phe339, Phe340, Leu362, Trp336, Trp367, and Tyr370 were observed for analogs 109 and 110.
Analog 109 had a total HINT score of 1065, whereas analog 110 had a HINT score of 881 (Table
7), suggesting that analog 109 makes overall more favorable interactions in docking mode 1 at the
5-HT2A receptor. However, the difference in total HINT scores does not appear to be substantial.
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Figure 51. Docking modes of analogs 109 (salmon) and 110 (green) at the 5-HT2A receptor
(docking mode 1). The red dashed lines indicate ionic interactions and the blue dashed lines
indicate hydrogen bonds.
Figure 52 shows analogs 109 and 110 docked at the 5-HT2A receptor. It can be compared to
docking mode 2 of risperidone (14), however, the 6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin4-one ring system ring system was flipped by ~180 º along the horizontal axis, and the fluorine
atom of analog 110 was oriented differently as compared to the fluorine atom of risperidone (14)
(Figure 52).
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Figure 52. A comparison of the docking modes of analogs 109 (salmon) and 110 (green) with
risperidone (14) (cyan) (docking mode 2).

Figure 53 depicts the receptor-ligand interactions that analogs 109 and 110 make with the 5-HT2A
receptor in docking mode 2. The nitrogen atoms of the indole rings of analogs 109 and 110 formed
a hydrogen bond with Asn363. An ionic interaction between the protonated amines and Asp155
as well as a hydrogen bond between the N1 nitrogen atom of the 6,7,8,9-tetrahydro-4H-pyrido[1,2a]pyrimidin-4-one ring system and Ser159 was observed. Hydrophobic interactions with the amino
acids Thr134, Trp151, Ile206, Leu228, Leu229, Ile236, Phe234, Phe339, Phe340, and Tyr370 were
observed for analogs 109 and 110. The fluorine atom of analog 110 was involved in a hydrophobic
interaction with Leu362. Analog 109 had a total HINT score of 1083, whereas analog 110 had a
HINT score of 1297 (Table 7), suggesting that analog 110 makes overall more favorable
interactions at the 5-HT2A receptor in docking mode 2. However, the difference in total HINT
scores does not appear to be substantial.
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Figure 53. Docking modes of analogs 109 (salmon) and 110 (green) at the 5-HT2A receptor
(docking mode 2). The red dashed lines indicate ionic interactions and the blue dashed lines
indicate hydrogen bonds.
Based on the total HINT scores both binding modes might exist for analog 109, whereas binding
mode 2 seems to be more likely for analog 110.

Table 7. Summary of HINT scores for binding modes 1 and 2 of risperidone (14) and analogs
109 and 110.
Binding mode

Polar

Hydrophobic

Total HINT score*

Risperidone (14) Mode 1

1523

1225

1204

Risperidone (14) Mode 1

1475

1280

1001

109; Mode 1

2038

952

1065

109; Mode 2

2175

1026

1083

110; Mode 1

2010

890

881

110; Mode 2

2160

1091

1297

*Other terms, e.g., hydrophobic-polar, acid-acid and base-base are reflected in this total.
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Analogs 111 and 112 showed two docking modes at the 5-HT2A receptor (Figures 54, 55 and 56).

Figure 54 shows analogs 111 and 112 docked at the 5-HT2A receptor. The binding mode was
consistent with binding mode 1 of risperidone (14), however, the 2-methyl-6,7,8,9-tetrahydro-4Hpyrido[1,2-a]pyrimidin-4-one ring system (“left half”) of analogs 111 and 112 was oriented
differently. Both analogs formed the essential ionic interaction with Asp155. The nitrogen atoms
of the indole rings of both analogs formed a hydrogen bond with Ser159. Hydrophobic interactions
with amino acid residues Trp151, Val156, Leu228, Leu229, Ile236, Trp336, Phe339, Phe340, and
Tyr370 were observed for both analogs.

Figure 54. Docking modes of risperidone (14) (cyan), and analogs 111 (violet) and 112 (magenta)
at the 5-HT2A receptor (docking mode 1). The red dashed lines indicate ionic interactions and the
blue dashed lines indicate hydrogen bonds.

In the second binding pose, analogs 111 and 112 were positioned in a manner similar to binding
mode 2 of risperidone (14) at 5-HT2A receptors (Figure 55). However, the 6,7,8,9-tetrahydro-4H-
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pyrido[1,2-a]pyrimidin-4-one ring system (“left half”) of analogs 111 and 112 was flipped by
~180º about the horizontal axis when compared to the “left half” of risperidone (14).

Figure 55. A comparison of docking modes of analogs 111 (violet) and 112 (magenta) with the
docking mode 2 of risperidone (14) (cyan) at 5-HT2A receptors.

The receptor-ligand interactions that analogs 111 and 112 make with the 5-HT2A receptor in
docking mode 2 are illustrated in Figure 56. The “left halves” of analogs 111 and 112
superimposed well, and were predominantly involved in hydrophobic interactions. The “right
halves” of analogs 111 and 112 are comprised of an indole ring system and were oriented
differently with respect to each other as well as with respect to the “right half” (benz[d]isoxazole
ring) of risperidone (14). The protonated amines of both analogs formed a bidentate ionic
interaction with the amino acid residue Asp155, and a hydrogen bond with Tyr370. The fluorine
atom of analog 112 formed a hydrogen bond with Thr134. Additional hydrophobic interactions
with amino acid residues Ile163, Trp151, Val156, Thr160, Leu228, Leu229, leu362, Trp336,
Phe340, Val366 and Tyr370 were observed.
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Figure 56. Docking modes of analogs 111 (violet) and 112 (magenta) at the 5-HT2A receptor
(docking mode 2). The red dashed lines indicate ionic interactions and the blue dashed lines
indicate hydrogen bonds.

Modeling studies suggest that both binding modes are equally possible. Total HINT scores for
analogs 111 and 112 are summarized in Table 8. Binding mode 2 seemed to have an overall higher
HINT score as compared to the HINT score for binding mode 1 for analogs 111 and 112, and
suggested more favorable interactions at 5-HT2A receptors in binding mode 2. However, the
differences in the total HINT scores do not appear to be substantial. Analog 111 represents the
desfluoro analog of compound 112. Preliminary biological data indicate that analog 111 (Ki ~ 285
nM) binds with ~57-fold lower affinity than analog 112 (Ki ~ 5 nM) , suggesting that the fluoro
group of analog 112 is playing a role in enhancing its binding affinity. In binding mode 1 for
analog 112, the fluorine atom did not seem to be making any significant contributions whereas in
binding mode 2 the fluorine atom of analog 112 formed a hydrogen bond with Thr134. Hence,
analogs 111 and 112 might be binding at the receptor in a manner that is consistent with binding
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mode 2. The binding affinity of analog 112 is similar to the binding affinity of risperidone (14)
suggesting that they might bind in a similar manner. However, the nitrogen atom of the indole ring
of 112 is a hydrogen bond donor whereas the nitrogen and oxygen atoms of the benz[d]isoxazole
ring of risperidone (14) are hydrogen bond acceptors and the nature of the hydrogen bonds they
make with the receptor are different. This also suggests that the bifurcated hydrogen bond may not
be crucial for binding affinity, and that risperidone (14) might be binding in a manner that is
consistent with binding mode 2, even though both modes might exist.

Table 8. Summary of HINT scores for binding modes 1 and 2 of risperidone (14) and analogs
111 and 112.
Binding mode
Polar
Hydrophobic
Total HINT score*
Risperidone (14), Mode 1

1523

1225

1204

Risperidone (14), Mode 2

1475

1280

1001

111 ; Mode 1

1316

1161

629

111; Mode 2

1495

1163

648

112; Mode 1

1263

1217

666

112; Mode 2

1411

1238

782

*Other terms, e.g., hydrophobic-polar, acid-acid and base-base are reflected in this total.

Analog 113 showed two docking modes at 5-HT2A receptors (Figures 57 and 58).

Figure 57 depicts analog 113 docked at the 5-HT2A receptor in a manner similar to docking mode
1 of risperidone (14). Analog 113 interacted with the 5-HT2A receptor in a manner that has been
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previously described for risperidone (14). The 2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one ring
system (“left half”) of analog 113 is oriented differently as compared to the 2-methyl-6,7,8,9tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one ring system (“left half”) of risperidone (14), and
makes an additional hydrophobic interaction with Leu362.

Figure 57. Docking modes of risperidone (14) (cyan) and analog 113 (pink) at the 5-HT2A receptor
(docking mode 1). The red dashed lines indicate ionic interactions and the blue dashed lines
indicate hydrogen bonds.

Figure 58 shows analog 113 docked at the 5-HT2A receptor in a manner similar to docking mode
2 of risperidone (14). Analog 113 interacts with the 5-HT2A receptor in a manner that has been
previously described for docking mode 2 of risperidone (14).
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Figure 58. Docking modes of risperidone (14) (cyan) and analog 113 (pink) at the 5-HT2A receptor
(docking mode 2). The red dashed lines indicate ionic interactions and the blue dashed lines
indicate hydrogen bonds.

Table 9 summarizes the HINT scores for docking modes 1 and 2 of analog 113. Both modes seem
possible, and there does not appear to be a substantial difference in the total HINT scores of
risperidone (14) and analog 113.

Table 9. Summary of HINT scores for binding modes 1 and 2 of risperidone (14), and analog 113.
Binding mode
Polar
Hydrophobic
Total HINT score*
Risperidone (14); Mode 1

1523

1225

1204

Risperidone (14); Mode 2

1475

1280

1001

113; Mode 1

1654

1131

904

113; Mode 2

1575

1008

1102

*Other terms, e.g., hydrophobic-polar, acid-acid and base-base are reflected in this total.
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Analogs 114, 115, 116 and 117 showed two docking modes at the 5-HT2A receptor (Figures 59,
60, 61 and 62).

Figure 59 shows analogs 114-117 docked at the receptor in a pose that is analogous to docking
mode 1 of risperidone (14). The benz[d]isoxazole rings (“right half”) of all four analogs (114, 115,
116 and 117) were oriented in a manner similar to risperidone (14), the nitrogen and oxygen atoms
of the benz[d]isoxazole rings form a bifurcated hydrogen bond with Ser159. The “left halves” of
the molecules were oriented differently with respect to each other as well as risperidone (14).
Hydrophobic interactions with amino acid residues Trp151, Val156, Thr134, Leu228, Leu229,
Trp336, Phe339, Phe340 and Tyr370 were observed for all analogs. The phenyl rings of analogs
115 and analogs 117 formed additional hydrophobic interactions with Leu362 and Asn363. Analog
116 and 118 formed additional hydrophobic interactions with Leu362 and Trp141, respectively.
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Figure 59. Docking modes of risperidone (14), and analogs 114 (violet), 115 (light orange), 116
(purple), and 117 (pale yellow) at the 5-HT2A receptor (docking mode 1). The red dashed lines
indicate ionic interactions and the blue dashed lines indicate hydrogen bonds.

Figure 60 shows analogs 114 and 116 docked at the 5-HT2A receptor. The orientation can be
compared to docking mode 2 of risperidone (14) at the 5-HT2A receptor.

Figure 60. A comparison of the docking modes of risperidone (14), and analogs 114 (violet) and
116 (purple), at the 5-HT2A receptor.

The receptor-ligand interactions that analogs 114 and 116 make with the 5-HT2A receptor are
depicted in Figure 61. The protonated amines of analogs 114 and 116 formed an ionic interaction
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with the amino acid residue Asp155, and a hydrogen bond with Tyr370. The carbonyl oxygen
atoms of both the molecules formed a hydrogen bond with Ser242, the carbonyl oxygen atom of
analog 114 formed an additional hydrogen bond with Thr160. Additional hydrophobic interactions
with Thr134, Ile206, Leu228, Leu229, Val235, Trp336, Phe339, Phe340, Asn343, and Val366
were observed for both analogs.

Figure 61. Docking modes of analogs 114 (violet) and 116 (purple) at the 5-HT2A receptor
(docking mode 2). The red dashed lines indicate ionic interactions and the blue dashed lines
indicate hydrogen bonds.

Figure 62 shows analogs 115 and 117 docked at the 5-HT2A receptor in an orientation similar to
the docking mode 2 of risperidone (14). The benz[d]isoxazole rings (“right half”) of both analogs
aligned with the benz[d]isoxazole ring of risperidone (14), and the oxygen and fluorine atoms of
benz[d]isoxazole rings of the analogs formed hydrogen bonds with Thr134 and Trp151,
respectively. Additionally, hydrophobic interactions with Ile135, Trp151, Ile152, Leu228, Leu229,
Phe234, Leu362, Trp336, Phe339, Phe340, Val 366, Trp367 and Tyr370 were observed.
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Figure 62. Docking modes of risperidone (14) (cyan), and analogs 115 (salmon) and 117 (pale
yellow) at the 5-HT2A receptor (docking mode 2). The red dashed lines indicate ionic interactions
and the blue dashed lines indicate hydrogen bonds.
The HINT scores for analogs 114, 115, 116, and 117 are summarized in Table 10.
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Table 10. Summary of HINT scores for binding modes 1 and 2 of risperidone (14) and analogs
114, 115, 116 and 117.
Binding mode
Polar
Hydrophobic
Total HINT score*
Risperidone (14); Mode 1

1523

1225

1204

Risperidone (14); Mode 2

1475

1280

1001

114; Mode 1

1510

838

992

114; Mode 2

1701

763

927

115; Mode 1

1344

931

1004

115; Mode 2

1285

897

1199

116; Mode 1

1669

784

769

116; Mode 2

1609

931

853

117; Mode 1

1548

984

1274

117; Mode 2

1287

807

996

*Other terms, e.g., hydrophobic-polar, acid-acid and base-base are reflected in this total.

Modeling studies suggest that both binding modes are possible for analogs 114, 115, 116 and 117.
The total HINT scores for the analogs do not appear to be substantially different.

3. Summary
Modeling studies suggest that risperidone (14) might bind in two different modes that might be
equally feasible. However, biological data suggests that a fluorine atom enhances binding affinity,
and that the carbonyl oxygen group might contribute towards enhancing 5-HT2A receptor
antagonist activity, albeit to a very small extent. This suggests that binding mode 2 of risperidone
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(14) might be the preferred orientation, since both the fluoro group and the carbonyl group make
interactions with the receptor in binding mode 2. Additionally, modeling studies suggest that
ketanserin might be utilizing binding mode 1 suggesting that risperidone (14) and ketanserin (36)
might have different orientations at the 5-HT2A receptor.

The different scenarios for preferred binding modes of risperidone (14) and its analogs are
summarized in Table 11.

Table 11. A summary of the preferred binding modes of risperidone (14) and its deconstructed
and elaborated analogs.
Binding modes
Analogs
Mode 1 = Mode 2

Risperidone (14), 64, 68, 103, 104, 111, 112, 113, 114, 115,
116, 117

Mode 1 > Mode 2

Ketanserin (36)

Mode 1 < Mode 2

110

No mode 1, only mode 2

57, 58, 59
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D. Specific Aim 4. mGlu2 receptor PAMs
a. Molecular modeling studies of the allosteric site of the mGlu2 receptor to determine
whether structurally diverse PAMs of the mGlu2 receptor bind in a similar manner and in
the same binding pocket
1. Approach
The mGlu2 receptor allosteric site is in the TMD.192 Molecular modeling studies of the TMD of
the mGlu2 receptor were conducted to study the allosteric binding site, and also to determine how
structurally diverse mGlu2 receptor PAMs bind relative to one another and whether they bind in
the same binding pocket.

At the time the modeling studies were conducted there was limited mutagenesis data available,
and the PAM binding pocket was not well defined. Schaffhauser et al.192 have identified that
Ser688 (TM4), Gly689 (TM4), and Asn735 (TM5) are important for positive allosteric modulation
of the mGlu2 receptor. They identified that either Ser688 or Gly689 in combination with Asn735
or a combination of all three residues together forms the binding pocket of the PAM LY487379
(44) (Figure 21).192 Hemstapat et al.193 subsequently reported mutagenesis data for LY487379 (44)
(Figure 21) binding that was consistent with previous studies by Schaffhauser et al.192 They
additionally reported that binding of the structurally diverse PAM BINA (43) (Figure 21) is also
affected by Ser 688 (TM4), Gly 689 (TM4) and Asn735 (TM5) mutants, and potentially binds in
the same binding pocket as LY487379 (44). LY487379 (44) and BINA(43) are selective for the
mGlu2 receptor over the mGlu3 receptor.192,193 Hempstapat et al.193 have demonstrated that the
negative allosteric modulator (NAM) MNI-135 is not affected by mutations of Ser688, Gly689
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and Asn735, and does not show any selectivity for the mGlu2 receptor over the mGlu3 receptor,
suggesting that the mGlu2 receptor might have multiple allosteric binding sites. Conversely,
Lundstrӧm et al.194 have reported that Asn 735 mutants do affect the activity of NAMs, albeit to a
lower extent than that of PAMs. However, they were not able to find any direct interactions
between NAMs and Asn735 and they have hypothesized that Asn735 might be important for
receptor stabilization. Additionally, Lundstrӧm et al.194 demonstrated that NAMs: RO4988546 and
RO5488608 can completely displace the [3H] PAM- [3H]-2,2,2-TEMPS, suggesting that NAMs
and PAMs of the mGlu2 receptor might occupy overlapping sites.

A cavity search was performed using the MOLCAD function in SYBYL-X 2.1. Five cavities were
detected. (Figure 63 A). Ser688, Gly689 and Asn735 were not a part of the same cavity. Asn735
was located close to a larger and more well defined pocket (Figure 63 B). Based on the cavity
search, and site-directed mutagenesis studies, we defined the PAM binding pocket as being within
a 10 Å radius of the amino acid residue Asn735 (TM5) for our docking studies. Figure 64 illustrates
the PAM JNJ-40411813 (45) docked in our homology model of the TMD of the mGlu2 receptor.
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Figure 63. (A) Potential binding pockets in the TMD of the mGlu2 receptor; (B) binding pockets
located close to residues Ser688, Gly689 and Asn735.
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Figure 64. JNJ-40411813 (45) docked in our mGlu2 receptor homology model.

Four known mGlu2 receptor PAMs: BINA (43), LY487379 (44), JNJ-40411813 (45), and JNJ40068782 (46) (Figure 21) were selected for our docking studies.

The mGlu2 receptor is composed of 872 amino acids and is about 96 kDa. [Universal Protein
Resource (UniProt) database; accession code: Q11416]. The extracellular domain of the mGlu2
receptor has been crystallized and houses the orthosteric binding site.195 Since the crystal structure
of the TMD of the mGlu2 receptor has not yet been solved, three-dimensional homology models
of the TMD of the mGlu2 receptor were constructed.

2. Results and discussion
a. Template, alignment and generation of homology models
The metabotropic glutamate receptor type 5 (mGlu5) shares high sequence identity (~50%) with
the mGlu2 receptor. The crystal structure of the TMD of mGlu5 receptor co-crystallized with the
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NAM mavoglurant has been solved (PDB ID:4OO9; resolution: 2.6 Å),196 and served as a template
for building homology models of the mGlu2 receptor. One major disadvantage of using this
template is that it is the crystal structure of the inactive form of the receptor. The X-ray crystal
structure of the mGlu5 receptor suggests that Lys665 in TM3 forms a salt-bridge interaction (ioniclock) with Glu770 in TM6, and also interacts with Ser 613 in intracellular loop 1 (ICL1).196 Arg668
in TM3 forms a H-bond with Ser614 in ICL1, and constitutes a secondary lock tethering TM3 to
TM6 via a secondary lock (Figure 65).196 Lys665, Glu770 and Ser613 are highly conserved across
most class C GPCRs, and this ionic-lock can be considered a hallmark feature of the inactive state
of the receptor.196 However, the mechanism of activation still lacks understanding and a likely
active state is still unknown.

Figure 65. Ionic lock mechanism for maintenance of the inactive state of the mGlu5 receptor.196

The mGlu2 receptor TMD sequence was obtained in the form of a FASTA file from the Universal
Protein Resource (UniProt) database (UniProt accession code: Q14416), whereas the FASTA file
for the sequence of the template was obtained from the Protein Databank (PDB ID: 4OO9). The
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mGlu2 receptor TMD amino acid sequence was aligned with the amino acid sequence of the TMD
of the mGlu5 receptor using CLUSTAL X 2.1.178 Since the sequence identity between the mGlu2
receptor and the mGlu5 receptor is high (~50%) the sequences aligned well. (Figure 66)

Figure 66. Sequence alignment of the mGlu5 receptor (template) with the mGlu2 receptor (to be
modeled).
(*) fully conserved residues between the sequences; (:) highly conserved residues between the
sequences; (.) weakly conserved residues between the sequences.
Homology models (100) were generated using MODELLER v9.12.179 Hydrogen atoms were
added to the homology models and disulfide bonds were built using SYBYL-X 2.1. Figure 67
illustrates a homology model of the TMD of the mGlu2 receptor that was generated as a part of
this study.
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Figure 67. A representative homology model of the TMD of the mGlu2 receptor that was generated
as a part of this study.

b. Validation and Docking studies
Ramachandran plots were generated using MolProbity.197 The plots (Figure 68) indicated that
97.5% (231/237) of the residues were in favored regions, 99.6% (236/237) of the residues were
in allowed regions, and there was one outlier (Gln790).
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Figure 68. Ramachandran plot for a homology model of the mGlu2 receptor [Gln211 corresponds
to Gln790 (amino acids were renumbered after generation of the Ramachandran plot)].

Molecules were sketched using SYBYL-X 2.1, energy-minimized, and docked into the 100
homology models of the mGlu2 receptor using GOLD Suite 5.2,187 The docking solutions were
scored using the ChemPLP function. Docked solutions were divided into clusters using a script
provided by Dr. Philip Mosier (Intracluster RMSD ≤ 2.0 Å). Top solutions (based on ChemPLP
scores and cluster size) were analyzed using SYBYL-X 2.1, and best models were selected. Best
models and solutions were merged and energy-minimized. HINT188 analysis was performed to
choose the best models.

Four well characterized PAMs- BINA (43), LY487379 (44), JNJ-40411813 (45), and JNJ40068782 (46) (Figure 21) were docked in our homology models, and all four ligands were found
to have a common docking pose and docked in the same binding pocket (Figure 69). Based on our
modeling studies we have proposed that the PAM binding pocket is comprised of the following
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amino acid residues: Arg635 (ECL2). Leu639, Gly640, Phe643 (TM3), Ser731, Met728, Leu732,
Asn735, Val736, Ser737 (TM5), Thr769, Ile772, Trp773 (TM6), Met794, Ser797, Val798 (TM7).

After the completion of our molecular modeling studies conducted to gain insight into the binding
mode of PAMs, a study characterizing the binding pocket of PAMs with mutagenesis data and
homology modeling of the TMD of the mGlu2 receptor by Farinha et al.198 and more recently by
Lundstrӧm et al.199 was reported. Site-directed mutagenesis data reported in the literature have
shown the following residues to be important for the activity of multiple PAMs : Arg635, Leu639,
Phe643 (TM3), Ser688, Gly689 (TM4), Leu732 (TM5) and Trp773, Phe776 (TM6),
Ser797(TM7),192,198,199 Trp773, and Asn735 mutants impact the activity and potency of most
PAMs to a greater extent as compared to mutants of other amino acid residues.198

The binding pocket for PAMs that we characterized is similar to what has now been reported in
the literature.198,199 Of these, the amino acid residues Arg635, Leu639, Phe643, Leu732, Asn735,
Trp773, and Ser797 were found important in prior site-directed mutagenesis studies

Ser688 and Gly689 were not located close to the binding pocket of PAMS. It has been suggested
that Ser688 and Gly689 might be involved in indirect signaling effects or in receptor
dimerization.198

The receptor-ligand interactions for PAMs: BINA (43), LY487379 (44), JNJ-40411813 (45), and
JNJ-40068782 (46) with the mGlu2 receptor are shown in Figure 69.
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The oxygen atoms of the indanone ring of BINA (43), the sulfonyl group of LY487379 (44), and
the oxygen atoms of the pyridone rings of JNJ-40411813 (45) and JNJ-40068782 (46) formed a
hydrogen bond with Ser797. The carboxylate group of BINA (43) formed an ionic salt-bridge
interaction with Arg635. Additionally, the molecules formed hydrophobic interactions with
Leu639, Phe643, Leu732, Val736, Ile739, Ile772, Trp773 and Val798. BINA (43) makes an
additional hydrophobic interaction with Met794. Site-directed mutagenesis data suggests that
Asn735 is important for binding of PAMs; however, we did not observe any hydrogen bonds with
Asn735 in this docking pose, and as previously suggested for NAMS, Asn735 might be involved
in receptor stabilization.194

Figure 69. Receptor-ligand interactions of BINA (43) (cyan), LY487379 (44) (salmon), JNJ40411813 (45) (yellow), and JNJ-40068782 (46) (magenta) with the mGlu2 receptor (binding
mode 1). The red dashed lines indicate ionic interactions and the blue dashed lines indicate
hydrogen bonds.

BINA (43) and LY487379 (44) also dock in a different orientation where we observed hydrogen
bonds with Asn735, and are shown in Figures 70 and 71, respectively.
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The receptor-ligand interactions for BINA (43) with the mGlu2 receptor (docking mode 2) are
shown in Figure 70. The oxygen atom of the indanone ring of BINA (43) forms a hydrogen bond
with Asn735. Hydrophobic interactions with the amino acid residues Leu639, Leu732, Val736,
Phe643, Met728, Trp773, Phe776, Ile 779, Val796, Val798, Thr793, and Leu800 were observed.

Figure 70. Receptor-ligand interactions for BINA (43) with the mGlu2 receptor (docking mode 2).
The blue dashed indicate hydrogen bonds.

The receptor-ligand interactions of LY487379 (44) with the mGlu2 receptor (docking mode 2) are
shown in Figure 71. The sulfonyl oxygen atom of LY487379 (44) formed a hydrogen bond with
Asn735, while the pyridinyl nitrogen atom formed a hydrogen bond with Ser801. Hydrophobic
interactions with several amino acid residues such as His723, Leu639, Leu732, Val736, Val798,
Phe643, Phe776, Trp773, Tyr647, Ile739, and Ile772 were observed.
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Figure 71. Receptor-ligand interactions for LY487379 (44) with the mGlu2 receptor (docking
mode 2). The blue dashed lines indicate hydrogen bonds.

HINT scores for PAMs: BINA (43), LY487379 (44), JNJ-40411813 (45), and JNJ-40068782 (46)
are summarized in Table 12. BINA (43) had a higher total HINT score in mode 1 as compared to
mode 2, and mode 1 might be the preferred orientation whereas the total HINT score for mode 2
of LY487379 (44) was higher as compared to mode 1, and LY487379 (44) might bind in a manner
that utilizes mode 2.
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Table 12. Summary of HINT scores for mGlu2 PAMs: BINA (43), LY487379 (44), JNJ-40411813
(45), and JNJ-40068782 (46).
Binding mode
Polar
Hydrophobic
Total HINT score*
BINA (43); Mode 1

2232

1941

1124

BINA (43); Mode 2

531

2083

554

LY487379 (44); Mode 1

881

1482

205

LY487379 (44); Mode 2

1645

883

996

JNJ-40411813 (45)

2227

1077

517

JNJ-40068782 (46)

545

889

113

*Other terms, e.g., hydrophobic-polar, acid-acid and base-base are reflected in this total.

Modeling studies suggest that BINA (43), JNJ-40411813 (45), and JNJ-40068782 (46) might be
binding similarly whereas LY487379 (44) might bind in a different orientation. Additionally, the
HINT scores for all four PAMs seem to be substantially different suggesting that they may have
different binding affinities and/or potencies.

b. Synthesis of the mGlu2 receptor PAM JNJ-40411813 (45)
1. Approach
A long-term goal of this project is to synthesize a bivalent ligand where a 5-HT2A receptor
antagonist will be tethered to an mGlu2 PAM via a linker. An mGlu2 PAM was chosen over an
mGlu2 receptor orthosteric agonist for two main reasons. The allosteric modulatory site is in the
TMD as opposed to the orthosteric agonist binding site that is in the extracellular domain of mGlu2
receptors. This is important because the 5-HT2A receptor antagonist binding site is in the TMD,
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and it might be easier to connect a PAM that binds to the TMD of the mGlu2 receptor as compared
to connecting an orthosteric agonist that binds in the extracellular domain via a linker. Another
reason was that mGlu2 receptor PAMS are selective for mGlu2 receptors over mGlu3 receptors,
whereas orthosteric mGlu2 agonists are not selective for mGlu2 over mGlu3 receptors.193

JNJ-40411813 (45) was chosen for several reasons: (i) the SAR of JNJ-40411813 (45) at the
mGlu2 receptor has been studied previously;119 (ii) JNJ-40411813 (45) has shown antipsychotic
potential in preclinical studies;119 and (iii) the nitrogen atom of the pyridone ring can serve as a
potential positon to attach a linker.

Based on SAR studies we know that the nitrogen atom of JNJ-40411813 (45) can tolerate longer
chain lengths, and our molecular modeling studies suggest that the binding pocket has room to
accommodate a longer chain length, making JNJ-40411813 (45) an ideal candidate.

The synthesis of JNJ-40411813 (45) has been reported by Cid et al,119 and is outlined in Scheme
23. A drawback of this scheme was that the nitrogen substituent was added in the first step. Our
aim was to synthesize multiple compounds, with varying linkers at the nitrogen atom of the
pyridine ring, and hence, we decided to utilize a different synthetic route where the linker would
be added in the penultimate/final step. This would enable us to synthesize multiple molecules
relatively quickly.
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Scheme 23. Synthesis of JNJ-40411813 (45)a (as reported by Cid et al.119).

a

Reagents and Conditions. (i) n-Butyl bromide, K2CO3, MeCN, reflux, 16 h; (ii) Hydrogen,
Pd/C, EtOH, 2 h, 20 ºC, 760.05 Torr; (iii) phosphorous oxybromide, DMF, 100 °C, 1 h; (iv) 4phenylpiperidine, palladium diacetate, sodium t-butanoate, BINAP, toluene, sealed tube, 100 ºC,
16 h; (v) N-chlorosuccinimide, CH2Cl2, 20 °C, 0.17 h.

2. Results and discussion
Scheme 24 outlines a synthetic route that we initially proposed for the synthesis of JNJ-40411813
(45). 4-Bromo-2-chloropyridine (148) was allowed to react with 4-phenylpiperidine to yield
intermediate 149. The product was characterized by mass spectrometry to ensure that the bromo
group, and not the chloro group had been substituted. The substitution of the chloro group of
intermediate 149 with a hydroxy group was attempted. Intermediate 150 is unknown and
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procedures for similar reactions were used. The reaction was carried out using reagents such as
potassium hydroxide,200 sodium hydroxide,201 and acetic acid202 (scheme 24 ii-iv). However, the
yields were low, and we could isolate most of the starting material. The reactions failed to go to
completion, hence, we modified the synthetic route.
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Scheme 24. Unsuccessful synthesis of JNJ-40411813 (45).a

a

Reagents and Conditions. (i) 4-Phenylpiperidine, K2CO3, DMF, 90 ºC, 6 h; (ii) 50% KOH,
DMF, (a) 24 h, reflux, 36 h; (iii) NaOH (2M), H2O, reflux, 30 h; (iv) AcOH, H2O, reflux, 15 h;
(v) KOH (50%), t-BuOH, reflux, 36 h.

The modified synthetic route is outlined in Scheme 25. Intermediate 149 was synthesized as
previously described, and we subsequently attempted to substitute the chloro group with a
benzyloxy group to yield intermediate 151, however the reaction did not progress. We next
modified the synthetic route further. We substituted the chloro group of 148 with a benzyloxy
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group to yield intermediate 152. Intermediate 152 was known and was synthesized using a
procedure for the same compound.203 The nucleophilic substitution of 152 with 4-phenylpiperidne
using K2CO3 in DMF as a solvent resulted in very low yields of 151. Hence, we used a BuchwaldHartwig reaction to synthesize intermediate 151. Intermediate 151 was not known and was
synthesized by a procedure for a similar compound.119 Intermediate 150 was synthesized by the
debenzylation of intermediate 151 using hydrogen and Pd/C as the catalyst. Intermediate 150 was
not known and was synthesized using a procedure for a similar compound.204 The N-alkylation of
intermediate 150 was attempted using various methods (Scheme 25 viii-x), however, they all
resulted in the formation of the O-alkylated product (153) (Figure 72). We further modified the
synthetic scheme.

Figure 72. O-Alkylated product.

159

Scheme 25. Proposed synthesis of JNJ-40411813 (45).a

Reagents and conditions (i) 4-Phenylpiperidine, K2CO3, DMF, 90 ºC, 6 h; (ii) benzyl alcohol, NaH,
THF; (a) room temperature, 48 h; (b) reflux, 24 h; (iii) (a) benzyl alcohol, NaH, THF, room
temperature 15 min; (b) 148, reflux, 3 h; (iv) 4-phenylpiperidine, K2CO3, KI, DMF, 90 ºC, 21 h;
(v) 4-phenylpiperidine, K2CO3, DMF, 110 ºC, 48 h; (vi) 4-phenylpiperidine, palladium diacetate,
sodium t-butanoate, BINAP, toluene, sealed tube, 100 ºC, 27 h; (vii) H2, Pd/C, 30-40 psi, MeOH,
EtOAc, room temperature, 2h; (viii) n-butyl bromide KI, K2CO3, MeCN, reflux, 20 h; (ix) (a) NaH,
DMF, room temperature, 30 minutes; (b) n-butyl bromide, 78 ºC, 4 days (x) (a) NaH, DMF, room
temperature, 1 h; (b) n-butyl bromide, 103 ºC, 3 days.
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The modified synthetic route is outlined in Scheme 26. Intermediate 150 was synthesized as
previously described. Intermediate 150 was chlorinated to yield intermediate 154. Intermediate
154 was unknown and was synthesized using a procedure for a similar compound.119 The Nalkylation of intermediate 154 was attempted using a procedure for N-alkylation of 2-pyridones in
water,205 however the reaction was not clean, and product could not be isolated.
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Scheme 26. Proposed synthesis of JNJ-40411813 (45).a

a

Reagents and conditions. (i) Benzyl alcohol, NaH, THF, reflux, 3 h; (ii) 4-phenylpiperidine,
palladium diacetate, sodium t-butanoate, BINAP, toluene, sealed tube, 100 ºC, 27 h; (iii) H2, Pd/C,
30-40 psi, MeOH, EtOAc, room temperature, 2h.; (iv) N-chlorosuccinimide, CH2Cl2, room
temperature, 10 min; (v) n-butyl bromide, tween 20, K2CO3, 70 ºC, 22 h.

We came within one step of our desired synthetic goal (Scheme 26). But we were ultimately unable
to synthesize JNJ-40411813 (45) using a modified procedure where the linker would be added in
the penultimate/ultimate step. Either an entirely new synthetic route will need to be devised, or the
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scheme that was originally reported in the literature might be used to add the linker in the very
first step since N-alkylation of the compound at a later stage did not yield the desired product.

In any event, such studies are beyond the scope of the present work, and further pursuit of a novel
method of preparation of JNJ-40411813 (45) was abandoned.
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E. Specific Aim 5. Redefining a pharmacophore for 5-HT2A receptor antagonists
1. Approach
5-HT2A Receptor antagonists belong to diverse chemical classes and a number of pharmacophore
models have been proposed to explain the receptor-ligand interactions.

156–159,206,207

Reported

pharmacophore models for 5-HT2A receptor antagonists include two aromatic/hydrophobic regions
and a protonated basic amine (Figure 73), and suggest that these agents might have multiple
binding modes.156–159 When a central ring is flanked by two other ring systems, the fold angle
between the rings seems to play a role as well.208

Figure 73. A representative pharmacophore for 5-HT2A receptor antagonists (data from
references 156-159).
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Risperidone (14) (Figure 8) has been studied in two pharmacophoric studies. A study by Sekhar
et al.209 has identified pharmacophoric features essential for atypical antipsychotic action (SDAs)
(Figure 74). However, the investigation did not specifically address 5-HT2A receptor binding, only
SDA action in general. Hence, it is not particularly relevant to the studies at hand. Another study
by Awadallah210 identified multiple pharmacophoric features for 5-HT2A receptor antagonist
activity (Figure 75).

Figure 74. A pharmacophore for 5-HT2A receptor antagonist action (adapted from Sekhar et al.209).
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F1

Figure 75. A representative pharmacophore for SDAs F1: H-bond acceptor center; F2: aromatic
or hydrophobic center; F3 and F5: Pi orbital accommodation; F4: aromatic center with a H-bond
donor group; F6: hydrophobic center; F7: H-bond acceptor center (adapted from Awadallah210).

The SAR of risperidone (14) at 5-HT2A receptors has not been studied extensively. Deconstruction
studies were conducted in our laboratory to determine the minimal structural requirements for
risperidone (14) to retain 5-HT2A receptor affinity and antagonism (described previously). We have
shown that analog 61 (Ki = 71.41 nM) (Figure 24) that has only half the structural features of
risperidone (14) (Ki = 5.29 nM) binds with ~ 14 fold lower affinity than risperidone (14) and retains
5-HT2A receptor antagonism.141 Furthermore, the N-methyl analog of 61 (analog 60, Ki = 12.27
nM) binds with even higher affinity and retains antagonist activity. This suggests that the entire
structure of risperidone (14) is not necessary for 5-HT2A receptor affinity and antagonism. Analog
61 has only one aromatic region and a basic protonated amine, as opposed to the previously
reported 5-HT2A receptor antagonist pharmacophores156–159 that consist of two aromatic regions
and a basic protonated amine (Figure 73), and lacks many of the features shown in Figures 74 and
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75. To define a revised pharmacophore, analog 155 was proposed (Figure 76) for synthesis and
evaluation. In analog 155 the nitrogen atom of the piperidine ring is located at a shorter distance
from the aromatic center (benzene-ring centroid; Table 13; see also Appendix A) as compared to
the distance for the same in analog 61 (6.81 Å) (in its lowest energy conformation), and will help
evaluate the effect of this distance on 5-HT2A receptor affinity and antagonism. For 5-HT (6), the
distance of the aromatic center from the terminal nitrogen atom is 6.51 Å, and lies in-between the
distances of the aromatic center from the nitrogen atoms for analogs 61 and 155. Analog 63 (Figure
76) will help evaluate the contribution to binding of the fluoro group.

Figure 76. Analogs proposed to define a 5-HT2A receptor antagonist pharmacophore as
compared to the structure of 5-HT (6).
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Table 13. Distances of the aromatic centroid from the N atom and the energy of the lowest
energy conformer (CNF_#) for the different isomers of analog 155 (see Appendix A).
Isomer
Distance (Å)
Energy (kcal/mol)
S equatorial* 155 (CNF_15)

5.75

15.56

R axial** 155 (CNF_1)

5.75

15.22

R equatorial* 155 (CNF_1)

6.45

15.56

S axial** 155 (CNF_1)

5.85

15.94

*Equatorial indicates that the benz[d]isoxazole ring is an equatorial substituent. **Axial indicates
that the benz[d]isoxazole ring is an axial substituent. Distances of the aromatic (benzene-ring)
centroid from the N atom for 5-HT and analog 61 are 6.51 Å and 6.81 Å, respectively.
2. Results
A. Synthesis
The synthesis of analog 155 is outlined in Scheme 27. The amine of nipecotic acid (156) was
protected using a formyl group. Formic acid and acetic anhydride were used to generate formic
acetic anhydride in situ, which then acted as a formylating agent to yield intermediate 157.
Intermediate 157 was unknown, and was synthesized using a procedure for a similar compound.143
The reaction of 157 with thionyl chloride yielded intermediate 158 that was subsequently
converted to 159 via a Friedel Crafts acylation reaction with 1,3-difluorobenzene. Intermediates
158 and 159 were unknown and were synthesized using procedures for similar compounds.153 The
Friedel Crafts acylation reaction was sensitive to moisture and it was necessary to use freshly
sublimed aluminum chloride for the reaction. The reaction of intermediate 159 with
hydroxylamine yielded the E and Z isomers of the oxime 160. The oxime intermediate 160 is not
known and was synthesized by a procedure for a similar compound.143 The cyclization of oxime
160 via intramolecular displacement of the 2-fluoro group to intermediate 161 was catalyzed by
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sodium hydride. It has been reported in the literature that only the Z isomer of the oxime
participates in the cyclization reaction for similar compounds.153 Intermediate 161 was deprotected
using conc. HCl to yield analog 155. Intermediate 161 and analog 155 are unknown and were
synthesized using procedures for similar compounds.153 Analog 155 was characterized by NMR
and C, H, N analysis.

Scheme 27. Synthesis of analog 155.a

a

Reagents and conditions: (i) (a) HCOOH, Ac2O, 65 ºC, 1 h; (b) room temperature, 16 h; (ii) SOCl2,
room temperature, 6 h; (iii) 1,3-difluorobenzene, AlCl3, reflux, 22 h; (iv) NH2OH•HCl,
NaOH/H2O, EtOH, reflux, 96 h; (v) NaH, DMF, THF 75 C, 4h; (vi) HCl (3 N), EtOH, reflux 3 h.
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B. Radioligand binding and functional activity studies
Radioligand binding studies were performed in HEK 293 cells expressing 5-HT2A receptors.
[3H]Ketanserin ([3H]36) was used as the radioligand, and non-specific binding was determined in
the presence of methysergide. Competition curves were generated and analyzed by non-linear
regression analysis to determine the binding affinities (Ki values) of the compounds.

As previously reported analog 61 has a binding affinity of 71.41 nM (log Ki = -7.14 ± 0.09), and
is a 5-HT2A receptor antagonist,141 whereas analog 63 binds to 5-HT2A receptors with an affinity
of ~200 nM (n = 1, performed in duplicate). Analog 155 has a binding affinity of ~256 nM (n = 1,
performed in duplicate) (Figure. 77). However, the racemic mixture of analog 155 was used, and
if any of the stereoisomers are inactive, the binding affinity of the other sterioisomers might be
higher.

.
Figure 77. [3H]Ketanserin binding competition curve by compound 155 in HEK 293 cell
membrane preparations expressing 5-HT2A receptors (n = 1, performed in duplicate).
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C. Molecular modeling studies
Analogs 61, 63, and 155 were docked in homology models of 5-HT2A receptors to study the
receptor-ligand interactions. The analogs were docked into 100 homology models of the receptor
and analyzed as previously described. Analogs 61 and 63 were docked by Dr. Supriya A.
Gaitonde.143

Figure 78 shows analogs 61, 63 and the R equatorial (CNF_1) and S equatorial (CNF_15) (see
Appendix A) isomers of analog 155 docked at the 5-HT2A receptor. They all seem to dock in a
similar manner, however, their benz[d]isoxazole rings are oriented slightly differently and do not
overlap, leading to differences in their interactions with the receptor.

R equatorial-155

S equatorial-155

Figure 78. Docking modes of analog 61 (salmon), 63 (green), R equatorial-155 (CNF_1; violet)
and S equatorial-155 (CNF_15; pink) at the 5-HT2A receptor.

Figure 79 illustrates the interactions that molecules 61 and 63 made with the 5-HT2A receptor. The
nitrogen and oxygen atoms of the benz[d]isoxazole rings formed two bifurcated hydrogen bonds
with Ser159 and Ser242. Both analogs formed a crucial bidentate ionic interaction with Asp155.
171

Additionally, the fluorine atom of analog 61 seemed to be making a potential hydrogen bond with
Ser239. The analogs made hydrophobic interactions with Phe234, Trp336, Phe339, Phe340,
Val156, and Val366.

Figure 79. Docking modes of analogs 61 (salmon) and 63 (green) at the 5-HT2A receptor. The
red dashed lines indicate ionic interactions and the blue dashed lines indicate hydrogen bonds.

Figure 80 shows the R equatorial (CNF_1) and S equatorial (CNF_15) isomers of analog 155
docked at the 5-HT2A receptor. Analog 155 interacts with the receptor in a manner that is different
from analogs 61 and 63. The benz[d]isoxazole rings of the molecules did not show a bifurcated
hydrogen bond. The oxygen atoms of the benz[d]isoxazole rings of both isomers formed hydrogen
bonds with Thr160 and Ser242, and the fluoro groups formed a hydrogen bond with Ser239. The
protonated amine of the R equatorial isomer formed a bidentate ionic interaction with Asp155,
whereas the protonated amine of the S equatorial isomer formed an ionic interaction with the
carbonyl oxygen of Asp155, and a hydrogen bond with Tyr370. Additionally, hydrophobic
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interactions with Phe234, Trp336, Phe339, Phe340, Val156, and Val366 were observed for both
isomers. HINT scores (Table 14) for the R equatorial and S equatorial isomers of analog 155 are
comparable and suggest that they might bind at 5-HT2A receptors with similar affinities.

R equatorial-155

S equatorial-155

Figure 80. Docking modes of R equatorial-155 (CNF_1; violet) and S equatorial-155 (CNF_15;
pink) at the 5-HT2A receptor. The red dashed lines indicate ionic interactions and the blue dashed
lines indicate hydrogen bonds.
HINT scores for analogs 61, 63 and the R equatorial (CNF_1) and S equatorial (CNF_15) isomers
of 155 are shown in Table 14. The HINT scores for all molecules seemed to be comparable. The
interactions of the fluorine atoms with Ser239 are quantified in Table 14.
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Table 14. Summary of HINT scores for analogs 61, 63 and 155.
Binding mode
Polar
Hydrophobic
Total HINT

Ser239

score*
61

1593

430

1366

33

63

1862

342

1463

1

R equatorial 155

1788

442

1391

17

1946

447

1467

14

(CNF_1)
S equatorial-155
(CNF_15)
*Other terms, e.g., hydrophobic-polar, acid-acid and base-base are reflected in this total.

3. Discussion
Based on the preliminary data available so far for analog 155, the distance of the nitrogen atom
from the aromatic center might be playing a role in enhancing the binding affinity of analog 61,
since analog 155 binds with ~3.5-fold lower affinity (if the isomers bind with equal affinity) than
analog 61. The fluorine atom might also be playing a role in enhancing the binding affinity of
analog 61 for 5-HT2A receptors, since analog 63 binds with ~3-fold lower affinity than analog 61.
However, functional activity data on analogs 63 and 155 are required to draw any further
conclusions. Also, remains to be determined: is it the benz[d]isoxazole, the presence of the fluoro
group, the aromatic-to-amine distance, or lack of -OH that converts 5-HT to antagonists.

Based on the data available for analog 61, we propose a new pharmacophore for 5-HT2A receptor
antagonists (Figure 81).
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61

Figure 81. A new pharmacophore for 5-HT2A receptor antagonists based on the structural features
of analog 61.

The proposed pharmacophore consists of only one aromatic region, as opposed to two aromatic
regions that has been previosly reported, a basic protonated amine, and hydrogn bond acceptors.
Interesting is that the centroid-N distance (6.8 Å) is exactly midway between the A-N distance
shown in Figure 72 (i.e., 6.8 Å). In addition, preliminary binding data show that although the fluoro
group of analog 61 is not required, it adds to affinity.
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V. CONCLUSIONS

The 5-HT2A/mGlu2 receptor heteromeric complex has been identified as a novel therapeutic target
for the treatment of schizophrenia.18 A long-term goal of this project is to synthesize a bivalent
ligand that will have a 5-HT2A receptor antagonist moiety tethered to an mGlu2 PAM. The atypical
antipsychotic agent risperidone (14) (Figure 82) is a known 5-HT2A receptor antagonist. However,
the SAR of risperidone (14) at 5-HT2A receptors has not been extensively studied. The current
investigation was conducted to determine the minimal structural requirements for risperidone (14)
to retain 5-HT2A receptor affinity and antagonist action, and to determine where on the
“minimized” structure of risperidone (14) an mGlu2 PAM can be introduced. A “deconstructionreconstruction-elaboration” approach was used to study the SAR of risperidone (14) at 5-HT2A
receptors. The current investigation was also aimed at identifying where on an mGlu2 PAM a
“partial” risperidone structure might be introduced.

The entire structure of risperidone (14) does not appear to be necessary for 5-HT2A receptor affinity
and antagonism since analog 60 (Figure 82) (Ki = 12.74 nM) that has only half the structural
features of risperidone (14) binds with only 2-fold lower affinity than risperidone (14) Ki = 5.29
nM) and is nearly equipotent as an antagonist. Analog 61 (Figure 82) (Ki = 71.41 nM) represents
the “right half” of risperidone (14), and binds with ~13-fold lower affinity than risperidone (14).
Analog 57 (Figure 82) (Ki ~ 2700 nM) represents the “left half” of risperidone (14), and binds with
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~500-fold lower affinity than risperidone (14) suggesting that the “right half” of risperidone (14)
might be more important for binding affinity at 5-HT2A receptors, however, the “left half”
contributes, and might be reinforcing binding affinity. Introduction of amine substituents showed
that the affinity of analog 61 can be enhanced. For example, compound 104 (Figure 82) (i.e.,
Ket/Ris, Ki = 0.96 nM) displayed 75-fold higher affinity than analog 61, and >5-fold higher affinity
than risperidone (14) for 5-HT2A receptors. Deconstruction studies have also suggested that the
fluorine atom of the benz[d]isoxazole ring might be playing a role in enhancing binding affinity
since analogs 62 (Ki ~300 nM) and 63 (Figure 82) (Ki ~200 nM) that are desfluoro analog of
compounds 60 and 61, respectively, bound with ~24- and ~3-fold lower affinities, respectively.
Analog 61, the desmethyl analog of 60, binds with ~6-fold lower affinity at 5-HT2A receptors than
analog 60, suggesting that the methyl group makes additional interactions at the receptor. Analog
63 (Figure 82) binds with similar affinity as analog 62, suggesting that the methyl group might not
be making additional favorable interactions in this case at the receptor, and that analogs 60 and 61
might have different binding modes as compared to analogs 62 and 63.

177

Figure 82. Compounds discussed in the conclusion section.
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Analogs 65 and 66 (Figure 82) bind with reduced binding affinity, and are less potent antagonists
as compared to risperidone (14). However, the carbonyl group might contribute.

Hybrid molecules Ris/Ket (103) and Ket/Ris (104) (Figure 82) were also examined to study the
relative binding modes of risperidone (14) and ketanserin (36) (Figure 82). The Ket/Ris (104)
hybrid that has the quinazolinedione ring of ketanserin (36) and the benz[d]isoxazole ring of
risperidone (14) bound to 5-HT2A receptors with high affinity (Ki = 0.96 nM), and had a 5-, 13-,
and 19-fold higher affinity than risperidone (14), the Ris/Ket (103) hybrid, and ketanserin (36).
This suggests that the quinazolinedione ring of the Ket/Ris (104) hybrid might be enhancing the
binding affinity of the “right half” of risperidone to a greater extent than the 6,7,8,9-tetrahydro4H-pyrido[1,2-a]pyrimidin-4-one ring system of risperidone (14). The Ris/Ket (Ki = 12.74 nM)
hybrid has the “left half” of risperidone (14), and binds with ~2-fold lower affinity than risperidone
(14) suggesting that the “right half” of risperidone (14) might be contributing to its binding affinity
to a greater extent as compared to the “left half”.

Functional activity data obtained from the TEVC assay suggests that the hybrids might have
different functional activities at 5-HT2A receptors. Ris/Ket (103) blocked the effects of 5-HT in a
manner similar to that of risperidone (14), and appears to be a 5-HT2A receptor antagonist whereas
Ket/Ris (104) did not block the effects of 5-HT. When examined in the absence of 5-HT, Ket/Ris
(104) demonstrated partial agonist activity. However, the observed efficacy of the Ket/Ris (104)
hybrid might have been due to its direct effects at the GIRK4* channel that might be masking its
potential antagonist activity, and this needs to be evaluated further. The “left” and “right” half of
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the Ket/Ris (104) hybrid is composed of 5-HT2A receptor antagonists ketanserin (36), and
risperidone (14), respectively. The “right half” of risperidone (14) is represented by analog 61 that
has been shown to be a 5-HT2A receptor antagonist as a part of this investigation as well as in
previous studies conducted in our laboratory.140 The 6-fluoro-(3-piperidinyl)benz[d]isoxazole
moiety is common to atypical antipsychotic agents such as risperidone (14), paliperidone (56)
(Figure 23), and iloperidone (24) (Figure 12), as well as in agents that produce antipsychotic effects
such as ADN-1184 (162) (Figure 83), a MARTA that is a high affinity 5-HT2A receptor antagonist
(Ki = 2 nM),211 and compound 163 (Figure 83), a 5-HT2A/dopamine D3 receptor antagonist that
has high affinity for 5-HT2A receptors (Ki = 2 nM).212 Binding affinities (Ki values) for ADN-1184
(162)211 and 163212 were determined in HEK 293 cell membrane preparations that utilized [3H]
ketanserin as the radioligand.

All of them have diverse “left halves”, however, they all retain 5-HT2A receptor affinity and
antagonism. Based on literature precedent, Ket/Ris (104) should be a 5-HT2A receptor antagonist
since it has a 6-fluoro-(3-piperidinyl)benz[d]isoxazole moiety that is common to multiple 5-HT2A
receptor antagonists. However, we can only speculate until further functional activity studies are
conducted.

Figure 83. Representative agents that show antipsychotic activity.
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Analog 60 (Ki = 12.27 nM) and the Ket/Ris (104) (Ki = 0.96 nM) hybrid bind with ~6- and ~74fold higher affinities than analog 61, respectively. Also, as previously discussed above, analog 61
is common to several high affinity 5-HT2A receptor antagonists that have diverse “left halves”.
This suggests that adding substituents to the piperidinyl nitrogen atom can enhance binding
affinity, and represents a position where a linker might be attached without potentially
compromising the molecules 5-HT2A receptor binding affinity. Additionally, studies have shown
that analog 61 can also crosstalk at the 5-HT2A receptor/mGlu2 receptor heteromer. This crosstalk
has been demonstrated for antipsychotic agents such as clozapine (8) and risperidone (14).22
Hence, analog 61 represents the “minimized risperidone” structure that could potentially be used
to synthesize the bivalent ligand.

Elaborated analog 112 (Figure 82) (Ki ~4.8 nM) has a 6-fluoro-N-methyltryptamine moiety instead
of the 6-fluorobenz[d]isoxazole ring of risperidone (14), and binds with an affinity that is
comparable to the binding affinity of risperidone (14) (Ki = 5.29 nM) at 5-HT2A receptors. This
suggests that the benz[d]isoxazole ring of risperidone (14) might not be crucial for its binding
affinity since it can be replaced by an indole ring. In fact, there are reports in the literature to
suggest that indole rings of tryptamines and benz[d]isoxazole rings are isosteric, and that they
might bind in a similar manner.213 Analog 111 (Figure 82) represents the desfluoro analog of
compound 112, and binds with ~57-fold lower affinity than analog 112, again suggesting that the
fluoro group might be important for binding affinity.
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Molecular modeling studies with deconstructed and elaborated analogs of risperidone (14) suggest
that the fluorine atom might be involved in a hydrogen bonding interaction with 5-HT2A receptors.
The amino acid residue that participates in the hydrogen bond with the fluorine atom varies for
different molecules. Additionally, risperidone (14) and its analogs might utilize more than one
binding mode.

Molecular modeling studies of the mGlu2 receptor suggested that the chemically diverse PAMS:
BINA (43), LY487379 (44), JNJ-40411813 (45), and JNJ-40068782 (46) (Figure 69) dock in the
same binding pocket.

Molecular modeling studies conducted as a part of this study as well as SAR studies reported in
the literature119 suggest that the pyridone nitrogen atom of the PAM JNJ-40411813 (45) can
tolerate longer chain lengths, and represents a potential position to attach a linker.

Deconstruction of risperidone (14) studies suggested that only half the structural features (analog
61) of risperidone (14) are required to retain binding affinity and 5-HT2A receptor antagonism.
This is in contrast to previously reported pharmacophores156–159 for 5-HT2A receptor antagonists in
the literature that consist of two aromatic regions. Binding data on analogs 61 and 155 (Figure 76)
suggests that the distance of the aromatic center from the protonated amine might influence
binding affinity, with a distance of ~6.8 Å being optimal. Binding data on analog 63 suggest that
the fluorine atom might be important for 5-HT2A receptor affinity. Based on the data available so
far, we have proposed a new pharmacophore for 5-HT2A receptor antagonists that is comprised of
182

only one aromatic center, a basic protonated amine and hydrogen bond acceptors. Perhaps this
pharmacophore was never previously identified because nearly all of the earlier agents possessed
two or more aromatic rings.

Overall we (i) identified a risperidone-like pharmacophore for 5-HT2A receptor antagonist action,
(ii) demonstrated that a fluoro group contributes to 5-HT2A receptor affinity, (iii) investigated
binding modes of risperidone (14) and risperidone analogs revealing that more than one mode of
binding might be possible, (iv) identified where on the pharmacophore (i.e, the piperidine amine)
substituents might be attached without loss (and, indeed, with enhancement) of 5-HT2A receptor
affinity, (v) examined the modes of binding of various mGlu2 PAMs at models of the mGlu2
receptor, (vi) identified, together with known SAR information, a PAM and a potential linker site
for eventual construction of bivalent ligands, and (vii) explored potential synthetic routes that
might be of value in the synthesis of bivalent ligands.
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VI. EXPERIMENTAL

A. Synthesis
Compounds were characterized using proton nuclear magnetic resonance (1H NMR), infrared (IR)
spectroscopy (where applicable), mass spectrometry (MS) (where applicable). and by elemental
analysis (if unkown) for C, H and N performed by Atlantic Microlab Inc. (Norcross, GA).
Compounds were considered pure if the elemental analysis values obtained were within 0.4% of
theoretical values. Melting points were measured on Thomas Hoover or MEL TEMP (if melting
points were above 200 ºC) melting point apparatuses and are uncorrected. 1H NMR spectra were
obtained using a Bruker ARX 400 MHz spectrometer using trimethylsilane (TMS) as an internal
standard. The 1H NMR spectra were reported by indicating the peak positions (parts per million,
δ), splitting pattern of peaks (s: singlet, d: doublet, t: triplet, q: quartet, dd: doublet of doublets, td:
triplet of doublets, m: multiplet), coupling constant (J, Hz) and integration values. IR spectra were
obtained using Thermo Nicolet iS10 FT-IR. MS was obtained using a Waters Acquity TQD
(tandem quadrapole) spectrometer that utilizes electrospray ionization. Reactions were monitored
using a combination of thin-layer chromatography (TLC) on silica gel GHLF plates (250 µm, 2.5
x 10 cm; Analtech Inc. Newark, DE) and/ or IR spectroscopy where applicable. Flash
chromatography was performed on a CombiFlash Companion/TS (Teledyne Isco Inc. Lincoln,
NE) using packed silica gel (Silica Gel 230-400 mesh) columns (RediSep Rf Normal-phase Silica
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Flash Column, Teledyne Isco Inc., Lincoln, NE). Hydrochloride or oxalate salts (if the
hydrochloride salt was hygroscopic) of compounds were prepared.

2-Methyl-3-(2-(piperidin-1-yl)ethyl)-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
Hydrochloride (57)
Method A:
3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (78) (0.10 g,
0.44 mmol) was added to a stirred suspension of piperidine (0.09 g, 0.44 mmol), anhydrous K2CO3
(0.06 g, 0.44 mmol) and KI (few crystals) in DMF (9 mL) under an N2 atmosphere. The stirred
reaction mixture was heated at reflux for 17 h. The reaction mixture was allowed to cool to room
temperature, diluted with H2O (~15 mL), and extracted with CHCl3 (3 x 10 mL). The combined
organic portion was washed with H2O (3 x 5 mL), brine (5 mL), dried (Na2SO4) and evaporated
under reduced pressure to yield 0.04 g of a pale yellow-colored solid. The solid was dissolved in
EtOH and cooled to 0 ºC (ice-bath). A saturated solution of gaseous HCl /EtOH was added and
the reaction mixture was allowed to stir at room temperature overnight. The precipitate was
collected by filtration to yield a yellow-colored solid (0.03 g) which upon recrystallization from
MeOH afforded 0.02 g (12%) of compound 57 as a pale yellow solid: mp 262-264 ºC.

Method B:
3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (78) (0.10 g,
0.44 mmol) was added to a stirred suspension of piperidine (0.09 g, 0.44 mmol), anhydrous K2CO3
(0.06 g, 0.44 mmol) and KI (few crystals) in MeCN (9 mL) under an N2 atmosphere. The stirred
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reaction mixture was heated at reflux for 17 h. The hot reaction mixture was filtered and the filtrate
was evaporated under reduced pressure to give 0.06 g of a pale yellow-colored solid. The solid
was dissolved in H2O, basified with NaOH (3 M to ~pH 12), and extracted with CHCl3 (3 x 5 mL).
The combined organic portion was washed with H2O (3 x 5 mL), brine (5 mL), dried (Na2SO4)
and evaporated under reduced pressure to yield 0.05 g of a pale yellow-colored solid. The solid
was dissolved in EtOH and cooled to 0 ºC (ice-bath). A saturated solution of gaseous HCl /EtOH
was added and the reaction mixture was allowed to stir at room temperature overnight. The
precipitate was collected by filtration to yield a yellow-colored solid (0.04 g) which upon
recrystallization from MeOH afforded 0.03 g (20%) of compound 57 as a pale yellow solid: mp
266-270 ºC.
1

H NMR (DMSO-d6)  1.36-1.39 (m, 2H, CH2), 1.69-1.82 (m, 8H, 4 CH2), 1.87-1.92 (m, 2H,

CH2), 2.42 (s, 3H, CH3), 2.91-2.95 (m, 6H, CH2, CH3), 3.47-3.51 (d, 2H, CH2, J = 11.5 Hz), 3.793.82

(t,

2H,

CH2, J

=

6.1

Hz),

10.59

(br

s,

1H,

NH+).

Anal.

Calcd

for

(C16H25N3O•2HCl•0.5H2O•0.5CH3OH) C, 53.08; H, 8.10; N, 11.26. Found: C, 52.96; H, 7.94; N,
11.45. MS calculated [M + H]+ : 276.2070, MS found [M + H]+ : 276.2084.

3-(2-(Dimethylamino)ethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
Oxalate (58)
3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (78) (0.50 g,
2.20 mmol) was added to a stirred suspension of N,N-dimethylamine (2 M solution in MeOH) (1.1
mL, 2.2 mmol), anhydrous K2CO3 (0.30 g, 2.20 mmol) and KI (few crystals) in MeCN (45 mL)
under an N2 atmosphere. The stirred reaction mixture was heated at reflux for 30 h. The hot reaction
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mixture was filtered and the filtrate was evaporated under reduced pressure to give 0.30 g of a
yellow liquid. The liquid was dissolved in H2O, basified with NaOH (3 M to ~pH 12), and
extracted with CHCl3 (5 x 5 mL). The combined organic portion was washed with H2O (3 x 5 mL),
brine (5 mL), dried (Na2SO4) and evaporated under reduced pressure to yield 0.21 g of crude free
base as a yellow-colored liquid. The liquid was purified using kugelrohr distillation (220 ºC, 0.75
millibar) to yield 0.11 g of a colorless oil which was dissolved in CHCl3, cooled to 0 C (ice-bath)
and treated with a saturated solution of (COOH)2 /Et2O and then the reaction mixture was allowed
to stir at room temperature overnight. The precipitate was collected by filtration to yield a white
solid (0.07 g) which upon recrystallization from EtOH afforded 0.05 g (12%) of compound 58 as
a white solid: mp 154-156 ºC. 1H NMR (DMSO-d6)  1.76-1.80 (m, 2H, CH2), 1.84-1.89 (m, 2H,
CH2), 2.24 (s, 3H, CH3), 2.50-2.52 (m, 10 H, 2CH2, 2CH3), 3.05-3.09 (t, 2H, CH2, J = 8.0 Hz),
3.78-3.81 (t, 2H, CH2, J = 6.2 Hz). Anal. Calcd for (C13H21N3O•1.5 (COOH)2) C, 51.89; H, 6.53;
N, 11.34. Found: C, 51.96; H, 6.66; N, 11.37.

3-(2-Aminoethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
Hydrochloride (59)
Compound 59 was synthesized using a literature procedure for a Gabriel synthesis reaction for a
different compound.214 Hydrazine hydrate (0.20 mL, 4.10 mmol) was added to a stirred suspension
of 79 (0.52 g, 1.55 mmol) in absolute EtOH (16 mL) under an N2 atmosphere. The stirred reaction
mixture was heated at reflux for 4 h, cooled to room temperature and heated at reflux for 5 min
with HCl (1 N, 15.5 mL) until a clear solution was formed. The solid that crystallized on cooling
was removed by filtration and washed with H2O (5 mL). The filtrate was basified with NaOH (3
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M to ~pH 12), and extracted with CHCl3 (3 x 5 mL). The combined organic portion was washed
with H2O (3 x 5mL), brine (5 mL), dried (Na2SO4) and evaporated under reduced pressure to yield
0.21 g (66%) as a yellow-colored oil. The oil was dissolved in EtOH and cooled to 0 C (ice-bath).
A saturated solution of gaseous HCl/EtOH was added and the reaction mixture was allowed to stir
at room temperature overnight, the precipitate was collected by filtration to yield a yellow-colored
solid which upon recrystallization from MeOH afforded 0.06 g (20%) of compound 59 as a pale
yellow solid: mp 268-270 ºC. 1H NMR (DMSO-d6)  1.79-1.82 (m, 2H, CH2), 1.90-1.93 (m, 2H,
CH2), 2.4 (s, 3H, CH3), 2.79 (m, 2H, CH2), 2.89-2.90 (m, 2H, CH2), 3.03-3.04 (m, 2H, CH2), 3.29
(m, 2H, CH2), 8.07 (br s, 2H, NH2+). Anal. Calcd for (C11H17N3O•2HCl) C, 47.15; H, 6.83; N,
14.99. Found: C, 46.93; H, 6.75; N, 14.76.

Compounds 60-63 were synthesized by Dr. Supriya A. Gaitonde as previously reported.143

5-(2-(4-(6-Fluorobenz[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-6-methylpyrimidin-4(3H)-one
Oxalate (64)
Compound 92 (0.24 g, 1.36 mmol) was added to a stirred suspension of 6-fluoro-3-(4piperidinyl)benz[d]isoxazole (61) (0.33 g, 1.50 mmol), anhydrous K2CO3 (0.19 g, 1.36 mmol) and
KI (few crystals) in DMF (4 mL). The stirred reaction mixture was heated in a sealed tube at 134
ºC for 18 h, and allowed to cool to room temperature. The reaction mixture was diluted with H2O
(~10 mL), and extracted with CHCl3 (3 x 10 mL). The combined organic portion was washed with
H2O (10 mL), brine (10 mL), dried (Na2SO4), and evaporated under reduced pressure to yield 0.38
g of an orange-colored oil which was purified by column chromatography (silica gel;
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CHCl3/MeOH; 100:0 to 85:15) to afford 0.08 g of a crude, brown sticky solid. The solid was
dissolved in CHCl3 (10 mL) and cooled to 0 C (ice-bath). A saturated solution of (COOH)2/Et2O
was added and the reaction mixture was allowed to stir at room temperature overnight. The
precipitate was collected by filtration to yield a pale brown-colored solid (0.06 g) which upon
recrystallization from EtOH afforded 0.03 g (5%) of compound 64 as a white solid: mp 228-230
ºC. 1H NMR (DMSO-d6)  1.96-2.04 (m, 2H, CH2), 2.17-2.24 (m, 2H, CH2), 2.28 (s, 3H, CH3),
2.68-2.80 (m, 5H, CH2), 2.44-2.47 (m, 2H, CH2), 3.43-3.48 (m, 2H, CH2), 7.30-7.35 (td, 1H, ArH,
J = 2.1, 9.1 Hz), 7.71-7.74 (dd, 1H, ArH, J = 2.1, 9.1 Hz), 8.01-8.07 (m, 2H, ArH) (The -NH of
the pyrimdone was not visible). Anal. Calcd for (C19H21N4O2F•0.5(COOH)2•0.9H2O) C, 57.52; H,
5.74; N, 13.41. Found C, 57.77; H, 5.47; N, 13.15. MS calculated [M+H]+ : 357.1726 MS found
[M+H]+ : 357.1754.

Compounds 65 and 66 were synthesized by Dr. Supriya A. Gaitonde as previously reported.143

3-[1-(4-Cyclohexylbutyl)piperidin-4-yl]-6-fluorobenz[d]isoxazole Hydrochloride (68)
Compound 102 (0.28 g, 0.92 mmol) was added to a stirred suspension of 6-fluoro-3-(4piperidinyl)benz[d]isoxazole (61) (0.26 g, 1.18 mmol), anhydrous K2CO3 (0.25 g, 1.83 mmol) in
MeCN (5 mL). The stirred reaction mixture was heated in a sealed tube at 80 °C for 96 h, filtered,
and the filtrate was evaporated under reduced pressure to give 0.42 g of a sticky solid. The solid
was purified by column chromatography (silica gel; CH2Cl2/MeOH; 9.5:0.5) to afford 0.15 g of a
sticky, white solid. The solid was dissolved in EtOH (2 mL), and cooled to 0 C (ice-bath). A
saturated solution of gaseous HCl/EtOH was added and the reaction mixture was allowed to stir at
189

room temperature overnight. The solvent was evaporated under reduced pressure to yield 0.09 g
of a white solid which upon recrystallization from i-PrOH/H2O afforded 0.08 g (23%) of
compound 68 as a white solid: mp 242-244 oC. 1H NMR (DMSO-d6)  0.86-0.91 (m, 2H, CH2),
1.11-1.36 (m, 8H, CH2), 1.61-1.74 (m, 7H, CH2,CH), 2.23-2.33 (m, 4H, CH2, J = 13.3 Hz) 3.083.11 (m, 4H, CH2 ) 3.41-3.51 (m, 1H, CH), 3.60-3.63 (d, 2H, CH2, J = 11.5 Hz) 7.33-7.38 (td, 1H,
ArH, J = 2.2, 9.2 Hz), 7.72-7.75 (dd, 1H, ArH, J = 2.0, 9.0 Hz), 8.15-8.22 (m, 1H, ArH), 10.16 (br
s, 1H, NH+). Anal. Calcd for (C22H31N2OF•1 HCl•0.4H2O) C, 65.70; H, 8.22; N, 6.97. Found C,
65.93; H, 8.21; N, 6.86.

2-(2-(2-Methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-3-yl)ethyl)isoindoline1,3-dione (79)
Compound 79 was synthesized using a literature procedure for a Gabriel synthesis reaction for a
different compound.214 Potassium phthalimide (0.72 g, 3.87 mmol) was added to a stirred
suspension of 3-(2-chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
(78) (0.80 g, 3.52 mmol) in anhydrous DMF (7.8 mL) under an N2 atmosphere. The stirred reaction
mixture was heated at reflux for 22 h, cooled to room temperature and quenched by the careful
addition of ice-cold H2O (15.5 mL). The precipitate was collected by filtration to yield a pale
yellow solid (0.60 g) which upon recrystallization from EtOH afforded 0.54 g (45%) of compound
79 as a yellow-colored solid: mp 164-166 °C. 1H NMR (DMSO-d6)  1.75-1.77 (m, 2H, CH2),
1.82-1.85 (m, 2H, CH2),2.13 (s, 3H, CH3), 2.75-2.76 (m, 4H, CH2), 3.69-3.73 (t, 4H, CH2, J =
5.7Hz), 7.84-7.85 (d, 4H, ArH, J = 2.6 Hz). Compound 79 was used in the preparation of
compound 59.
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Ethyl 2-acetyl-4-ethoxybutanoate (89)
Compound 89 was synthesized using a modified literature procedure for the same compound.144
Sodium ethoxide (1.36 g, 19.99 mmol) was dissolved in EtOH (20 mL) and ethyl acetoacetate (88)
(2.55 g, 19.59 mmol) was added at 0 °C (ice-bath) and stirred at room temperature for 0.5 h. 2Bromoethyl ether (3.00 g, 19.61 mmol) was added dropwise when the reaction mixture started
refluxing, and the reaction mixture was heated at reflux for 18 h. The reaction mixture was allowed
to cool to room temperature, filtered and concentrated under reduced pressure. The residue was
diluted with Et2O and filtered. The filtrate was concentrated under reduced pressure to yield 3.20
g of a crude, yellow oil, which was purified using vacuum distillation (110 °C, 1.33 millibar) to
yield 1.57 g (40%) of compound 89 as a colorless oil. 1H NMR (DMSO-d6)  1.08-1.12 (t, 3H,
CH3, J = 7.0 Hz), 1.21-1.24 (t, 3H, CH3, J = 7.1 Hz), 1.91-2.1 (m, 2H, CH2), 2.22 (s, 3H, CH3),
3.34-3.41 (m, 4H, CH2), 3.67-3.71 (t, 1H, CH, J = 7.0 Hz), 4.12-4.18 (q, 2H, CH2, J = 7.1 Hz).
Compound 89 was used in the preparation of compound 90.

5-(2-Ethoxyethyl)-6-methyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one (90)
Compound 90 was synthesized using a literature procedure for a similar compound.146 Thiourea
(2.93 g, 38.49 mmol) and a solution of intermediate 89 (1.56 g, 7.71 mmol) in EtOH (22 mL) were
added to a stirred solution of sodium ethoxide (3.20 g, 47.03 mmol) in EtOH (25 mL) at 0 ºC (icebath). The reaction mixture was heated at reflux for 4 h, allowed to cool to room temperature and
concentrated under reduced pressure to yield a crude residue The residue was dissolved in H2O,
acidified with HCl (1 M, ~ pH 4), and filtered to yield 1.70 g of a pale yellow solid which was
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purified using column chromatography (silica gel; CH2Cl2/MeOH; 100:0 to 90:10) to afford 0.91
g (55%) of compound 90 as a pale yellow solid: mp 196-198 ºC (lit.145 mp 203-203.5 ºC). 1H NMR
(DMSO-d6)  1.10-1.13 (t, 3H, CH3, J = 7.0 Hz), 2.17 (s, 3H, CH3), 3.35-3.45 (m, 6H, CH2), 12.15
(br s, 1H, NH), 12.36 (br s, 1H, NH). Compound 90 was used in the preparation of compound 91.

5-(2-Ethoxyethyl)-6-methylpyrimidin-4(3H)-one (91)
Compound 91 was synthesized using a literature procedure for a similar compound.147 NiCl2 (1.62
g, 12.50 mmol) was added to a stirred solution of 90 (0.90 g, 4.20 mmol) in anhydrous MeOH (70
mL). This was followed by the slow addition of NaBH4 (1.43 g, 37.66 mmol) at room temperature.
The reaction mixture was allowed to stir at room temperature for 0.5 h and filtered over celite. The
filtrate was evaporated under reduced pressure and the residue was washed with CHCl3 (15 mL).
The CHCl3 was evaporated under reduced pressure to yield 0.46 g (61%) of compound 91 as a
pale green solid: mp 144-148 °C (lit.145 mp 147.5-148 ºC) 1H NMR (DMSO-d6)  1.10-1.13 (t, 3H,
CH3, J = 7 Hz), 2.27 (s, 3H, CH3), 2.66-2.70 (t, 2H, CH2, J = 7.08 Hz), 3.41-3.46 (m, 4H, CH2),
7.98 (s, 1H, ArH) (-NH of the pyrimidone was not visible). Compound 91 was used in the
preparation of compound 92.

5-(2-Chloroethyl)-6-methylpyrimidin-4(3H)-one (92)
Compound 92 was synthesized using a literature procedure for the same compound with a
modified work-up procedure.145 Compound 91 (0.46 g, 2.52 mmol) was dissolved in HCl (12 N,
6 mL) and heated in a sealed tube at 150 °C for 3 h, allowed to cool to room temperature, diluted
with H2O (30 mL) and filtered. The filtrate was neutralized to ~pH 7 using a saturated aqueous
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NaHCO3 solution and extracted with CHCl3 (3 x 15 mL). The combined organic portion was
washed with H2O (10 mL), brine (10 mL), dried (Na2SO4), and evaporated under reduced pressure
to yield 0.31 g of a brown-colored oil which was purified by column chromatography (silica gel;
CHCl3/MeOH; 100:0 to 90:10) to afford 0.25 g (57%) of compound 92 as an orange-colored oil.
1

H NMR (DMSO-d6)  2.37 (s, 3H, CH3), 3.24-3.28 (t, 2H, CH2, J = 8.32 Hz), 4.64-4.69 (t, 2H,

CH2, J = 8.7 Hz), 8.46 (s, 1H, ArCH), (-NH of the pyrimidone was not visible). Compound 92 was
used in the preparation of compound 64.

1-Cyclohexylcyclobutan-1-ol (97)
Compound 97 was synthesized using a literature procedure for the same compound.148,149 Iodine
(few crystals) and magnesium turnings (0.16 g, 6.41 mmol) were added to a stirred solution of
freshly distilled cyclohexyl bromide (96) (1.00 g, 6.13 mmol) in anhydrous Et2O (5 mL) at 0 ºC
(ice-bath) under an N2 atmosphere. The stirred reaction mixture was heated at 40 ºC for 2 h, cooled
to 0 ºC (ice-bath), and cyclobutanone (0.43 g, 6.13 mmol) was added dropwise. The reaction
mixture was allowed to stir at room temperature for 4 h, cooled to 0 ºC (ice-bath) and quenched
by the careful addition of H2O (~10 mL). The organic portion was separated, and the aqueous
portion was extracted with Et2O (3 x 10 mL). The combined organic portions were washed with
H2O (10 mL), brine (10 mL), dried (Na2SO4), and evaporated under reduced pressure to yield 0.31
g of a colorless oil. The oil was purified using Kugelrohr distillation (72-80 ºC, 1.33 millibar) to
yield 0.21 g (21%) of compound 97 as a colorless oil 1H NMR (DMSO-d6)  0.96-1.3 (m, 6H,
CH2), 1.38-1.50 (m, 1H, CH), 1.66-1.79 (m, 6H), 1.83-1.90 (m, 2H, CH2), 2.01-2.08 (m, 2H, CH2).
Compound 97 was used in the preparation of compound 98.
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1-Cyclohexyl-4-hydroxybutan-1-one (98)
Intermediate 98 was synthesized using a literature procedure for the same compound.150
Phenyliodine diacetate (0.43 g, 1.36 mmol) was added to a stirred solution of 97 (0.2 g, 1.30 mmol)
in 1,1,1,3,3,3-hexafluoro-2-propanol/H2O (10 mL, 9/1). The reaction mixture was allowed to stir
at room temperature for 15 min, and was quenched using a saturated aqueous NaHCO3 solution
(10 mL), and was extracted using EtOAc (3 x 10 mL). The combined organic portion was washed
with H2O (10 mL), brine (10 mL), dried (Na2SO4), and evaporated under reduced pressure to yield
0.18 g of a crude colorless oil. The oil was purified by column chromatography (silica gel;
hexanes/EtOAc; 3:1) to afford 0.12 g (50%) of compound 98 as a colorless oil. 1H NMR (DMSOd6)  1.09-1.26 (m, 5H, CH2), 1.53-1.76 (m, 7H, CH2), 2.32-2.37 (m, 1H, CH), 2.45-2.49 (t, 2H,
CH2, J = 7.2 Hz), 3.31-3.34 (t, 2H, CH2, J = 6.5 Hz), 4.40-4.42 (t, 1H, OH, D2O ex., J = 4.7 Hz).
IR (diamond, cm-1) 1700 (-C=O), 3400 (-OH). Compound 98 was used in the preparation of
compound 99 and 100.

4-Cyclohexyl-4-oxobutyl 4-methylbenzenesulfonate (99)
Compound 99 was synthesized using a modified literature procedure for a similar compound.151
Intermediate 98 (0.11 g, 0.65 mmol) was added to a stirred solution of tosyl chloride (0.19 g, 0.98
mmol) and Et3N (0.20 g, 1.96 mmol) in CH2Cl2 (5 mL). The reaction mixture was allowed to stir
at room temperature for 48 h, filtered, and the filtrate was evaporated under reduced pressure to
give 0.15 g of a crude residue. The residue was purified by column chromatography (silica gel;
hexanes/EtOAc; 8.5:1.5) to afford 0.07 g (33%) of compound 99 as a colorless oil. 1H NMR
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(DMSO-d6)  1.07-1.26 (m, 5H, CH2), 1.56-1.76 (m, 7H, CH2), 2.26-2.33 (m, 1H, CH), 2.46-2.51
(m, 5H, CH2, CH3), 3.98-4.01 (t, 2H, CH2, J = 6.4 Hz), 7.48-7.50 (d, 2H, ArH, J = 8.0 Hz) 7.777.79 (dd, 2H, ArH, J = 1.72 Hz, 6.7 Hz).

4-Cyclohexylbutan-1-ol (100)
Method A:
Compound 100 is known and was synthesized using a literature procedure for a similar
compound.215 KOH (0.09 g, 1.61 mmol) and hydrazine hydrate (0.15 g, 4.68 mmol) were added
to a solution of compound 98 (0.06 g, 0.35 mmol) in diethylene glycol (4 mL) at 0 ºC (ice-bath).
The stirred reaction mixture was heated at 135 ºC for 2 h, a Dean-Stark apparatus was connected
to the flask, and the temperature was increased to 200 ºC. The stirred reaction mixture was heated
at 200 ºC for 6 h, diluted with H2O (~5 mL), and extracted with CH2Cl2 (3 x 5 mL). The combined
organic portion was washed with H2O (10 mL), brine (10 mL), dried (Na2SO4), and evaporated
under reduced pressure to yield 0.03 g (58%) of compound 100 as a colorless oil.

Method B:
Compound 100 was synthesized using a literature procedure for a similar compound.152 A solution
of 4-cyclohexylbutanoic acid (101) (1.00 g, 5.87 mmol) in anhydrous THF (5 mL) was added to a
stirred suspension of LiAlH4 (0.44 g, 11.74 mmol) in anhydrous THF (10 mL) at 0 ºC (ice-bath)
under an N2 atmosphere The reaction mixture was allowed to stir at room temperature for 6 h,
cooled to 0 ºC (ice-bath), quenched by addition of H2O (0.5 mL), 15% NaOH (0.5 mL) and H2O
(1.5 mL). The suspension was filtered over Celite and the residue was washed with THF. The
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aqueous portion was basified with 15% NaOH (pH ~12) and extracted with Et2O (3 x 10 mL). The
combined organic portion was washed with H2O (10 mL), brine (10 mL), dried (Na2SO4), and
evaporated under reduced pressure to yield 0.49 g (54%) of compound 100 as a colorless oil.
Intermediate 100 was used without further purification in the next step.
IR (diamond, cm-1) 3388 (-OH). 1H NMR (DMSO-d6)  0.83-0.92 (m, 2H, CH2), 1.12-1.24 (m,
6H, CH2), 1.28-1.35 (m, 2H, CH2) 1.39-1.46 (m, 2H, CH2), 1.63-1.71 (m, 5H, CH2, CH), 3.393.43 (m, 2H, CH) 4.30-4.33 (t, 1H, OH, J = 5.2 Hz). Compound 100 was used in the preparation
of compound 102.

4-Cyclohexylbutyl 4-methylbenzenesulfonate (102)
Compound 102 was synthesized using a modified literature procedure for the same compound.151
Compound 100 (0.48 g, 3.08 mmol) was added to a stirred solution of tosyl chloride (0.88 g, 4.62
mmol) and Et3N (0.94 g, 9.23 mmol) in CH2Cl2 (15 mL). The reaction mixture was allowed to stir
at room temperature for 48 h, filtered, and the filtrate was evaporated under reduced pressure to
give 1.21 g of a crude residue. The residue was purified by column chromatography (silica gel;
hexanes/EtOAc; 8.5:1.5) to afford 0.29 g (30%) of compound 102 as a white solid: mp 40-42 ºC.
(lit.151 mp 41.5-42.5 ºC). Intermediate 102 was used without further purification in the next step.
Compound 102 was used in the preparation of compound 68.
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3-[2-(4-(4-Fluorobenzoyl)piperidin-1-yl)ethyl]-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2a]pyrimidin-4-one Oxalate (103)
3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (78) (0.40 g,
1.76 mmol) was added to a stirred suspension of 4-(4-fluorobenzoyl) piperidine hydrochloride
(0.43 g, 1.76 mmol), anhydrous K2CO3 (0.49 g, 3.52 mmol) and KI (few crystals) in MeCN (40
mL) under an N2 atmosphere. The stirred reaction mixture was heated at reflux for 24 h, filtered
while hot, and the filtrate was evaporated under reduced pressure to give 0.60 g of a yellow, sticky
solid. The sticky solid was dissolved in H2O, basified with NaOH (3 M to pH ~12), and extracted
with CHCl3 (3 x 5 mL). The combined organic portion was washed with H2O (3 x 5 mL), brine (5
mL), dried (Na2SO4) and evaporated under reduced pressure to yield 0.51 g of crude free base as
a yellow-colored solid. The free base was purified using a short column (silica gel; CHCl3/MeOH;
90:10) to afford 0.36 g of a yellow-colored solid that was dissolved in CHCl3 (2 mL), cooled to 0
°C (ice-bath) and treated with a saturated solution of (COOH)2/Et2O and then the reaction mixture
was allowed to stir at room temperature overnight. The precipitate was collected by filtration to
yield a white solid (0.40 g) which upon recrystallization from EtOH afforded 0.30 g (27%) of
compound 57 as a white solid: mp 194-198 °C. 1H NMR (DMSO-d6)  1.74-1.85 (m, 6H, CH2),
1.89-2.01 (d, 2H, CH2, J = 13.2 Hz), 2.23 (s, 3H, CH3), 2.76-2.8 (m, 4H, CH2 ) 2.97-2.99 (m, 4H,
CH2), 3.46-3.51 (m, 2H, CH2), 3.66-3.68 (m, 1H, CH), 3.78-3.81 (t, 2H, CH2, J = 6.2 Hz), 7.377.41 (t, 2H, ArH, J = 8.8 Hz), 8.07-8.11 (m, 2H, ArH). Anal. Calcd for (C23H28N3O2F•1.5 (COOH)2
C, 58.64; H, 5.87; N, 7.89. Found C, 58.63; H, 6.03; N, 8.10.

Compound 104 was synthesized by Dr. Supriya A. Gaitonde as previously reported.143
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Tryptamine Hydrochloride (105)
Method A:
Compound 105 was synthesized using a literature procedure for a similar compound.167 BF3•Et2O
(0.60 mL, 4.40 mmol) was added to a stirred suspension of NaBH4 (0.14 g, 4.00 mmol) in THF
(10 mL) at 0 ºC (ice-bath), and was allowed to stir at room temperature for 15 min. A solution of
compound 125 (0.14g, 0.75 mmol) in anhydrous THF (2 mL) was added in a dropwise manner,
and the reaction mixture was heated at reflux for 2 h, cooled to room temperature and quenched
with addition of ice-H2O. The reaction mixture was acidified with HCl (1 N, to ~pH 2) and heated
at 85 °C for 2 h. The reaction mixture was allowed to cool to room temperature and extracted with
Et2O (3 x 10 mL). The aqueous portion was basified with NaOH (1 N to ~pH 12) and extracted
with Et2O (3 x 10 mL). The combined organic portion was washed with H2O (10 mL), brine (10
mL), dried (Na2SO4), and evaporated under reduced pressure to yield 0.09 g as a brown-colored
oil. The oil was dissolved in Et2O (5 mL) and cooled to 0 °C (ice-bath). A gaseous solution of
HCl/Et2O was added and the reaction mixture was allowed to stir at room temperature for 1 h. The
precipitate was filtered to yield a beige-colored solid that was recrystallized from EtOH/Et2O to
yield 0.06 g (40%) of compound 105 as a beige solid: mp 242-244 ºC (lit.168 mp 248-249 °C).

Method B:
Compound 105 was synthesized using a literature procedure for the same compound.168 LiAlH4
(0.56 g, 14.75 mmol) was added to a stirred solution of compound 125 (0.14 g, 0.77 mmol) in
anhydrous Et2O (8.4 mL) at 0 °C (ice-bath) under an N2 atmosphere. The stirred reaction mixture
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was heated at reflux for 3 h, allowed to stir at room temperature for 12 h, cooled to 0 °C (ice-bath),
and quenched by addition of H2O (0.6 mL), 15% NaOH (0.6 mL) and H2O (1.8 mL). The
suspension was filtered and the residue was washed with Et2O. The aqueous portion was extracted
with Et2O (3 x 10 mL). The combined organic portion was washed with water (3 x 10 mL), brine
(10 mL), dried (Na2SO4), and evaporated under reduced pressure to yield 0.13 g as a brown-colored
oil. The oil was dissolved in Et2O (5 mL) and cooled to 0 °C (ice-bath). A gaseous solution of
HCl/Et2O was added and the reaction mixture was allowed to stir at room temperature for 1 h. The
precipitate was filtered to yield a beige-colored solid that was recrystallized from EtOH/Et2O to
yield 0.11 g (80%) of compound 105 as a beige solid: mp 246-248 ºC (lit.168 mp 248-249 °C).

2-(6-Fluoro-1H-indol-3-yl)ethan-1-amine Oxalate (106)
LiAlH4 (0.58 g, 15.33 mmol) was added to a stirred solution of compound 123 (0.63 g, 3.07 mmol)
in anhydrous THF (8.5 mL) and anhydrous Et2O (9.5 mL) at 0 °C (ice-bath) under an N2
atmosphere. The stirred reaction mixture was heated at 60 °C for 1 h, cooled to 0 °C (ice-bath),
quenched by addition of H2O (0.6 mL), 15% NaOH (0.6 mL) and H2O (1.8 mL). The suspension
was filtered and the residue was washed with THF. The aqueous portion was extracted with Et2O
(3 x 10 mL). The combined organic portion was washed with brine (10 mL), dried (Na2SO4), and
evaporated under reduced pressure to yield 0.42 g as a brown-colored oil. The oil was dissolved
in Et2O (5 mL) and cooled to 0 °C (ice-bath). A saturated solution of (COOH)2/Et2O was added
and the reaction mixture was allowed to warm to room temperature and stirred for 1 h. The
precipitate was filtered to yield a brown-colored solid that was heated at reflux in MeCN for 0.5
h, and recrystallized from acetone/H2O to yield 0.22 g (27%) of compound 106 as a beige-colored
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solid: mp 152-154 ºC. 1H NMR (DMSO-d6)  2.99-3.08 (m, 4H, CH2), 6.86-6.91 (m, 1H, ArH),
7.14-7.17 (d, 1H, ArH, J = 9.6 Hz) 7.24 (s, 1H, ArH), 7.53-7.57 (t, 1H, ArH, J = 7.1 Hz), 11.08 (s,
1H, NH). Anal. Calcd for (C10H11N2F•1(COOH)2•0.2H2O•0.1CH3COCH3) C, 53.21; H, 5.08; N,
10.09. Found C, 53.03; H, 5.14; N, 9.99.

2-(1H-Indol-3-yl)-N-methylethanamine (107)
Compound 107 was synthesized using a literature procedure for the same compound.172 LiAlH4
(0.86 g, 22.75 mmol) was added to a stirred solution of intermediate 131 (1.76 g, 7.59 mmol) in
anhydrous THF (16 mL) at 0 ºC (ice-bath) under an N2 atmosphere. The stirred reaction mixture
was heated at reflux for 1.5 h, cooled to 0 °C (ice-bath), and quenched by addition of H2O (0.9
mL), 15% NaOH (0.9 mL) and H2O (2.7 mL). The suspension was filtered and the residue was
washed with THF. The aqueous portion was extracted with CH2Cl2 (3 x 10 mL). The combined
organic portion was washed with brine (10 mL), dried (Na2SO4), and evaporated under reduced
pressure to yield 0.83 g (48%) of compound 107 as a white solid: mp 82-84 °C (lit.173 mp 80-84
°C).

2-(6-Fluoro-1H-indol-3-yl)-N-methylethan-1-amine Hydrochloride (108)
LiAlH4 (0.23 g, 6.03 mmol) was added to a stirred solution of 127 (0.50 g, 2.01 mmol) in anhydrous
THF (18 mL) at 0 ºC (ice-bath) under an N2 atmosphere. The stirred reaction mixture was heated
at reflux for 1.5 h, cooled to 0 ºC (ice-bath), quenched by addition of H2O (0.2 mL), 15% NaOH
(0.2 mL) and H2O (0.6 mL). The suspension was filtered and the residue was washed with THF.
The aqueous portion was extracted with CH2Cl2 (3 x 10 mL). The combined organic portion was
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washed with brine (10 mL), dried (Na2SO4), and evaporated under reduced pressure to yield 0.28
g of crude free base as an oil. The free base was dissolved in Et2O (3 mL) and cooled to 0 °C (icebath). A saturated solution of gaseous HCl/Et2O was added and the reaction mixture was allowed
to stir at room temperature overnight. The precipitate was collected by filtration to yield a browncolored solid which upon recrystallization from acetone/H2O afforded 0.36 g (78%) of compound
108 as a brown-colored solid: mp 216-220 ºC. 1H NMR (DMSO-d6)  2.58-2.61 (t, 3H, CH3, J =
5.48 Hz), 3.01-3.05 (t, 2H, CH2, J = 7.28 Hz), 3.13-3.18 (m, 2H, CH2), 6.87-6.92 (m, 1H, ArH),
7.14-7.17 (dd, 1H, ArH, J = 2.2, 10.16 Hz), 7.24-7.25 (d, 1H, ArH, J = 2.32 Hz), 7.56-7.60 (m,
1H, ArH), 8.58 (s, 1H, NH+), 11.01 (s, 1H, NH). Anal. Calcd for (C11H13N2F•1HCl) C, 57.77; H,
6.17; N, 12.25. Found C, 57.52; H, 6.15; N, 11.98).

3-[2-((2-(1H-Indol-3-yl)ethyl)amino)ethyl]-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2a]pyrimidin-4-one Oxalate (109)
3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (0.20 g, 0.88
mmol) was added to a stirred suspension of tryptamine (105) (0.31 g, 1.96 mmol) and anhydrous
K2CO3 (0.12 g, 0.88 mmol) in MeCN (40 mL) under an N2 atmosphere. The stirred reaction
mixture was heated at reflux for 17 h. The hot reaction mixture was filtered and the filtrate was
evaporated under reduced pressure to give 0.32 g of crude free base as a yellow liquid. The free
base was purified using a short column (silica gel; CH2Cl2/MeOH/NH4OH; 8.5:1.5:0.1) to yield
0.06 g of a liquid, that was dissolved in CHCl3 (2 mL), cooled to 0 C (ice-bath). A saturated
solution of (COOH)2/Et2O was added and the reaction mixture was allowed to stir at room
temperature overnight. The precipitate was collected by filtration to yield a yellow-colored solid
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(0.05 g) which upon recrystallization from MeOH afforded 0.03 g (6%) of compound 109 as a
yellow solid: mp 112-114 ºC. 1H NMR (DMSO-d6)  1.75-1.90 (m, 4H, CH2), 2.24 (s, 3H, CH3),
2.78-2.82 (m, 4H, CH2 ), 3.03-3.07 (t, 4H, CH2, J = 7.0 Hz), 3.22-3.23 (m, 2H, CH2), 3.78-3.82 (t,
2H, CH2, J = 6.2 Hz), 7.00-7.04 (t, 1H, ArH, J = 7.0 Hz), 7.09-7.13 (t, 1H, ArH, J = 7.2 Hz ), 7.24
(s, 1H, ArH), 7.37-7.39(d, 1H, ArH, J = 8.1 Hz), 7.58-7.60 (d, 1H, ArH, J = 7.8 Hz), 8.67-8.76
(brs, 1H, NH+), 11.0 (s, 1H, NH). Anal. Calcd for (C21H26N4O•2(COOH)2•1H2O•1CH3OH) C,
53.79; H, 6.25; N, 9.65. Found: C, 53.84; H, 5.95; N, 9.84.

3-(2-((2-(6-Fluoro-1H-indol-3-yl)ethyl)amino)ethyl)-2-methyl-6,7,8,9-tetrahydro-4Hpyrido[1,2-a]pyrimidin-4-one Oxalate (110)
3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (78) (0.22 g,
0.98 mmol) was added to a stirred suspension of compound 106 (0.35 g, 1.96 mmol) and anhydrous
K2CO3 (0.12 g, 1.98 mmol) in MeCN (40 mL) under an N2 atmosphere. The stirred reaction
mixture was heated at reflux for 17 h. The reaction mixture was allowed to cool and evaporated
under reduced pressure to give 0.66 g of a yellow semi-solid. The semi-solid was dissolved in
H2O, basified with NaOH (2 M to ~pH 12) and extracted with CH2Cl2 (5 x 5 mL). The combined
organic portion was washed with H2O (3 x 5 mL), brine (5 mL), dried (Na2SO4) and evaporated
under reduced pressure to yield 0.40 g of crude free base as a yellow-colored liquid. The free base
was purified using a short column (silica gel; CHCl3/MeOH/NH4OH; 9:1:0.1) to afford 0.06 g of
a liquid, that was dissolved in CHCl3 (2 mL) and cooled to 0 ºC (ice-bath). A saturated solution of
(COOH)2/Et2O was added and the reaction mixture was allowed to stir at room temperature
overnight. The precipitate was collected by filtration to yield a yellow-colored solid (0.05g) which
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upon recrystallization from MeOH afforded 0.03 g (17%) of compound 110 as a yellow solid: mp
188-192 ºC. 1H NMR (DMSO-d6)  1.75-1.90 (m, 4H, CH2), 2.24 (s, 3H, CH3), 2.78-2.81 (t, 4H,
CH2, J = 6.6 Hz), 3.01-3.05 (m, 4H, CH2), 3.22-3.23 (m, 2H, CH2), 3.78-3.81, (t, 2H, CH2 J = 6.2
Hz ), 6.86-6.91 (td, 1H, ArH, J = 2.3 Hz, 7.5 Hz ), 7.14-7.17 (dd, 1H, ArH, J = 2.3 Hz, 7.9 Hz ),
7.24-7.25 (d, 1H, ArH, J = 1.6 Hz), 7.56-7.59 (m, 1H, ArH), 8.70 (brs, 1H, NH+) 11.01 (s, 1H,
NH). Anal. Calcd for (C21H25N4OF•2(COOH)2) C, 54.74; H, 5.32; N, 10.21. Found: C, 54.87; H,
5.50; N, 10.20.

3-[2-((2-(1H-Indol-3-yl)ethyl)(methyl)amino)ethyl]-2-methyl-6,7,8,9-tetrahydro-4Hpyrido[1,2-a]pyrimidin-4-one Oxalate (111)
3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (78) (0.30 g,
1.32 mmol) was added to a stirred suspension of 107 (0.23 g, 1.32 mmol), anhydrous K2CO3
(0.18 g, 1.32 mmol) and KI (few crystals) in MeCN (27 mL) under an N2 atmosphere. The stirred
reaction mixture was heated at reflux for 48 h, and evaporated under reduced pressure to give 0.60
g of a yellow sticky solid. The sticky solid was dissolved in H2O, basified with NaOH (1 M to ~pH
12), and extracted with CH2Cl2 (3 x 10 mL). The combined organic portion was washed with H2O
(5 mL), brine (5 mL), dried (Na2SO4) and evaporated under reduced pressure to yield 0.41 g of a
crude free base as a yellow-colored solid. The free base was purified using a short column (silica
gel; CHCl3/MeOH/NH4OH; 9:1:0.1) to afford 0.38 g of a solid, that was dissolved in CH2Cl2 (2
mL) and cooled to 0 C (ice-bath). A saturated solution of (COOH)2/Et2O was added and the
reaction mixture was allowed to stir at room temperature overnight. The precipitate was collected
by filtration to yield a white solid (0.40 g) which upon recrystallization from EtOH afforded 0.31
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g (47%) of compound 111 as a white solid: mp 190-192 ºC. 1H NMR (DMSO-d6)  1.74-1.90 (m,
4H, CH2), 2.25 (s, 3H, CH3), 2.77-2.88 (m, 4H, CH2 ), 2.95 (s, 3H, CH3), 3.11-3.18 (m, 4H, CH2),
3.40-3.44 (m, 2H, CH2), 3.78-3.81 (t, 2H, CH2, J = 6.2, 12.3 Hz), 7.00-7.04 (m, 1H, ArH,), 7.097.13 (m, 1H, ArH), 7.26-7.27 (d, 1H, ArH, J = 2.0 Hz), 7.37-7.39 (d, 1H, ArH, J = 8.1 Hz), 7.627.64 (d, 1H, ArH J = 7.8 Hz), 11.00 (s, 1H, NH). Anal. Calcd for (C22H28N4O•1.5(COOH)2) C,
60.10; H, 6.25; N, 11.21. Found C, 59.92; H, 6.24; N, 11.12. MS calculated [M+H]+: 365.2263
MS found [M+H]+: 365.2260.

3-[2-((2-(6-Fluoro-1H-indol-3-yl)ethyl)(methyl)amino)ethyl]-2-methyl-6,7,8,9-tetrahydro4H-pyrido[1,2-a]pyrimidin-4-one Hydrogen Oxalate (112)
3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (0.30 g, 1.31
mmol) was added to a stirred suspension of compound 108 (0.30 g, 1.31 mmol), anhydrous K2CO3
(0.36 g, 2.62 mmol) and KI (few crystals) in MeCN (20 mL) under an N2 atmosphere. The stirred
reaction mixture was heated at reflux for 48 h. The hot reaction mixture was filtered and the filtrate
was evaporated under reduced pressure to give 0.36 g of a yellow liquid. The liquid was dissolved
in H2O, basified with NaOH (2 M to ~pH 12) and extracted with CH2Cl2 (5 x 5 mL). The combined
organic portion was washed with H2O (3 x 5 mL), brine (5 mL), dried (Na2SO4) and evaporated
under reduced pressure to yield 0.22 g of crude free base as a yellow-colored liquid. The free base
was purified using a short column (silica gel; CH2Cl2/MeOH/NH4OH; 9:1:0.1) to afford 0.17 g of
a liquid that was dissolved in CH2Cl2 (2 mL) and cooled to 0 C (ice-bath). A saturated solution of
(COOH)2/Et2O was added and the reaction mixture was allowed to stir at room temperature
overnight. The precipitate was collected by filtration to yield a yellow-colored solid (0.19 g) which
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upon recrystallization from EtOH afforded 0.14 g (16%) of compound 112 as a yellow solid: mp
78-82 ºC. 1H NMR (DMSO-d6)  1.76-1.90 (m, 4H, CH2), 2.25 (s, 3H, CH3), 2.78-2.87 (m, 4H,
CH2 ), 2.95 (s, 3H, CH3), 3.11-3.18 (m, 4H, CH2), 3.40-3.46 (m, 2H, CH2), 3.78-3.81 (t, 2H, CH2,
J = 6.2 Hz), 6.86-6.92 (td, 1H, ArH, J = 2.32, 9.84 Hz), 7.14-7.17 (dd, 1H, ArH, J = 2.24, 10.12
Hz), 7.27 (s, 1H, ArH), 7.61-7.65 (q, 1H, ArH, J = 5.4 Hz), 11.01 (s, 1H, NH). Anal. Calcd for
(C22H27N4OF•1.5 (COOH)2 •0.7CH2Cl2•0.1 C2H5OH) C, 53.49; H, 5.55; N, 9.63. Found: C, 53.46;
H, 5.47; N, 9.36). MS calculated [M+H]+: 383.2169 MS found [M+H]+: 383.2244.

3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2-methyl-4H-pyrido[1,2a]pyrimidin-4-one Oxalate (113)
3-(2-Chloroethyl)-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (136) (0.20 g, 0.90 mmol) was
added to a stirred suspension of 6-fluoro-3-(4-piperidinyl)benz[d]isoxazole (0.20 g, 0.90 mmol),
anhydrous K2CO3 (0.12 g, 0.90 mmol) and KI (few crystals) in MeCN (20 mL) under an N2
atmosphere. The stirred reaction mixture was heated at reflux for 20 h, cooled to room temperature
and filtered. The residue was washed with MeOH (2 x 10 mL) and H2O to yield 0.18 g of a pinkcolored solid: mp 172-174 ºC (lit.174 mp 170.4 ºC). The solid (0.18 g) was dissolved in CH2Cl2 (2
mL) and cooled to 0 C (ice-bath). A saturated solution of (COOH)2/Et2O was added and the
reaction mixture was allowed to stir at room temperature overnight. The precipitate was collected
by filtration to yield a white solid (0.25 g) which upon recrystallization from EtOH/H2O afforded
0.17 g (5%) of compound 113 as a white solid: mp 198-200 ºC. 1H NMR (DMSO-d6)  1.04-1.07
(t, 3H, CH3 from EtOH), 2.09-2.33 (m, 4H, CH2), 3.04-3.17 (m, 6H, CH2 ) 3.42-3.48 (m, 3H, CH2
from EtOH, CH), 3.65 (s, 2H, CH2), 7.31-7.36 (m, 2H, ArH), 7.62-7.64 (d, 1H, ArH, J = 8.8 Hz),
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7.73-7.75 (dd, 1H, ArH, J = 2.1 Hz, 9.1 Hz), 7.90-7.94 (m, 1H, ArH), 8.07-8.10 (m, 1H, ArH),
8.90-8.92 (d, 1H, ArH, J = 6.6 Hz)), (3H are under the DMSO peak, verified by COSY). Anal.
Calcd for (C23H23N4O2F.1(COOH)2•1C2H5OH.0.2H2O) C, 59.38; H, 5.79; N, 10.26. Found C,
59.11; H, 5.62; N, 10.20. MS calculated [M+H]+: 407.1805 MS found [M+H]+: 407.1883.

4-[4-(6-Fluorobenz[d]isoxazol-3-yl)piperidin-1-yl]-1-phenylbutan-1-one

Hydrochloride

(114)
4-Chlorobutyrophenone (137) (1.19 g, 0.82 mmol) was added to a stirred suspension of 6-fluoro3-(4-piperidinyl)benz[d]isoxazole (1.43 g, 0.82 mmol), anhydrous K2CO3 (0.90 g, 0.82 mmol) and
KI (few crystals) in MeCN (50 mL) under an N2 atmosphere. The stirred reaction mixture was
heated at reflux for 20 h, filtered, and the filtrate was evaporated under reduced pressure to give
1.9 g of a yellow oil. The yellow oil was dissolved in CH2Cl2 and 1M HCl (10 mL) was added to
afford a precipitate that was insoluble in H2O. The precipitate was collected by filtration and
washed with CH2Cl2 (3 x 15 mL) and H2O (3 x 15 mL) to yield a white solid (1.44 g) which upon
recrystallization from EtOH/H2O afforded 0.42 g (15%) of compound 114 as a white solid: mp
224-228 °C. 1H NMR (DMSO-d6)  2.05-2.15 (m, 2H, CH2), 2.22-2.25 (d, 2H, CH2, J = 12.4 Hz)
2.33-2.42 (m, 2H, CH2), 3.11-3.27 (m, 6H, CH2 ) 3.47-3.53 (m, 1H, CH), 3.65-3.68 (d, 2H, CH2,
J = 11.7 Hz), 7.33-7.38 (m, 1H, ArH), 7.54-7.58 (t, 2H, ArH, J = 7.4 Hz), 7.65-7.69 (t, 1H, ArH,
J = 7.4 Hz), 7.72-7.75 (dd, 1H, ArH, J = 2, 9.1 Hz), 8.00-8.02 (m, 2H, ArH), 8.20-8.24 (m, 1H,
ArH) 10.58 (br s, 1H, NH+, D2O ex). Anal. Calcd for (C22H23N2O2F•1HCl) C, 65.59; H, 6.00; N,
6.95. Found C, 65.29; H, 6.01; N, 6.89.
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6-Fluoro-3-[1-(4-phenylbutyl)piperidin-4-yl]benz[d]isoxazole Hydrochloride (115)
1-Chloro-4-phenylbutane (138) (0.14 g, 0.82 mmol) was added to a stirred suspension of 6-fluoro3-(4-piperidinyl)benz[d]isoxazole (0.18 g, 0.82 mmol), anhydrous K2CO3 (0.11 g, 0.82 mmol) and
KI (few crystals) in MeCN (15 mL) under an N2 atmosphere. The stirred reaction mixture was
heated at reflux for 36 h, filtered, and the filtrate was evaporated under reduced pressure to give
0.28 g of crude free base as a yellow oil. The free base was unsuccessfully purified using Kugelrohr
distillation and was purified by column chromatography (silica gel; CH2Cl2/MeOH; 9:1) to afford
0.20 g of a yellow-colored oil, that was dissolved in EtOAc (2 mL), cooled to 0 C (ice-bath) and
treated with a saturated solution of gaseous HCl/EtOAc, and then the reaction mixture was allowed
to stir at room temperature overnight. The precipitate was collected by filtration to yield a white
solid (0.19 g) which upon recrystallization from EtOH/H2O afforded 0.13 g (40%) of compound
115 as a white solid: mp 200-204 ºC. 1H NMR (DMSO-d6)  1.62-1.81 (m, 4H, CH2), 2.21-2.36
(m, 4H, CH2), 2.63-2.67 (t, 2H, CH2, J = 7.4 Hz), 3.05-3.17 (m, 4H, CH2), 3.43-3.51 (m, 1H, CH),
3.59-3.62 (d, 2H, CH2, J = 12.0 Hz), 7.18-7.38 (m, 6H, ArH), 7.72-7.76 (m, 1H, ArH), 8.17-8.21
(m, 1H, ArH), 10.38 (br s, 1H, NH+). Anal. Calcd for (C22H25N2OF•1 HCl) C, 67.94; H, 6.74; N,
7.20. Found C, 67.65; H, 6.81; N, 7.11.

4-[4-(6-Fluorobenz[d]isoxazol-3-yl)piperidin-1-yl]-1-phenylpentan-1-one

Hydrochloride

(116)
Compound 141 (0.20 g, 1.01 mmol) was added to a stirred suspension of 6-fluoro-3-(4piperidinyl)benz[d]isoxazole (0.25 g, 1.12 mmol), anhydrous K2CO3 (0.15 g, 1.12 mmol) and KI
(few crystals) in MeCN (5 mL). The stirred reaction mixture was heated in a sealed tube at 80 ºC
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for 48 h, filtered, and the filtrate was evaporated under reduced pressure to give 0.29 g of a sticky
solid. The solid was purified by column chromatography (silica gel; CH2Cl2/MeOH; 9:1) to yield
0.13 g of a sticky solid. The solid was dissolved in EtOH, cooled to 0 °C (ice-bath) and a saturated
solution of gaseous HCl/EtOH was added. The EtOH was removed under reduced pressure to yield
a white solid (0.06 g; mp 206-208 ºC) which upon recrystallization from MEOH/H2O afforded
0.05 g (13%) of compound 116 as a white solid: mp 206-208 ºC. 1H NMR (DMSO-d6)  1.68-1.80
(m, 4H, CH2), 2.15-2.22.28 (m, 4H, CH2), 3.07-3.20 (m, 6H, CH2), 3.49-3.51 (m, 1H, CH), 3.623.65 (d, 2H, CH2, J = 11.84 Hz), 7.34-7.39 (td, 1H, ArH, J = 2.0, 8.9 Hz ), 7.53-7.57 (t, 2H, ArH,
J = 7.4 Hz), 7.64-7.68 (t, 1H, ArH, J = 7.32 ), 7.74-7.76 (dd, 1H, ArH, J = 2.1, 9.1 Hz), 7.97-8.01
(m, 2H, ArH), 8.12-8.15 (m, 1H, ArH), 9.97 (brs, 1H, NH+). Anal. Calcd for
(C23H25N2O2F•1HCl•0.2CH3OH•0.7H2O) C, 63.92; H, 6.52; N, 6.43. Found C, 63.65; H, 6.14; N,
6.40.

6-Fluoro-3-[1-(5-phenylpentyl)piperidin-4-yl]benz[d]isoxazole Hydrochloride (117)
1-Chloro-5-phenylpentane (142) (0.50 g, 2.73 mmol) was added to a stirred suspension of 6fluoro-3-(4-piperidinyl)benz[d]isoxazole (0.66 g, 2.97 mmol), anhydrous K2CO3 (0.41 g, 2.97
mmol) and KI (few crystals) in MeCN (4 mL). The stirred reaction mixture was heated at 80 °C
in a sealed tube for 96 h, allowed to cool to room temperature, filtered, and the filtrate was
evaporated under reduced pressure to give 0.90 g of a yellow oil. The oil was purified by column
chromatography (silica gel; CH2Cl2/MeOH; 9.5:0.5) to afford 0.23 g of a sticky white solid. The
solid was dissolved in MeOH (2 mL), and cooled to 0 C (ice-bath). A saturated solution of gaseous
HCl/EtOH was added and the reaction mixture was allowed to stir at room temperature overnight.
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The solvent was evaporated under reduced pressure to yield a white solid (0.21 g) which upon
recrystallization from MeOH/H2O afforded 0.14 g (12%) of compound 117 as a white solid: mp
166 °C. 1H NMR (DMSO-d6)  1.30-1.38 (m, 2H, CH2), 1.59-1.66 (m, 2H, CH2), 1.76-1.84 (m,
2H, CH2), 2.18-2.21 (d, 2H, CH2, J = 13.3 Hz), 2.33-2.43 (m, 2H, CH2 ), 2.59-2.63 (t, 2H, CH2, J
= 7.7 Hz), 3.04-3.17 (m, 4H, CH2), 3.40-3.50 (m, 1H, CH), 3.60-3.62 (d, 2H, CH2, J = 11.8 Hz),
7.16-7.36 (m, 6H, ArCH), 7.71-7.74 (dd, 1H, ArCH, J = 2.0, 9.0 Hz), 8.22-8.25 (m, 1H, ArCH),
10.84 (br s, 1H, NH+). Anal. Calcd for (C23H27N2OF•1 HCl) C, 68.56; H, 7.00; N, 6.95. Found C,
68.66; H, 7.10; N, 6.93.

6-Fluoro-3-(2-nitrovinyl)-1H-indole (123)
Compound 123 was synthesized using a literature procedure for the same compound.165
Trifluoroacetic acid (3.7 mL) was added to 6-fluoroindole (120) (0.5 g, 3.69 mmol) and 1dimethylamino-2-nitroethylene (0.43 g, 3.71 mmol) under an N2 atmosphere. The reaction mixture
was allowed to stir at room temperature for 1 h, and quenched carefully with a saturated aqueous
NaHCO3 solution. The residue was collected by filtration, washed with H2O and dried to yield
0.65 g (85%) of compound 123 as a yellow solid. mp 172-174 ºC (lit.166 mp 170-172 ºC).
Compound 123 was used in the preparation of compound 106.

3-(2-Nitrovinyl)-1H-indole (125)
Compound 125 was synthesized using a literature procedure for a similar compound.165
Trifluoroacetic acid (3.7 mL) was added to indole (124) (0.43 g, 3.69 mmol) and 1-dimethylamino2-nitroethylene (0.43 g, 3.71 mmol) under an N2 atmosphere. The reaction mixture was allowed
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to stir at room temperature for 1 h and quenched carefully with a saturated aqueous NaHCO3
solution. The residue was collected by filtration, washed with H2O and dried to yield 0.56 g (81%)
of compound 125 as a yellow solid: mp 164-168 ºC (lit.168 mp 167-168 ºC). Compound 125 was
used in the preparation of compound 105.

Ethyl (2-(6-fluoro-1H-indol-3-yl)ethyl)carbamate (127)
Compound 127 was synthesized using a literature procedure for a similar compound.172 Ethyl
chloroformate (0.37 mL, 3.92 mmol) was added in a dropwise manner at 0 oC (ice-bath) to a stirred
solution of 106 (0.7 g, 3.91 mmol) and Et3N (0.549 mL, 3.92 mmol) in anhydrous CH2Cl2 (13 mL)
under an N2 atmosphere. The reaction mixture was allowed to stir at room temperature for 3 h. The
organic portion was washed with H2O (13 mL), 1M HCl (5 mL), 5% NaHCO3 solution (5 mL),
H2O (5 mL), brine (5 mL), dried (Na2SO4), and evaporated under reduced pressure to yield 0.84 g
(86%) as an orange-colored oil. An attempt was made to isolate the product using a short column
(silica gel; Ethyl acetate /Hexanes; 4:6). 0.50 g (51%) of a mixture of 127 and impurities was
isolated as an orange-colored oil and was used without further purification in the next step. IR
(diamond, cm-1) 1689 (-NH), 3318 (-C=O). Compound 127 was used in the preparation of
compound 108.

Indolyl-3-glyoxyl chloride (128)
Compound 128 was synthesized using a literature procedure for the same compound.169 Oxalyl
chloride (0.71 mL, 8.17 mmol) was added dropwise to a stirred solution of indole 124 (0.83 g, 7.08
mmol) in anhydrous Et2O (15 mL) at 0 ºC (ice-bath) under an N2 atmosphere, and was allowed to
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stir at 0 ºC for 3 h, and at room temperature for 1 h. The reaction mixture was filtered, and the
residue was washed with cold Et2O, and dried to yield 1.02 g (73%) of compound 128 as yellow
crystals: mp 120-124 ºC (decomposes) (lit.216 mp 116-117 °C). Compound 128 was used in the
preparation of compound 129.

Indole-3-yl-N-methylglyoxalylamide (129)
Compound 129 is known and was synthesized using a literature procedure for the same
compound.217 A solution of compound 128 (0.60 g, 2.89 mmol) in THF was added to methylamine
(40% in H2O, 30 mL) at 0 ºC (ice-bath), and the reaction mixture was allowed stirred at room
temperature for 24 h. The solvent was removed under reduced pressure to yield a crude sticky
residue that was dried and recrystallized from MeOH to yield 0.4 g (68%) of compound 129 as a
beige-colored solid: mp 214-216 ºC (lit.217 mp 220-222 ºC). Compound 129 was used in the
preparation of compound 130.

Hydroxy-indol-3-yl-acetic acid methylamide (130)
Compound 130 was obtained as a side-product and was synthesized using a literature procedure
for a compound similar to analog 107.172 A solution of compound 129 (0.30 g, 1.50 mmol) in THF
(40 mL) was added to a stirred solution of LiAlH4 (0.29 g, 7.50 mmol) in anhydrous THF (50 mL)
at 0 ºC under an N2 atmosphere. The reaction mixture was heated at reflux for 8 h, cooled to 0 °C
(ice-bath), and quenched by addition of H2O (0.3 mL), 15% NaOH (0.3 mL) and H2O (1.5 mL).
The suspension was filtered, and the residue was washed with Et2O. The filtrate was extracted with
Et2O (3 x 10 mL). The combined organic portion was washed with brine (10 mL), dried (Na2SO4),
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and evaporated under reduced pressure to yield 0.10 g (33%) of compound 130 as a white solid:
mp 184-188 °C (lit.171 mp 193-194 °C). IR (diamond, cm-1) 3277 (-OH).

Ethyl 2-(1H-indol-3-yl)ethylcarbamate (131)
Compound 131 was synthesized using a literature procedure for the same compound.172 Ethyl
chloroformate (1.48 mL, 15.61 mmol) was added dropwise at 0 ºC (ice-bath) to a stirred solution
of tryptamine (105) (2.5 g, 15.61 mmol) and Et3N (2.17 mL, 15.61 mmol) in anhydrous CH2Cl2
(39 mL). The stirred reaction mixture was allowed to warm to room temperature. The organic
portion was washed with H2O (10 mL), 1M HCl (10 mL), 5% NaHCO3 solution (10 mL), H2O (10
mL), brine (10 mL), dried (Na2SO4), and evaporated under reduced pressure to yield 2.80 g (77%)
as an orange-colored oil. The oil was purified using column chromatography (silica gel;
EtOAc/Hexanes; 3:7) to yield 1.76 g (49%) of compound 131 as an orange-colored oil. IR
(diamond, cm-1) 1689 (-C=O), 3318 (-NH). Compound 131 was used in the preparation of
compound 107.

N,N-bis(3-(2-Ethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4onyl)tryptamine (132)
3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (0.10 g, 0.4
mmol) was added to a stirred suspension of tryptamine (105) (0.079 g, 0.44 mmol), KI (catalytic
amount) and anhydrous K2CO3 (0.07 g, 0.44 mmol) in MeCN (3 mL) The stirred reaction mixture
was heated in a sealed tube at 80 ºC for 5 days. The hot reaction mixture was filtered and the filtrate
was evaporated under reduced pressure to give 0.15 g of a crude residue. The crude residue was
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purified using a short column (silica gel; CH2Cl2/MeOH/NH4OH; 8.5:1.5:0.1) to yield 0.03 g
(13%) of compound 132 as a sticky white solid. 1H NMR (DMSO-d6)  1.73-1.85 (m, 8H, CH2),
2.21 (s, 6H, CH3), 2.62 (s, 8H, CH2), 2.72-2.76 (t, 4H, CH2 ), 2.83 (s, 4H, CH2), 3.76-3.79 (t, 4H,
CH2, J = 6.2 Hz), 6.94-6.98 (t, 1H, ArH, J = 7.4 Hz), 7.03-7.07 (t, 1H, ArH, J = 7.5 Hz ), 7.12 (s,
1H, ArH), 7.31-7.33 (d, 1H, ArH, J = 8.0 Hz), 7.52-7.54 (d, 1H, ArH, J = 7.8 Hz), 10.76 (s, 1H,
NH). MS calculated [M+H]+: 541.3213 MS found [M+H]+: 541.3313.

N-Benzyltryptamine (133)
Compound 133 is known and was synthesized using a literature procedure for the same
compound.218 MgSO4 (0.01 g, 0.1 mmol), tryptamine (105) (0.16 g, 1.00 mmol), and benzaldehyde
(0.14 g, 1.3 mmol) were added to EtOH (10 mL), and the stirred reaction mixture was heated at 60
ºC for 1 h. The reaction mixture was filtered and NaBH4 (0.04 g, 1 mmol) was added to the filtrate.
The reaction mixture was allowed to stir at room temperature for 1.5 h and was quenched by the
addition of ice-H2O at 0 ºC (ice-bath). The aqueous portion was extracted with CH2Cl2 (3x 5 mL),
and the combined organic portion was washed with H2O (5 mL), brine (5 mL), dried (Na2SO4),
and evaporated under reduced pressure to yield 0.18 g (78%) of compound 133 as a brown-colored
oil. NMR (DMSO-d6)  2.77-2.88 (m, 4H, CH2), 3.74 (s, 2H, CH2), 6.93-6.97 (m, 1H, ArH), 7.037.07 (td, 1H, ArH, J = 1.1, 8.1 Hz), 7.12-7.13 (d, 1H, ArH, J = 2.3 Hz), 7.19-7.23 (m, 1H, ArH),
7.28-7.34 (m, 5H, ArH), 7.48-7.50 (d, 1H, ArH, J = 7.9 Hz). 10.76 (s, NH). Compound 133 was
used in the preparation of compound 134.
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3-(2-((2-(1H-Indol-3-yl)ethyl)(benzyl)amino)ethyl)-2-methyl-6,7,8,9-tetrahydro-4Hpyrido[1,2-a]pyrimidin-4-one (134)
3-(2-Chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (0.16 g, 0.73
mmol) was added to a stirred suspension of intermediate 133 (0.18 g, 0.73 mmol), anhydrous
K2CO3 (0.10 g, 0.73 mmol) and KI (few crystals) in MeCN (15 mL) under an N2 atmosphere. The
stirred reaction mixture was heated at reflux for 48 h. The hot reaction mixture was filtered and
the filtrate was evaporated under reduced pressure to give 0.24 g of a crude residue. The residue
was dissolved in H2O (~5 mL), and extracted with CH2Cl2 (3 x 5 mL). The combined organic
portion was washed with H2O (5 mL), brine (5 mL), dried (Na2SO4) and evaporated under reduced
pressure to yield 0.20 g of a sticky, yellow-colored liquid that was purified using a short column
(silica gel; CH2Cl2/MeOH/NH4OH; 9:1:0.1) to afford 0.12 g of a liquid, that was dissolved in
CH2Cl2 (2 mL), cooled to 0 C (ice-bath), and treated with a saturated solution of gaseous
HCl/EtOH, and then the reaction mixture was allowed to stir at room temperature overnight. The
precipitate was collected by filtration to yield 0.07 g (20%) of compound 134 as a sticky, pale
gray-colored solid. NMR (DMSO-d6)  1.77-1.94 (m, 4H, CH2), 2.36 (s, 3H, CH3), 3.02-3.43 (m,
10 H, CH2), 3.81-3.84 (t, 2H, CH2, J = 6.3 Hz), 4.55-4.57 (d, 2H, CH2, J = 5.2 Hz), 6.96-7.00 (m,
1H, ArH), 7.07-7.11 (m, 1H, ArH, J = 1.1, 8.1 Hz), 7.21 (d, 1H, ArH, J = 3.96 Hz), 7.35-7.37 (d,
1H, ArH, J = 8.1 Hz), 7.48-7.51 (m, 4H, ArH), 7.77-7.79 (m, 2H, ArH, J = 7.9 Hz). 11.01 (s, 1H,
NH), 11.41 (brs, 1H, NH+).
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5-Chlorovaleroyl chloride (140)
Compound 140 was synthesized using a literature procedure for the same compound.175 Thionyl
chloride (2.0 mL, 28.09 mmol) was added to 5-chlorovaleric acid (139) (2.00 g, 14.64 mmol), and
heated at reflux for 3 h under an N2 atmosphere. The reaction mixture was allowed to cool to room
temperature and the thionyl chloride was evaporated under reduced pressure to give 2.04 g (90%)
of compound 140 as a crude yellow oil. Compound 140 was used without further purification in
the next step. IR (diamond, cm-1) 1791 (-C=O). Compound 140 was used in the preparation of
compound 141.

5-Chloro-1-phenyl-1-pentanone (141)
Compound 141 was synthesized using a literature procedure for the same compound.176 AlCl3
(1.89 g, 14.17 mmol) was added to a stirred solution of 140 (2.04 g, 13.16 mmol ) in benzene (3.2
mL, 35.88 mmol) at 0 ºC (ice-bath). The reaction mixture was stirred at 0 ºC for 1 h, and was
allowed to cool to room temperature and stirred for an additional hour. It was quenched by pouring
into ice-H2O, and the organic portion was separated. The aqueous portion was extracted with
benzene (3 x 10 mL). The combined organic portion was washed with H2O (10 mL), brine (10
mL), dried (Na2SO4), and concentrated under reduced pressure to yield 2.4 g of a crude pale brown
solid: mp 42-43 ºC, that was recrystallized using hexane to give 2.2 g of a pale yellow solid: mp
43-44 ºC that was further purified by column chromatography (silica gel; hexanes/ EtOAc; 100:0
to 94:06) to yield 2.1 g (81%) of compound 141 as a pearly white solid: mp 49 ºC (lit.176 mp 5051 °C). 1H NMR (DMSO-d6)  1.70-1.84 (m, 4H, CH2), 3.07-3.10 (t, 2H, CH2, J = 6.8 Hz), 3.683.71 (t, 2H, CH2, J = 6.4 Hz), 7.51-7.55 (t, 2H, ArCH, J = 7.4 Hz), 7.62-7.66 (t, 1H, ArCH, J = 7.4
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Hz), 7.96-7.99 (d, 2H, ArCH, J = 7.1 Hz). Compound 141 was used in the preparation of compound
116.

4-(4-Phenylpiperidin-1-yl)pyridin-2(1H)-one (150)
Compound 150 was unknown and was synthesized using a literature procedure for a similar
compound.204 A solution of 151 (0.11 g, 0.32 mmol) in EtOAc/MeOH (27 mL, 1/2) was
hydrogenated (30-40 psi) using 10% Pd/C (0.01 g) as a catalyst at room temperature for 2 h. The
reaction mixture was filtered over Celite and the filtrate was evaporated under reduced pressure to
yield 0.07 g (86%) of compound 150 as a yellow-colored solid: mp 110-114 ºC. 1H NMR (DMSOd6)  1.57-1.68 (m, 2H, CH2), 1.82-1.85 (d, 2H, CH2, J = 11.4 Hz), 2.77-2.83 (m, 1H, CH), 2.912.97 (t, 2H, CH2, J = 11.5 Hz) 3.94-3.97 (d, 2H, CH2, J = 13.3 Hz), 5.53 (s, 1H, ArH), 6.14-6.17
(dd, 1H, ArH, J = 2.4 Hz, 7.6 Hz), 7.16-7.32 (m, 6H, Ar H). IR (diamond, cm-1) 1611 (-C=O),
2917 (-NH). Compound 150 was used in the preparation of compounds 153 and 154.

2-(Benzyloxy)-4-(4-phenylpiperidin-1-yl)pyridine (151)
Compound 151 was not known and was synthesized using a procedure for a similar compound.119
4-Phenyl piperidine (1.71 g, 10.67 mmol), palladium diacetate (0.79 g, 3.53 mmol), BINAP (0.33
g, 0.53 mmol) and sodium tert-butoxide (1.38 g, 14.33 mmol) were added to a stirred solution of
152 (1.5 g, 5.73 mmol) in toluene (15 mL). The reaction mixture was heated in a sealed tube at
100 ºC for 27 h and filtered over Celite. The filtrate was diluted with water (~20 mL) and extracted
with EtOAC (3x 20 mL). The combined organic portion was washed with H2O (10 mL), brine (10
mL), dried (Na2SO4), and concentrated under reduced pressure to yield 2.01 g of a crude, yellow
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oil that was further purified by column chromatography (silica gel; hexanes/ EtOAc; 100:0 to
94:06) to yield 0.43 g (22%) of compound 151 as a white solid: mp 106-108 ºC. 1H NMR (DMSOd6)  1.62-1.69 (m, 2H, CH2), 1.82-1.85 (d, 2H, CH2, J = 12.12 Hz), 2.75-2.82 (m, 1H, CH), 2.892.96 (m, 2H, CH2), 4.01-4.04 (d, 2H, CH2, J = 13.3 Hz), 5.30 (s, 2H, CH2), 6.23 (s, 1H, ArH),
6.60-6.62 (dd, 1H, ArH, J = 2.3 Hz, 6.2 Hz), 7.18-7.44 (m, 10H, Ar H), 7.80-7.82 (d, ArH, 1H, J
= 6.2 Hz). Compound 151 was used in the preparation of compound 150.

2-(Benzyloxy)-4-bromopyridine (152)
Compound 152 is known and was synthesized using a literature procedure for the same
compound.203 Sodium hydride (0.93 mg, 38.75 mmol) was added to a stirred solution of benzyl
alcohol (2.65 mL, 25. 51 mmol) in THF (8 mL) at 0 ºC and was allowed to stir at room temperature
for 15 min. 4-Bromo-2-chloro pyridine (148) (1.50 g, 7.79 mmol) in THF (2 mL) was added, the
stirred reaction mixture was heated at reflux for 3 h, and quenched by the addition of H2O (~10
mL). The aqueous portion was extracted with EtOAC (3x 10 mL). The combined organic portion
was washed with H2O (10 mL), brine (10 mL), dried (Na2SO4), and concentrated under reduced
pressure to yield 2.20 g of a crude yellow oil that was further purified by column chromatography
(silica gel; hexanes/ EtOAc; 100:0 to 80:20) to yield 1.5 g (73%) of compound 152 as a colorless
oil. 1H NMR (DMSO-d6)  5.41 (s, 2H, CH2), 7.26 (s, 1H, ArH), 7.30-7.31 (dd, 1H, ArH, J = 1.6
Hz, 5.5 Hz), 7.36-7.51 (m, 5H, Ar H), 8.14-8.16 (d, ArH, 1H, 5.5 Hz). Compound 152 was used
in the preparation of compound 151.
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2-Butoxy-4-(4-phenylpiperidin-1-yl)pyridine (153)
Compound 153 was obtained as a side-product instead of compound 147 and was synthesized
using a literature procedure for a similar compound.219 Sodium hydride was added to a solution of
compound 150 (0.22 g, 0.85 mmol) in DMF (10 mL) at 0 ºC under an N2 atmosphere and was
stirred at room temperature for 1 h. n-Butyl bomide (0.1 mL, 0.91 mmol) was added dropwise and
the reaction mixture was heated at 103 ºC for 3 days. The reaction mixture was diluted with H2O
(~10 mL) and extracted with EtOAC (3x 10 mL). The combined organic portion was washed with
H2O (10 mL), brine (10 mL), dried (Na2SO4), and concentrated under reduced pressure to yield
0.16 g of a crude yellow oil that was further purified by column chromatography (silica gel;
hexanes/ EtOAc; 100:0 to 80:20) to yield 0.04 g (17%) of compound 153 as a yellow-colored oil.
1

H NMR (DMSO-d6)  0.91-0.95 (t, 3H, CH3, J = 7.4 Hz), 1.25-1.27 (d, 1H, CH, J = 10 Hz), 1.38-

1.46 (m, 2H, CH2), 1.62-1.69 (m, 4H, CH2), 1.82-1.85 (d, 2H, CH2, J = 10.6 Hz), 2.76-2.81 (m,
1H, CH), 2.87-2.93 (m, 2H, CH2), 3.99-4.02 (d, 2H, CH2, J = 12.8 Hz), 4.17-4.20 (t, 2H, CH2, J =
6.6 Hz), 6.12-6.13 (d, 1H, ArH, J = 2.2 Hz), 6.56-6.58 (dd, 1H, ArH, J = 2.2 Hz, 6.2 Hz), 7.167.32 (m, 5H, ArH), 7.77-7.78 (d, 1H, ArH, J = 6.1 Hz).

3-Chloro-4-(4-phenylpiperidin-1-yl)pyridin-2(1H)-one (154)
Compound 154 was unknown and was synthesized using a literature procedure for a similar
compound.119 N-Chlorosuccinimide (0.08 g, 0.63 mmol) was added to a stirred solution of
Compound 150 (0.16 g, 0.63 mmol) in CH2Cl2 (30 mL). The reaction mixture was allowed to stir
at room temperature for 10 min and was quenched by the addition of a saturated aqueous NaHCO3
solution. The aqueous portion was extracted with CH2Cl2 (3 x 10 mL) and the combined organic
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portion was washed with H2O (10 mL), brine (10 mL), dried (Na2SO4), and concentrated under
reduced pressure to yield 0.12 g of a crude residue that was was further purified by column
chromatography (silica gel; CH2Cl2/ MeOH; 90:10) to yield 0.05 g (81%) of compound 154 as a
white solid: mp 274 ºC. 1H NMR (DMSO-d6)  1.67-1.86 (m, 4H, CH2), 2.65-2.73 (m, 1H, CH),
2.83-2.91 (t, 2H, CH2, J = 11.55 Hz), 3.64-3.68 (d, 2H, CH2, J = 12.3 Hz), 6.08-6.11 (d, 1H, ArH,
J = 7.2 Hz), 6.14-6.17 (m, 6H, ArH).

(±)6-Fluoro-3-(piperidin-3-yl)benz[d]isoxazole Hydrochloride (155)
Compound 155 was synthesized using a literature procedure for a similar compound.153 Compound
161 (0.07 g, 0.27 mmol) was added to a solution of HCl (3N, 1 mL) and EtOH (1 mL), and heated
at reflux for 3 h. It was allowed to cool to room temperature and evaporated to dryness under
reduced pressure to yield a crude yellow-colored solid (mp 258-260 °C) that was recrystallized
from EtOH/H2O to yield 0.05 g (74%) of compound 155 as a yellow-colored solid: mp 262-264
°C. 1H NMR (DMSO-d6)  1.78-1.92 (m, 3H, CH2), 2.21-2.25 (d, 1H, CH2, J = 13.2 Hz), 3.04 (s,
1H, CH), 3.27-3.34 (m, 2H, CH2), 3.59-3.72 (m, 2H, CH2), 7.34-7.39 (m, 1H, ArH), 7.75-7.78 (m,
1H, ArH), 8.13-8.16 (m, 1H, ArH), 9.25 (br s, 2H, NH+) ; Anal. Calcd for (C12H13N2OF•1HCl) C,
56.15; H, 5.50; N, 10.91. Found C, 56.11; H, 5.52; N, 10.84.

N-Formylpiperidine-3-carboxylic acid (157)
Compound 157 was synthesized using a literature procedure for a similar compound.143 A solution
of HCOOH (9 mL, 222.98 mmol) and Ac2O (22 mL, 222.98 mmol) was heated at 60 ºC for 1 h,
cooled to 0 °C (ice-bath) and nipecotic acid (156) (5.00 g, 38.71 mmol) was added portion-wise.
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The reaction mixture was allowed to stir at room temperature for 16 h. and concentrated under
reduced pressure to yield a colorless oil that was crystallized using i-PrOH and diisopropyl ether
to give a crude white solid (mp 110-112 °C). The solid was recrystallized using i-PrOH to yield
5.14 g (85%) of compound 157 as a white solid: mp 114 °C and used without further purification
in the next step. Compound 157 was used in the preparation of compound 158.

N-Formylpiperidine-3-carboxylic acid chloride (158)
Compound 158 was synthesized using a literature procedure for a similar compound.153 SOCl2 (3
mL, 41.30 mmol) was added to 157 (2.00 g, 12.72 mmol) at 0 ºC (ice-bath) under an N2
atmosphere. It was allowed to stir at room temperature for 6 h and the SOCl2 was evaporated under
reduced pressure to afford 2.18 g (98%) of compound 158 as a crude orange-colored oil that was
verified spectrally and used without further characterization and purification in the next step. IR
(diamond, cm-1) 1668 (-C=O). Compound 158 was used in the preparation of compound 159.

N-Formyl-3-(2,4-difluorobenzoyl)piperidine (159)
Compound 159 was synthesized using a literature procedure for a similar compound.153 Compound
158 (2.18 g, 12.41 mmol) was added dropwise to a stirred suspension of AlCl3 (3.00 g, 22.50
mmol) suspended in 1,3-difluorobenzene (13 mL, 132.51 mmol) at 0 °C (ice-bath) under an N2
atmosphere. The reaction mixture was heated at reflux for 22 h, allowed to cool to room
temperature, and quenched by pouring into ice-H2O (50 mL). The aqueous portion was extracted
using CHCl3 (3 x 15 mL) and the combined organic portion was washed with H2O (10 mL), brine
(10 mL), dried (Na2SO4), and evaporated under reduced pressure to yield 2.98 g (95%) of 159 as
220

an orange-colored oil that was used without further purification in the next step. Compound 159
was used in the preparation of compound 160.

N-Formyl-3-((2,4- difluorophenyl)(hydroxyimino)methyl)piperidine (160)
Compound 160 was synthesized using a literature procedure for a similar compound.143
Hydroxylamine hydrochloride (2.37 g, 34.09 mmol) was added to a solution of 159 (2.89 g, 11.41
mmol) in EtOH (58 mL)and was followed by the addition of a solution of NaOH (1.39, 34.70
mmol) in H2O (9 mL). The reaction mixture was heated at reflux for 96 h, allowed to cool to room
temperature, and filtered. The filtrate was evaporated under reduced pressure to give a crude
yellow-colored oil that was purified by column chromatography (silica gel; CH2Cl2/CH3OH; 100:0
to 95:5) to afford 0.60 g (40%) of 160 as a yellow-colored solid: mp 158-160 °C. IR (diamond,
cm-1) 1639 (-C=N), 2864-3180 (-OH). Compound 160 was used in the preparation of compound
161.

N-Formyl-3-(6-fluorobenz[d]isoxazol-3-yl)piperidine (161)
Compound 161 was synthesized using a literature procedure for a similar compound.153 A solution
of 160 (0.59 g, 2.14 mmol) in DMF (3 mL) was added dropwise to a suspension of NaH (0.09 g,
3.63 mmol) in THF (5 mL) at 0 °C (ice-bath) under an N2 atmosphere. The reaction mixture was
heated at 75 °C for 4 h, allowed to cool to room temperature and poured into ice-H2O (30 mL).
The aqueous portion was extracted with EtOAc (3 x 15 mL) and the combined organic portion was
washed with H2O (10 mL), brine (10 mL), dried (Na2SO4) and evaporated under reduced pressure
to give a crude yellow-colored solid that was purified by column chromatography (silica gel;
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CH2Cl2/MeOH; 100:0 to 95:5) to afford 0.08 g (15%) of compound 161 as a pale yellow-colored
solid: mp 104-106 ºC. Compound 161 was used in the preparation of compound 155.

B. Radioligand binding studies
i. For risperidone (14), ketanserin (36), and compounds 60, 61, 65, 66, Ris/Ket (103) and
Ket/Ris (104)
Radioligand binding studies of the compounds were conducted in Dr. Javier Gonzalez-Maeso’s
laboratory as previously reported.141 Binding affinities of risperidone (14), ketanserin (36) and
compounds 60, 61, 65, 66, Ris/Ket (103) and Ket/Ris (104) were determined by Dr. Jose L.
Moreno.

ii. For compounds 57, 62, 63, 111, 112 and 155
Radioligand binding studies of the compounds were conducted in Dr. Javier Gonzalez-Maeso’s
laboratory. Binding affinities of analogs 62 and 63 were determined by Dr. Supriya A. Gaitonde.

The radioligand binding studies were performed in HEK 293 cells that stably express human 5HT2A receptors. The cell pellets were homogenized using a Teflon-glass grinder (50 up-and-down
strokes) in 5 mL of binding buffer (5 mM Tris-HCl; pH 7.4). The volume was made up to 10 mL
with binding buffer and the crude homogenate was centrifuged at 3000 rpm for 5 min at 4 °C. The
supernatant was centrifuged at 18,000 rpm for 10 min at 4 °C. The resultant pellet (P2 fraction)
was washed with 10 mL of binding buffer (5 mM Tris-HCl pH 7.4) and re-centrifuged at 18,000
rpm for 15 minutes. Aliquots were stored at -80 °C until assay. Protein concentration was
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determined using the Bio-Rad protein estimation assay. Curves were carried out by incubating
each drug (10-10-10-4 M; 13 concentrations) in binding buffer containing 5 nM [3H]-ketanserin.
Nonspecific binding was determined in the presence of 10 μM methysergide. Incubations were
terminated by dilution with 200 μL ice-cold incubation buffer, and free ligand was separated from
bound ligand by rapid filtration under vacuum through GF/C glass fiber filters using a microbeta
filtermat-96 harvester (PerkinElmer). These filters were then rinsed twice with 200 μL of ice-cold
incubation buffer, air-dried for 0.5 h, dried at 65 ºC for 1 h and counted for radioactivity by liquid
scintillation spectrometry, using a MicroBeta2 detector (PerkinElmer). Radioligand binding data
were analyzed by nonlinear regression by GraphPad PRISM (version 7 for Windows 10, GraphPad
Software, La Jolla California, US).

C. Functional activity studies
The TEVC and calcium imaging assays were performed in Dr. Diomedes Logothetis’s laboratory
by Dr. Jason Younkin, Amr Ellaithy, and Dr. Lia Baki as previously reported.141

D. Molecular modeling studies
i. Docking studies at 5-HT2A receptors
The ligands were sketched in and energy minimized using the Tripos Force Field (GasteigerHückel charges, distance-dependent dielectric constant = 4.0) in SYBYL X-2.1 (Tripos
International). Docking studies at 5-HT2A receptors were conducted using the genetic algorithm
docking program GOLD suite 5.4187 (Cambridge Crystallographic Data Centre, Cambridge, UK),
with ChemPLP as the chosen scoring function. The binding site was defined to include all amino
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acid residues within a radius of 10 Å from Asp155 The docking poses were clustered (intracluster
RMSD ≤ 2 Å) using a script that was provided by Dr. Philip Mosier. The top solutions were merged
into homology models of the 5-HT2A receptor and the receptor-ligand complexes were energy
minimized using the Tripos Force Field (Gasteiger-Hückel charges, distance-dependent dielectric
constant = 4.0) in SYBYL X-2.1 (Tripos International). HINT188 analysis was performed in
SYBYL-8.1 to quantify the receptor-ligand interactions observed in molecular modeling studies.
PYMOL220 was used to generate images.

ii. Homology modeling of mGlu2 receptors
The amino acid sequences of the crystal structure of the mGlu5 receptor (PDB ID: 4OO9) was
retrieved as a FASTA file from the Protein Databank (PDB) The sequences retrieved consisted of
a dimer and only residues from one monomer were retained. The sequence was prepared by
removal of water molecules, ligand and other molecules. The amino acid sequence of the human
mGlu2 receptor was (entry code: Q14416), were retrieved as a FASTA files from the Universal
Protein Resource (UniPort) Database. The amino acid sequences of the TMD of the mGlu5 receptor
and the mGlu2 receptor were aligned using Clustal X 2.1.178. Homology models (100) of the TMD
of the mGlu2 receptor were generated using MODELLER v9.12179 (University of California San
Francisco, San Francisco, CA) Hydrogen atoms were added to the homology models and disulfide
bonds were built using SYBYL-X 2.1 (Tripos International, St. Louis, MO, USA). Ramachandran
plots using MolProbity197 were generated to examine the models.
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iii. Docking studies at mGlu2 receptors
The ligands were sketched in and energy minimized using the Tripos Force Field (GasteigerHückel charges, distance-dependent dielectric constant = 4.0) in SYBYL X-2.1 (Tripos
International). Docking studies at mGlu2 receptors were conducted using the genetic algorithm
docking program GOLD suite 5.2187 (Cambridge Crystallographic Data Centre, Cambridge, UK)
with ChemPLP as the chosen scoring function. The binding site was defined to include all amino
acid residues within a radius of 10 Å from Asn735. The docking poses were clustered (intracluster
RMSD ≤ 2 Å) using a script that was provided by Dr. Philip Mosier. The top solutions were merged
into homology models of the mGlu2 receptor and the. The receptor-ligand complexes were energy
minimized using the Tripos Force Field (Gasteiger-Hückel charges, distance-dependent dielectric
constant = 4.0) in SYBYL X-2.1 (Tripos International).

HINT188 analysis was performed in SYBYL-8.1 to quantify the receptor-ligand interactions
observed in molecular modeling studies. PYMOL220 was used to generate images.

iv. Distance measurements for 5-HT (6) and analogs 61, 63 and 155
A systematic search was performed on SYBYL-X 2.1 (Tripos International) to determine the
lowest energy conformation of the molecules. The benzene ring centroid was defined as the
aromatic center, and the distances of the aromatic centers from the nitrogen atoms (for 5-HT (6),
analogs 61, 63 and 155) as well as the distances of the hydrogen bond acceptors from the nitrogen
atom (for analog 61) were measured using SYBYL-X 2.1.
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APPENDIX A

Analog 155 (Figure A1) has a chiral carbon atom, and can have multiple conformational isomers.
A systematic search was performed using SYBYL-X 2.1 (Tripos International) to determine the
lowest energy conformations of analog 155. Figure A1 illustrates the bonds that were set as
rotatable bonds (RB) as well as the closure bond. The increment value, and the maximum energy
difference, were set as 10 degrees and 9999 kcal/mol, respectively. Default options were used for
the other parameters. The benzene-ring centroid was defined as the aromatic center, and the
distances of the aromatic centers from the nitrogen atoms were also measured as part of the
systematic search. The systematic search was performed on the S equatorial, R axial, R equatorial,
and S axial isomers of 155, and the results of the conformational search are tabulated in Tables
A1, A2, A3 and A4, respectively. In the lowest energy conformations of the S equatorial, R axial,
R equatorial, and S axial isomers of analog 155, the piperidine ring was in a chair conformation,
and are shown in Figure A2.

Figure A1. Analog 155. Blue arrows indicate rotatable bonds (RB).
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Table A1. Results of the systematic search for S equatorial-155.
Name

RB1*

RB2*

RB3*

RB4*

RB5*

RB6*

Energy

Distance

(kcal/mol)

(Å)**

1. CNF_15

280

56.3

303.6

56.8

302

58

15.5630

5.75

2. CNF_1

270

56.3

303.6

56.8

302

58

15.6464

5.85

3. CNF_14

290

56.3

303.6

56.8

302

58

15.6809

5.65

4. CNF_8

200

56.3

303.6

56.8

302

58

15.7319

6.35

5. CNF_2

260

56.3

303.6

56.8

302

58

15.7662

5.95

6. CNF_7

210

56.3

303.6

56.8

302

58

15.7855

6.25

7. CNF_6

220

56.3

303.6

56.8

302

58

15.8622

6.25

8. CNF_3

250

56.3

303.6

56.8

302

58

15.8743

5.95

9. CNF_9

190

56.3

303.6

56.8

302

58

15.8863

6.35

10. CNF_5

230

56.3

303.6

56.8

302

58

15.9212

6.15

11. CNF_4

240

56.3

303.6

56.8

302

58

15.9315

6.05

12. CNF_13

300

56.3

303.6

56.8

302

58

16.9391

5.55

13. CNF_10

180

56.3

303.6

56.8

302

58

17.2677

6.35

14. CNF_12

60

56.3

303.6

56.8

302

58

17.3462

5.55

15. CNF_11

170

336.3

323.6

66.8

332

328

27.2139

5.45

*RB: rotatable bond (degrees). **Aromatic (benzene-ring) to amine distance.
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Table A2. Results of the systematic search for R axial-155.
Name
RB1* RB6* RB5* RB4* RB3*

RB2*

Energy

Distance

(kcal/mol)

(Å)**

1. CNF_1

161.7

303.3

58.5

301.9

56.2

304.4

15.2224

5.75

2. CNF_62

171.7

303.3

58.5

301.9

56.2

304.4

15.4034

5.75

3. CNF_60

181.7

303.3

58.5

301.9

56.2

304.4

17.1884

5.65

4. CNF_37

81.7

23.3

38.5

291.9

26.2

34.4

23.6635

6.05

5. CNF_41

71.7

23.3

38.5

291.9

26.2

34.4

23.6724

5.95

6. CNF_33

91.7

23.3

38.5

291.9

26.2

34.4

23.6975

6.15

7. CNF_36

81.7

33.3

28.5

291.9

36.2

24.4

23.7202

6.05

8. CNF_32

91.7

33.3

28.5

291.9

36.2

24.4

23.7492

6.15

9. CNF_29

101.7

23.3

38.5

291.9

26.2

34.4

23.7506

6.25

10. CNF_40

71.7

33.3

28.5

291.9

36.2

24.4

23.7628

5.95

11. CNF_28

101.7

33.3

28.5

291.9

36.2

24.4

23.802

6.25

12. CNF_23

111.7

23.3

38.5

291.9

26.2

34.4

23.8169

6.35

13. CNF_45

61.7

23.3

38.5

291.9

26.2

34.4

23.8227

5.85

14. CNF_22

111.7

33.3

28.5

291.9

36.2

24.4

23.8653

6.35

15. CNF_17

121.7

23.3

38.5

291.9

26.2

34.4

23.8978

6.35

16. CNF_16

121.7

33.3

28.5

291.9

36.2

24.4

23.9309

6.35

17. CNF_10

131.7

33.3

28.5

291.9

36.2

24.4

24.0114

6.45

18. CNF_11

131.7

23.3

38.5

291.9

26.2

34.4

24.0238

6.45

19. CNF_5

151.7

323.3

68.5

331.9

326.2

64.4

24.0278

6.05
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20. CNF_2

161.7

323.3

68.5

331.9

326.2

64.4

24.0727

6.05

21. CNF_44

61.7

33.3

28.5

291.9

36.2

24.4

24.085

5.85

22. CNF_8

141.7

323.3

68.5

331.9

326.2

64.4

24.0919

6.05

23. CNF_14

131.7

323.3

68.5

331.9

326.2

64.4

24.2301

6.05

24. CNF_7

141.7

333.3

68.5

321.9

336.2

64.4

24.2679

6.15

25. CNF_64

171.7

323.3

68.5

331.9

326.2

64.4

24.2811

5.95

26. CNF_4

151.7

333.3

68.5

321.9

336.2

64.4

24.2888

6.15

27. CNF_58

301.7

23.3

38.5

291.9

26.2

34.4

24.3342

5.35

28. CNF_49

51.7

23.3

38.5

291.9

26.2

34.4

24.3522

5.75

29. CNF_13

131.7

333.3

68.5

321.9

336.2

64.4

24.3568

6.15

30. CNF_20

121.7

323.3

68.5

331.9

326.2

64.4

24.4141

5.95

31. CNF_19

121.7

333.3

68.5

321.9

336.2

64.4

24.5013

6.05

32. CNF_26

111.7

323.3

68.5

331.9

326.2

64.4

24.6469

5.95

33. CNF_25

111.7

333.3

68.5

321.9

336.2

64.4

24.6739

6.05

34. CNF_57

301.7

33.3

28.5

291.9

36.2

24.4

24.7407

5.45

35. CNF_48

51.7

33.3

28.5

291.9

36.2

24.4

25.2815

5.75

36. CNF_51

41.7

23.3

38.5

291.9

26.2

34.4

25.5312

5.65

37. CNF_54

311.7

23.3

38.5

291.9

26.2

34.4

26.7319

5.25

38. CNF_35

81.7

43.3

18.5

291.9

46.2

14.4

27.2489

6.05

39. CNF_39

71.7

43.3

18.5

291.9

46.2

14.4

27.2763

5.95

40. CNF_31

91.7

43.3

18.5

291.9

46.2

14.4

27.3276

6.15

41. CNF_42

71.7

13.3

48.5

291.9

16.2

44.4

27.3566

5.95
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42. CNF_46

61.7

13.3

48.5

291.9

16.2

44.4

27.3805

5.85

43. CNF_38

81.7

13.3

48.5

291.9

16.2

44.4

27.4161

6.05

44. CNF_27

101.7

43.3

18.5

291.9

46.2

14.4

27.4313

6.25

45. CNF_34

91.7

13.3

48.5

291.9

16.2

44.4

27.5012

6.15

46. CNF_21

111.7

43.3

18.5

291.9

46.2

14.4

27.5322

6.25

47. CNF_30

101.7

13.3

48.5

291.9

16.2

44.4

27.5977

6.25

48. CNF_15

121.7

43.3

18.5

291.9

46.2

14.4

27.6072

6.35

49. CNF_9

131.7

43.3

18.5

291.9

46.2

14.4

27.6525

6.45

50. CNF_50

51.7

13.3

48.5

291.9

16.2

44.4

27.6563

5.75

51. CNF_6

141.7

43.3

18.5

291.9

46.2

14.4

27.6825

6.45

52. CNF_3

151.7

43.3

18.5

291.9

46.2

14.4

27.6952

6.45

53. CNF_24

111.7

13.3

48.5

291.9

16.2

44.4

27.6983

6.35

54. CNF_43

61.7

43.3

18.5

291.9

46.2

14.4

27.7931

5.85

55. CNF_53

31.7

23.3

38.5

291.9

26.2

34.4

27.7996

5.55

56. CNF_18

121.7

13.3

48.5

291.9

16.2

44.4

27.8048

6.35

57. CNF_63

171.7

43.3

18.5

291.9

46.2

14.4

27.8064

6.45

58. CNF_12

131.7

13.3

48.5

291.9

16.2

44.4

27.9582

6.45

59. CNF_59

301.7

13.3

48.5

291.9

16.2

44.4

28.0038

5.15

60. CNF_56

301.7

43.3

18.5

291.9

46.2

14.4

28.6003

5.65

61. CNF_52

41.7

13.3

48.5

291.9

16.2

44.4

28.6801

5.65

62. CNF_55

311.7

13.3

48.5

291.9

16.2

44.4

29.0222

5.15

63. CNF_61

181.7

43.3

18.5

291.9

46.2

14.4

29.2778

6.45
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64. CNF_47

51.7

43.3

18.5

291.9

46.2

14.4

30.2279

5.75

*RB: rotatable bond (degrees). **Aromatic (benzene-ring) to amine distance.

Table A3. Results of the systematic search for R equatorial-155.
Name

RB1*

RB2*

RB3*

RB4*

RB5*

RB6*

Energy

Distance

(kcal/mol)

(Å)**

1. CNF_1

283.2

56.9

301.6

58.2

303.3

56.1

15.558

6.45

2. CNF_2

273.2

56.9

301.6

58.2

303.3

56.1

15.6152

6.45

3. CNF_11

203.2

56.9

301.6

58.2

303.3

56.1

15.7263

5.95

4. CNF_4

263.2

56.9

301.6

58.2

303.3

56.1

15.7295

6.45

5. CNF_12

193.2

56.9

301.6

58.2

303.3

56.1

15.7835

5.85

6. CNF_10

213.2

56.9

301.6

58.2

303.3

56.1

15.793

6.05

7. CNF_16

293.2

56.9

301.6

58.2

303.3

56.1

15.8182

6.45

8. CNF_6

253.2

56.9

301.6

58.2

303.3

56.1

15.8422

6.35

9. CNF_9

223.2

56.9

301.6

58.2

303.3

56.1

15.8683

6.15

10. CNF_7

243.2

56.9

301.6

58.2

303.3

56.1

15.9138

6.25

11. CNF_8

233.2

56.9

301.6

58.2

303.3

56.1

15.9189

6.25

12. CNF_13

183.2

56.9

301.6

58.2

303.3

56.1

16.6131

5.85

13. CNF_14

63.2

56.9

301.6

58.2

303.3

56.1

17.2443

5.75

14. CNF_15

303.2

56.9

301.6

58.2

303.3

56.1

17.891

6.45

15. CNF_3

273.2

346.9

311.6

68.2

343.3

316.1

27.2003

6.25

16. CNF_5

263.2

346.9

311.6

68.2

343.3

316.1

27.3223

6.25
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*RB: rotatable bond (degrees). **Aromatic (benzene-ring) to amine distance.

Table A4. Results of the systematic search for S axial-155.
Name
RB1* RB2*
RB3*
RB4*
RB5*

RB6*

Energy

Distance

(kcal/mol)

(Å)**

1. CNF_1

80

54.9

299.7

60.2

304.7

52.2

15.9379

5.85

2. CNF_3

70

54.9

299.7

60.2

304.7

52.2

15.9942

5.85

3. CNF_41

90

54.9

299.7

60.2

304.7

52.2

16.0544

5.85

4. CNF_37

100

54.9

299.7

60.2

304.7

52.2

16.2338

5.85

5. CNF_33

110

54.9

299.7

60.2

304.7

52.2

16.4354

5.85

6. CNF_12

170

54.9

299.7

60.2

304.7

52.2

16.4431

5.05

7. CNF_29

120

54.9

299.7

60.2

304.7

52.2

16.6118

5.75

8. CNF_25

130

54.9

299.7

60.2

304.7

52.2

16.7173

5.65

9. CNF_5

60

54.9

299.7

60.2

304.7

52.2

16.8652

5.75

10. CNF_8

180

54.9

299.7

60.2

304.7

52.2

18.6755

4.85

11. CNF_18

160

334.9

69.7

320.2

334.7

62.2

23.6483

6.05

12. CNF_15

170

334.9

69.7

320.2

334.7

62.2

23.7422

5.95

13. CNF_21

150

334.9

69.7

320.2

334.7

62.2

23.7704

6.15

14. CNF_24

140

334.9

69.7

320.2

334.7

62.2

23.9774

6.15

15. CNF_28

130

334.9

69.7

320.2

334.7

62.2

24.1841

6.25

16. CNF_16

160

34.9

289.7

30.2

34.7

292.2

24.3245

5.55

17. CNF_32

120

334.9

69.7

320.2

334.7

62.2

24.3255

6.35
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18. CNF_19

150

34.9

289.7

30.2

34.7

292.2

24.3952

5.65

19. CNF_36

110

334.9

69.7

320.2

334.7

62.2

24.3987

6.35

20. CNF_11

180

334.9

69.7

320.2

334.7

62.2

24.4115

5.75

21. CNF_13

170

34.9

289.7

30.2

34.7

292.2

24.448

5.45

22. CNF_42

90

34.9

289.7

30.2

34.7

292.2

24.4602

6.15

23. CNF_40

100

334.9

69.7

320.2

334.7

62.2

24.4681

6.45

24. CNF_2

80

34.9

289.7

30.2

34.7

292.2

24.4715

6.05

25. CNF_22

140

34.9

289.7

30.2

34.7

292.2

24.5117

5.85

26. CNF_38

100

34.9

289.7

30.2

34.7

292.2

24.5393

6.05

27. CNF_4

70

34.9

289.7

30.2

34.7

292.2

24.6103

6.05

28. CNF_26

130

34.9

289.7

30.2

34.7

292.2

24.6265

5.95

29. CNF_34

110

34.9

289.7

30.2

34.7

292.2

24.64

6.05

30. CNF_30

120

34.9

289.7

30.2

34.7

292.2

24.6809

6.05

31. CNF_9

180

34.9

289.7

30.2

34.7

292.2

25.7056

5.25

32. CNF_7

190

334.9

69.7

320.2

334.7

62.2

26.3994

5.65

33. CNF_14

170

4.9

299.7

60.2

354.7

312.2

26.7008

5.75

34. CNF_17

160

4.9

299.7

60.2

354.7

312.2

26.7645

5.85

35. CNF_10

180

4.9

299.7

60.2

354.7

312.2

26.8825

5.65

36. CNF_20

150

4.9

299.7

60.2

354.7

312.2

26.8877

6.05

37. CNF_23

140

4.9

299.7

60.2

354.7

312.2

27.0264

6.15

38. CNF_27

130

4.9

299.7

60.2

354.7

312.2

27.1553

6.15

39. CNF_31

120

4.9

299.7

60.2

354.7

312.2

27.2394

6.25
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40. CNF_35

110

4.9

299.7

60.2

354.7

312.2

27.2777

6.35

41. CNF_39

100

4.9

299.7

60.2

354.7

312.2

27.3496

6.35

42. CNF_6

190

4.9

299.7

60.2

354.7

312.2

28.1301

5.55

*RB: rotatable bond (degrees). **Aromatic (benzene-ring) to amine distance.

Figure A2. The lowest energy conformers of S equatorial-155 (CNF_15; pink), R equatorial 155
(CNF_1; violet), S axial-155 (CNF_1; salmon), and R axial-155 (CNF_1; green).

Discussion
The systematic search on S-equatorial 155 and R-equatorial 155 resulted in only 15 (Table A1),
and 16 (Table A3) isomers, respectively. Hence, we modified the Van der Waals radius scale
factors general parameter to 0.7, and performed the systematic search as previously described. This
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change resulted in 123 isomers for both S-equatorial 155 and R-equatorial 155. The lowest energy
conformer for the S-equatorial isomer had the same energy as CNF_15 (Table A1), however, the
distance of the aromatic (benzene-ring centroid) center from the amine increased to 5.95 Å. The
lowest energy conformer for the R-equatorial isomer had the same energy and aromatic center
(benzene-ring centroid) to amine distance as CNF_1 (Table A3).
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